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 The available antiretroviral compounds can effectively suppress the 
replication of HIV-1 and block the disease progression. However it is impossible to 
eradicate the virus from the organism as the HIV-1 integrated in the genome is not 
affected by the existing anti-HIV-1 drugs. Therefore, new latency reversing agents 
are being actively developed as part of “shock and kill” therapy to reactivate the 
provirus and clear the reservoir. Normosang (heme arginate; HA) is a human hemin-
containing compound used to treat acute porphyria. Heme is physiologically 
catabolised by heme oxygenases to form iron (Fe2+), carbon monoxide (CO) and 
biliverdin that is further converted to bilirubin by biliverdin reductase.  
 In this study, we have demonstrated that HA inhibited HIV-1 replication during 
the acute infection, which was accompanied by the inhibition of reverse transcription. 
On the other hand, HA synergised with phorbol myristyl acetate (PMA) and 
reactivated the HIV-1 provirus in ACH-2 cells and the HIV-1 “mini-virus” in Jurkat cell 
clones A2 and H12. HIV-1 ‘‘mini-virus’’ was reactivated also by HA-alone. Further, 
we have studied the effects of heme degradation products on latent HIV-1 
reactivation when added individually. We employed addition of ascorbate to generate 
Fe2+, resulting in an increased expression of both HIV-1 provirus and “mini-virus”. 
The other two heme degradation products, CO or bilirubin, decreased the provirus 
expression. Antioxidant N-acetyl cysteine as well as iron chelator desferrioxamine 
inhibited the reactivation of HIV-1 provirus stimulated by PMA alone and in 
combination with either HA or ascorbate, suggesting that the effects of HA were 
mediated by heme- and iron-induced redox stress. Additionally, the effective 
concentrations of HA did neither affect activation of a T-cell line with PMA nor induce 
activation of the unstimulated cells. Finally, we demonstrated the synergistic effects 
of HA and PMA on HIV-1 expression in peripheral blood mononuclear cells of HIV-
infected patients effectively controlled by antiretrovirals cultured ex vivo. These 
results may point towards a new direction in the latent HIV-1 reactivation and 
therapy. 
Key words: HIV-1, latency, reactivation, heme arginate, iron, CO, bilirubin, 




V současnosti dostupná antiretrovirotika efektivně potlačují replikaci HIV-1 a 
blokují progresi onemocnění. Virus však není možné eliminovat z organismu, neboť 
HIV-1 integrovaný do genomu není existujícími antiretrovirotiky ovlivňován. Aktivně 
se proto vyvíjejí nové látky schopné reaktivovat provirus a zlikvidovat latentní 
rezervoár, tzv. terapie “shock and kill”. Normosang (hem arginát; HA) je preparát 
obsahující lidský hemin využívaný k léčbě akutní porfyrie. Hem je fyziologicky 
degradován hem oxygenasami na železo (Fe2+), oxid uhelnatý (CO) a biliverdin, 
který je dále přeměňován biliverdin reduktasou na bilirubin.  
V této práci jsme prokázali, že HA inhibuje replikaci HIV-1 při akutní infekci, 
což bylo doprovázeno inhibicí reversní transkripce. Naproti tomu HA působil 
synergicky s forbol myristyl acetátem (PMA) a reaktivoval HIV-1 provirus v buňkách 
ACH-2 a HIV-1 „minivirus“ v klonech buněk Jurkat A2 a H12. HIV-1 „minivirus“ byl 
reaktivován i samotným HA. Dále jsme studovali efekty degradačních produktů 
hemu na reaktivaci latentního HIV-1 přidaných jednotlivě. K tvorbě Fe2+ jsme využili 
askorbát, jehož přidání zvyšovalo expresi HIV-1 proviru i „miniviru“. Další dva 
degradační produkty hemu, CO a bilirubin, expresi proviru inhibovaly. Antioxidans N-
acetylcystein stejně jako chelátor železa desferrioxamin inhibovaly reaktivaci HIV-1 
proviru stimulovanou samotným PMA nebo jeho kombinací s HA či askorbátem, což 
naznačuje, že efekty HA byly zprostředkovány redoxním stresem indukovaným 
hemem či železem. Navíc efektivní koncentrace HA neovlivnily aktivaci T-buněčné 
linie pomocí PMA ani neindukovaly aktivaci nestimulovaných buněk. Synergické 
působení HA a PMA na expresi HIV-1 se nám podařilo prokázat i v periferních 
mononukleárech HIV-infikovaných pacientů s antiretrovirovou terapií při kultivaci ex 
vivo. Tyto výsledky naznačují nový směr v reaktivaci latentního proviru a v terapii 
HIV infekce. 
Klíčová slova: HIV-1, latence, reaktivace, hem arginát, železo, CO, bilirubin, 












AIDS  - Aquired immunodeficiency syndrome 
APOBEC3G  - Apolipoprotein B mRNA-editing enzyme 3G  
ART  - Antiretroviral therapy  
Asc  - Ascorbate 
BVR  - Biliverdin reductase 
CA  - Capsid protein 
cART  - Combined antiretroviral therapy 
CDK9  - Cyclin-dependent kinase 9  
CO  - Carbon monoxide 
CORM-A1 - Carbon monoxide releasing molecule –A1 
ddPCR - digital droplet PCR 
DFO  - Desferrioxamine 
DNMT  - DNA methyltransferase 
DNMTi - DNA methyltransferase inhibitor 
EGFP  - Enhanced green fluorescence protein 
Env  - Envelop 
HA  - Heme arginate 
HAART - Highly active antiretroviral therapy  
HAT  - Histone acetyl transferase 
HDAC  - Histone deacetylase 
HDACi  - Histone deacetylase inhibitor 
HIV  - Human immunodeficiency virus 
HKMT  - Histone lysine methyltransferase 
HMT  - Histone methyltransferase 
HO-1  - Heme oxygenase-1 
IN  - Integrase 
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LRA  - Latency reversing agent 
LTR  - Long terminal repeats 
MA  - Matrix protein 
NAC  - N-Acetyl cysteine 
NC  - Nucleocapsid 
Nef  - Negative factor 
NFAT  - Nuclear factor of activated T cells 
NF-kB  - Nuclear factor kappa B  
Nrf2  - Nuclear factor (erythroid-derived 2)-like 2 
PBMC  - peripheral blood mononuclear cell 
PKC  - Protein kinase C 
PMA  - Phorbol myristate acetate 
PR  - Protease 
PRMT  - Protein arginine methyltransferase 
P-TEFb  - Positive transcription elongation factor b  
PTEN  - Phosphatase and tensin homolog  
RCI  - Resting CD4+T cell infection 
Rev  - Regulator of viral transport 
ROS  - Reactive oxygen species 
RT  - Reverse transcriptase 
SAHA  - Suberoylanilide hydroxamic acid  
SIV  -  Simian immunodeficiency virus 
snPP IX - Tin protoporphyrin IX 
TALE   - Transcription activator-like effector 
TAR   - Transactivation response element 
Tat  - Transactivator of transcription 
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TNF-α  - Tumor necrosis factor -α  
Vif  - Viral infectivity factor 
Vpr  - Viral protein R 
















3.1 Human immunodeficiency virus 
 Depletion of CD4+ T cells and a resulting severe immunodeficiency was first 
observed in 1981 in groups of young homosexual men and injection drug users in 
the United States who had Kaposi’s sarcoma or Pneumocystis carinii infection (CDC, 
1981). The new disease was recognised and the name acquired immunodeficiency 
syndrome (AIDS) was designated by CDC in 1982 (CDC, 1982). Immediately in the 
following years, the virus that causes AIDS was isolated by various groups in France 
and in the USA. Luc Montagnier and colleagues isolated the virus in 1983 from 
France and named it lymphadenopathy-associated virus (LAV) (Barre-Sinoussi et al., 
1983). In 1984, two groups from the USA independently isolated the virus; Robert 
Gallo and colleagues called it human T-lymphotropic virus III (HTLV III) (Gallo et al., 
1984) and the Jay Levy and his co-workers named their isolate as AIDS-associated 
retrovirus (ARV) (Levy et al., 1984). The common name human immunodeficiency 
virus-1 (HIV-1) was assigned in 1986 by The International Committee on the 
Taxonomy of Viruses. Barre-Sinoussi and Luc Montagnier were awarded Nobel 
Prize in 2008 for their discovery.  
3.1.1 HIV classification and phylogeny  
 HIV was renamed as HIV-1 when another virus related to HIV-1 but 
antigenically distinct, today known as HIV-2 was reported to cause AIDS in western 
Africa (Clavel et al., 1986). Both HIV-1 and HIV-2 belong to the genus lentivirus of 
retroviridae family. Also, both of them have originated in non human primates and as 
a result of zoonotic transfer they crossed the species barrier and became infectious 
viruses of human beings (Sharp and Hahn, 2011).  HIV-1 is phylogenetically related 
to simian immunodeficiency virus that infects chimpanzees (SIVcpz), endemic to 
subspecies Pan troglodytes troglodytes (SIVcpzptt) (Gao et al., 1999), while HIV-2 
has its origin from SIV that infects sooty mangabeys (SIVsm). The four distinct 
lineages of HIV-1 are: Group M (Main), Group O (Outlier), Group N (non-M, non-O) 
and Group P (Pending). Group M is responsible for more than 95% of the global 
pandemic (Merson et al., 2008) and is further divided in to sub types or clades from 
A to K. Group O is endemic to west-central Africa (mostly in Cameroon) and 
accounts to less than 1% of HIV-1 infection globally (Mauclere et al., 1997). Group N 
is found only in few cases in Cameroon (Simon et al., 1998) and Group P was 
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isolated in two Cameroonian women living in France (Plantier et al., 2009, Vallari et 
al., 2011). Origin of HIV-1 Group O and P was also from SIVcpzptt, but the primate 
reservoir of these viruses was found to be wild gorillas (Van Heuverswyn et al., 
2006, Plantier et al., 2009). 78 million people have become infected with HIV and 35 
million people have died from AIDS-related illnesses since the start of the epidemic. 
(http://www.unaids.org/en/resources/fact-sheet)  
3.1.2 HIV-1 structure, genes and proteins  
 HIV-1 is a spherical, enveloped virus of about 120nm diameter. As shown in 
Fig. 1, the genetic material of HIV-1 is two single-stranded positive sense RNA, 
which is covered by a conical capsid formed by a capsid protein (p24). The single-
stranded RNA is tightly bound to nucleocapsid (NC) protein (p7) and other functional 
enzymes like integrase, reverse transcriptase and protease. The capsid is 
surrounded by a matrix (MA) protein (p17). The outer bi-layered lipid envelope is 
studded with three glycoprotein cap molecules (gp120) and three transmembrane 
glycoproteins (gp41) that connect gp120 with the lipid envelope. 
 
Fig. 1. Structure of HIV-1. The two copies of single stranded RNA genome and other 
functional enzymes are packed inside a conical capsid protein, which in turn is covered by a 
matrix protein. The bi-layered lipid membrane of HIV-1 contains gp120 and gp41 
glycoproteins. (Image source: NIAID). 
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 The genome of HIV-1 is approximately 9.8kb in length (Muesing et al., 1985) 
(Fig. 2). Both the 5’ and 3’ ends are flanked by long terminal repeats (LTR). Between 
the 5’ and 3’ LTR, the HIV-1 genes are coded in three open reading frames. Gag 
gene encodes the structural proteins like matrix, capsid and nucleocapsid proteins. 
Pol gene codes for the functional proteins like the protease, reverse transcriptase 
and integrase enzymes. Env gene encodes the envelope glycoproteins gp120 and 
gp41. Apart from these three major gene segments, the HIV-1 genome codes for 
other regulatory proteins like, transactivator of viral transcription (Tat), regulator of 
RNA transport (Rev), and accessory proteins such as viral infectivity factor (Vif), viral 
protein R (Vpr) viral protein U (Vpu), negative factor (Nef). 5’ and 3’ LTRs are 
necessary for the integration of HIV-1 into the host genome and 5’ LTR acts as a 
promoter region. 
 
Fig. 2. Genomic organization of HIV-1. The three major genes Gag, Pol and Env and other 
genes encoding regulatory and accessory proteins are coded in three open reading frames 
in between 5’ and 3’ LTRs of HIV-1 genome. 
(Image source: https://web.stanford.edu/group/virus/retro/2005gongishmail/HIV.html) 
 HIV-1 protease (PR) is an aspartyl protease and is necessary for gag and 
gag-pol precursor protein cleavage during HIV maturation. The 55kD gag precursor 
protein (p55) is cleaved after budding by the viral protease enzyme to yield capsid 
(p24), matrix (p17) and nucleocapsid (p9) and (p6) proteins (Göttlinger et al., 1989). 
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160kD env protein (gp160) is also cleaved by protease to gp120 and gp41 subunits 
that are present in the envelope and involved in the interaction between HIV-1 and 
target cells (Landau et al., 1988). The Reverse transcriptase (RT) is a RNA-
dependent and DNA-dependent polymerase enzyme which produces double-
stranded DNA from the positive-sense single-stranded viral RNA. Incorporation of 
HIV DNA into the host genome is mediated by integrase (IN). Tat is a RNA binding 
protein and is essential for transcriptional transactivation and full length elongation of 
HIV-1 transcription (Feinberg et al., 1991).  Transition from early to late gene 
expression is induced by rev protein (Cochrane, 2014). CD4 and MHC class-I 
molecules on the host cell surface is down regulated by nef (Garcia and Miller, 
1992), it also enhances infectivity of the virion (Miller et al., 1994; Pereira and 
daSilva, 2016). Vpr is found incorporated within the virions and has been shown to 
modulate the host and viral gene transcription, induction of cell cycle arrest and 
apoptosis, involved in importing viral DNA in to the nucleus of the non-dividing cells 
(Guenzel et al., 2014). Vpu down regulates CD4 molecules in the endoplasmic 
reticulum (Willey et al., 1992) and enhances virion release from plasma membrane 
of the infected cells (Schubert et al., 1996). Vif is a 23kD protein that enhances HIV-
1 infectivity by preventing the action of host antiretroviral factors of APOBEC-3 family 
(Salter et al., 2014). 
3.1.3 HIV-1 infection and life cycle 
 The HIV-1 replication cycle can be divided into two phases: the early phase 
starting from binding and fusion of virus at the cell surface to the integration of HIV-1 
viral DNA into the host genome. and The late phase includes the events from 
expression of HIV-1 genes to the release and maturation of new virions (Freed, 
2015). HIV-1 trimeric surface protein gp120 binds to the primary receptor CD4 
molecule present in the target cell. This binding results in a conformational change in 
gp120 and enables it to attach to one of the two co-receptors - the chemokine 
receptor CCR5 or CXCR4. Macrophage tropic, non-syncytium-inducing (R5) viruses 
bind to CCR5 and the T-cell-tropic, syncytium-inducing (X4) viruses bind to the 
CXCR4. Binding of gp120 to cellular receptors changes the conformation of gp41 
that results in gp41 penetrating the plasma membrane, inducing fusion of HIV-1 with 
target cell (Wilen et al., 2012).  
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 Upon fusion and entry into the cytoplasm, the capsid protein is uncoated and 
the viral single-stranded RNA genetic material is reverse transcribed to double-
stranded DNA by virus-encoded reverse transcriptase (RT) (Hu and Hughes, 2012). 
The pre-integration complex (PIC) containing the newly formed viral DNA and 
associated viral and cellular proteins migrates to the nucleus using the cellular 
dynein and microtubule network (McDonald et al., 2002) and integrase catalyses the 
integration of double-stranded viral DNA into the host chromosome (Craigie and 
Bushman, 2012) and establishes a functional provirus. 
 The integrated provirus can either enter into a latent form or be actively 
transcribed by the cellular RNA polymerase II transcription machinery that is 
promoted by the viral transcription transactivator protein (Tat) (Lucic and Lusic, 
2016). From early multiply spliced viral mRNAs, the regulatory proteins Tat, Nef and 
rev are produced, later larger incompletely spliced mRNA encoding accessory 
proteins Vif, Vpr and Vpu is transcribed, and finally an unspliced transcript yielding 
the Gag-Pol polyprotein is produced; the same full length transcript is used as new 
viral genomic RNA (Karn and Stolzfus, 2012). The viral mRNAs are then exported to 
the cytoplasm, where the viral proteins are synthesised and the new virus particles 
are assembled at the plasma membrane, which is mediated by Gag-Pol polyprotein 
as well as Nef and Env. The ESCRT (endosomal sorting complexes required for 
transport) machinery plays a key role in budding and releasing of the newly formed 
virions. Virus maturation concomitantly takes place with budding and release. HIV-1 
protease enzyme cleaves the Gag and Gag-Pol polyproteins to form fully processed 
MA, CA, NC, p6, PR, RT, and IN proteins (Sundquist and Krausslich, 2012; Freed, 




Fig. 3. HIV-1 replication and lifecycle. The early and late phase of HIV-1 life cycle 
beginning with fusion and entry of HIV-1 into target cell, reverse transcription of viral RNA to 
DNA, integration of viral DNA into host genome, transcription of viral genes, translation of 
viral proteins in the cytoplasm, assembly of viral proteins and finally budding and releasing of 
matured new HIV-1 particles. (Image source: Rambaut et al., 2004) 
3.1.4 HIV-1 Latency and reactivation – a molecular insight 
3.1.4.1 HIV-1 infection: Targets and latent reservoirs 
 Although HIV-1 can infect and provirus has been found in monocytes 
(McElrath et al., 1991), dendritic cells (Langhoff et al., 1991), CD8+ T cells (De Maria 
et al., 1991), endothelial cells (Steffan et al., 1992), astrocytes (Churchill et al., 
2009), and hematopoetic stem cells (Carter et al., 2010), macrophages and CD4+ T 
lymphocytes are the major targets of HIV-1 (Zhang et al., 1999). Among these cells, 
resting CD4+ T cells, mean half-life of which can reach 44 months, are considered to 
be the most important reservoirs of latent HIV-1 in the body and it has been 
estimated that it would require over 60 years of cART to eradicate the latent 
reservoirs from the body (Finzi et al., 1999, Siliciano et al., 2003). 
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 HIV-1 infection in the resting CD4+ T cells is blocked by several cellular 
restriction factors like apolipoprotein B mRNA-editing enzyme 3G (APOBEC3G), 
bone marrow stromal cell antigen 2 (BST-2), cyclophilin A, tripartite motif protein 5 
alpha (Trim5α) and cellular microRNAs (miRNAs) (Chiu et al., 2005; Van Damme et 
al., 2008; Qi et al., 2008; Yap et al., 2006, Ahluwalia et al., 2008). These blocks 
prevent the integration of the virus into the host genome resulting in a relatively short 
latent state known as pre-integration latency. On the other hand, in active T cells the 
viral RNA is reverse transcribed efficiently and the pre-integration complex is 
imported into the nucleus and integrated within the host genome. Hence, when a 
small portion of infected active CD4+ T cells returns to a quiescent state, it results in 
a transcriptionally silent and more stable latent state known as post-integration 
latency (Chun et al., 1995; Marcello, 2006). However, a recent study has showed 
that latency can be established directly and early in both resting and activated 
primary T cells (Chavez et al., 2015). 
 The successful reactivation of latent virus from its reservoir requires both 
transcription initiation and its efficient elongation. Since the HIV-1 provirus is 
integrated into the host genome, these steps depend upon the effects of cis- and 
trans- acting factors of both the host and the virus (Marcelo, 2006). Understanding 
the factors that limit both initiation and elongation of HIV-1 provirus gene 
transcription is necessary for developing strategies to eliminate the latent reservoir. 
3.1.4.2 Epigenetic regulation of transcriptional silence  
 Heritable changes that modify the gene expression and activity without 
altering the source DNA sequence are termed as epigenetic regulation (Goldberg et 
al., 2007). Covalent and reversible modifications of histone proteins (eg. Acetylation, 
methylation, phosphorylation, ubiquitination and sumoylation), DNA methylation, 
chromatin remodelling, RNA interference are the major epigenetic mechanisms by 
which the genes are regulated (Handel et al., 2010). Cell development, 
differentiation, stress response etc., can be influenced by epigenetic modifications. 
Both the host genome and the HIV-1 proviral DNA incorporated within it are 
susceptible to epigenetic modifications. 
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(A) Histone acetylation 
 Chromatin environment and integration site of HIV-1 is one of the factors 
determining transcriptional silence. The condensed chromatin in eukaryotes, known 
as heterochromatin, reduces the accessibility of DNA to transcriptional regulators 
and is associated with the transcriptionally silent regions of the genome. The relaxed 
chromatin region conducive for active transcription is called euchromatin (Craig, 
2005). This condensation and relaxation of chromatin can be regulated by a variety 
of mechanisms, including ATP-dependent chromatin remodelling and post-
translational modifications of histone proteins. Interaction of the negatively charged 
DNA and positively charged histone is decreased by acetylation of histone tail which 
results in relaxed, transcriptionally active chromatin. This can be reversed by 
deacetylation. Histone acetyl transferases (HATs) and histone deacetylases 
(HDACs) are the enzymes responsible for acetylation and deacetylation of histones 
in the nucleosomes (Haberland et al., 2009). In vitro infection of T-cell lines with HIV-
1 showed a preferential integration in heterochromatin (Jordan, 2001).  In contrast to 
this observation, HIV-1 has been found in introns of actively transcribed genes in the 
resting memory CD4+ cells derived from patient on HAART (Han et al., 2004). 
However, a genome-wide analysis of HIV-1 integration sites in T-cell lines showed 
virus latency could occur from integration into heterochromatin as well as in actively 
transcribed genes (Lewinski et al., 2005). 
(B) Histone methylation  
 Methylation of histone and DNA is another important epigenetic mechanism 
that regulates gene expression in eukaryotes. Histones are methylated on arginine 
and lysine residues and the methylation is carried out by protein arginine 
methyltransferases (PRMTs) and histone lysine methyltransferases (HKMTs) 
respectively. PRMTs and HKMTs catalyze the transfer of one to three methyl groups 
from the cofactor S-adenosylmethionine (SAM) to lysine and arginine residues of 
histone tails. The methylation of histones is reversed by two families of 
demethylases : the lysine specific demethylase 1 (LSD1) family and the Jumonji C 
(JmjC) domain family. (Jenuwein and Allis, 2001; Kouzarides, 2007). Trimethylation 
of histone H3 lysine at position 9 (H3K9me3) by SUV39H1 and G9a 
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methyltransferases; and at position 27 (H3K27me3) by EZH2 or dimethylation at 
lysine 9 (H3K9me2) by G9a has been shown to suppress HIV-1 provirus 
transcription. (Kouzarides, 2002; Friedman, 2011; du Chene, 2007 and Imai, 2010). 
Also it has been showed that Suv39H1, heterochromatin protein 1 gamma (HP1γ) 
and histone H3K9 trimethylation play a major role in chromatin‐mediated repression 
of integrated HIV‐1 gene expression in different cell lines, including PBMCs isolated 
from HIV‐1‐infected donors (du Chene, 2007).  
(C) DNA methylation 
 DNA methylation involves covalent transfer of methyl group to the carbon at 
the 5th position (C-5) of the cytosine ring of DNA by DNA methyltransferases 
(DNMTs) (Jin et al 2011). While over 98% of methylation occurs at CpG islands 
(CGIs) in the somatic cells, but in embryonic stem cells around 25% of all 
methylation occurs at non CpG context (Lister et al., 2009). DNA methylation, 
together with histone modification, regulates the gene transcription by condensing 
the chromatin and restricting the cellular transcription factors from accessing the 
DNA (Cedar and Bergman, 2009). The role of CpG methylation as an important 
factor in the maintenance and stability of HIV latency has been showed by many 
research groups (Bednarik et al., 1990, Schulze-Forster et al., 1990, Blazkova et al., 
2009, Kauder et al., 2009). The two CpG islands flanking the transcription start site 
of HIV-1 5’LTR are methylated in latently infected J-Lat T cells and primary CD4+T 
cells and methyl-CpG binding domain protein 2 (MBD2) and HDAC2 are found at 
one of these CpG islands during latency. Also, MBD2 acts as a regulator of HIV-1 
latency. (Kauder et al., 2009). However, results from memory CD4+T cells separated 
from HIV-1 infected aviremic individuals are contrasting as high (19 - 100%) CpG 
methylation at 5’LTR was observed in long term (over 11 years) cART treated 
indvidulas where as the methylated CpGs in individuals treated for less than 5 years 
are very low ( only 1 - 2%) (Blazkova et al., 2009; Blazkova et al., 2012 and 
Trejbalova et al., 2016). The percentage of methylation in HIV-1 proviral promoters is 
higher in long-term nonprogressor and elite controller patients who control viremia 
than aviremic patients receiving HAART (Palacios et al., 2012). 
27 
 
(D) Chromatin remodelling of HIV promoter  
 Independent of the host integration site, the HIV-1 LTR has two nucleosomes, 
nuc-0 and nuc-1 upstream and downstream of transcription start site, separated by 
approximately 265 nt nucleosome-free region (Verdin et al., 1993). The nucleosomes 
are positioned near the cis- acting regulatory elements in the 5’LTR. The nuc-1 is 
positioned downstream and in close proximity of transcription initiation site. The 
cellular transcription factors such as late SV40 factor (LSF), ying yang 1 (YY1), 
activating protein 4 (AP-4), NFkB p50/50 homodimers, C-promoter binding factor-1 
(CBF-1) etc., have been showed to recruit HDAC1 to the latent HIV-1 5’LTR 
(Romerio et al., 1997; Imai and Okamoto, 2006; Williams et al., 2006;  Tyagi and 
Karn, 2007) which leads to deacetylation of nuc-1 and configuring nuc-1 to 
repressive state. Disruption and displacement of nuc-1 during transcriptional 
activation suggests the chromatin remodelling of nuc-1 and its crucial role in 
maintaining the provirus transcriptionally silent (Van Lint et al., 1996). 
(E) RNA interference 
 The microRNAs (miRNA) are single-stranded noncoding RNAs approx. 19-25 
nucleotides in length. They are ubiquitous, endogenously expressed and function as 
gene regulators by inducing degradation or inducing translational inhibition of their 
target mRNAs (Tan Gana et al., 2012). The primary-miRNA precursor is transcribed 
from the intergenic regions of the genome by RNA polymerase II (RNAP-II) which is 
cleaved to 70 nt long preliminary-miRNA by RNase III endonuclease Drosha and 
DiGeorge critical region gene 8 (DGCR8), a ribonuclease binding protein (RBP) and 
transported from nucleus to cytoplasm (Faller et al., 2010). In the cytoplasm the pre-
miRNA is cleaved by Dicer (also an RNase III endonuclease) to an asymmetric 
duplex of mature-miRNA (Hammond, 2005). Post-transcriptional gene silencing 
(PTGS) of gene expression by miRNA is achieved by guiding the RNA-induced 
Silencing Complex (RISC), the effector complex of RNAi, to the target mRNA that 
results in endonucleolytic cleavage of the target. 
 Post transcriptional modification by RNA interference has been shown as one 
of the factors involved in inhibiting HIV-1 replication and silencing provirus gene 
expression (Sanchez-Del Cojo et al., 2011). Cellular miRNAs, including miR-28, 
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miR-125b, miR-150, miR-223 and miR-382 share sequence complementarity with 
the 3’ end of HIV mRNA and can inhibit HIV replication. Specific inhibitors of these 
miRNAs substantially increased virus production in resting CD4+T isolated from HIV-
1-infected individuals on suppressive HAART and also in CD4+ T cells transfected 
with HIV-1 infectious clones. This finding indicates that cellular miRNAs are pivotal in 
HIV-1 latency maintenance (Huang et al., 2007). In general, the quiescent monocyte 
is not supportive for HIV-1 infection, while the monocyte-derived macrophages are 
highly susceptible (Bergamaschi and Pancino, 2010). Also these miRNAs (miRNA-
28, miRNA-150, miRNA-223, and miRNA-382) are enriched in monocytes in 
comparison with monocyte-derived macrophages. The suppression of these anti-
HIV-1 miRNAs in monocytes facilitates HIV-1 infectivity, whereas increase of the 
anti-HIV-1 miRNA expression in macrophages inhibited HIV-1 replication. These 
results support the anti-HIV-1 properties of the cellular miRNAs (Wang et al., 2009). 
Cellular miRNA, namely miR-15a, miR-15b, miR-16, miR-24, miR-29a, miR-29b, 
miR-150, and miR-223 that are directly targeting HIV-1 Nef-3′-LTR region, exhibiting 
significant inhibitory effects on HIV-1 replication and promoting latency (Sun et al., 
2012, Patel et al., 2014). Recent studies suggest two more cellular microRNAs, miR-
196b and miR-1290 target the 3' untranslated region of HIV-1 and affect its 
expression in latently infected and productively infected cells, again emphasizing the 
role of cellular miRNAs in HIV-1 latency regulation (Wang et al., 2015). In addition to 
binding to the HIV-1 mRNA and regulating its expression, cellular miRNAs also 
interfere with the cellular factors that are directly or indirectly required for HIV gene 
expression. For example, miR-198 inhibits HIV-1 gene expression and replication in 
monocytes via repression of cyclin T1 which is a regulatory subunit of a cellular RNA 
polymerase II elongation factor known as P-TEFb (positive transcription elongation 
factor b). Cyclin T1 is also required for Tat transactivation of HIV-1 LTR-directed 
gene expression (Sung and Rice, 2009). When the virus replication is inhibited by 
type III RNases Dicer and Drosha, the HIV-1 in turn, actively suppressed the 
expression of the polycistronic miRNA cluster miR-17/92 to support its own 
replication. As miR-17/92 can target and block cellular proteins such as p300-CREB 
binding protein-associated factor (PCAF) that are necessary for HIV gene 
expression, the counter attack on miR-17/92 by HIV becomes important. These 
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results highlight the involvement of the miRNA-silencing pathway in HIV-1 replication 
and latency (Triboulet et al., 2007). 
 On the other hand, though very low in number, HIV-1 encoded viral 
micoRNAs (vmiRNA) also interact with viral and cellular mRNAs and proteins (Yeung 
et al., 2009). HIV-1 TAR microRNA (hiv1-miR-TAR) transcribed from the TAR 
element in the 5’ LTR, H1 microRNA (hiv1-miR-H1) originated from 3′ U3 LTR 
region, Nef microRNA (hiv1-miR-N367) and HIV-1 anti-sene microRNAs are 
examples of the vmiRNA families that were shown to interact with various potent 
cellular and viral targets to enhance HIV-1 replication or to maintain latency (Tan 
Gana et al., 2012, Swaminathan et al., 2014). 
3.1.4.3 LTR and Transcription factors: the cis and trans elements in latency 
and reversal 
 The HIV 5’LTR is functionally divided into four elements; the Tat activating 
region (TAR), the promoter, the enhancer and the modulatory element (Schiralli 
Lester and Henderson, 2012). The U3 region of 5’LTR contains binding sites for 
several transcription factors that are ubiquitous or tissue specific and play a key role 
in HIV gene expression (Verdin et al., 1993; Van Lint et al., 1996; Rohr et al., 2003). 
The key sites of the promoter sequence are TATA box, a potent initiator sequence 
and the GC-rich binding sites for the Sp family of transcription factors including Sp-1 
(specificity protein 1) (Jones and Peterlin, 1994). The enhancer element contains two 
binding sites for nuclear factor kappa B (NF-kB) and related factors (Nabel and 
Baltimore, 1987). The modulatory region, which is upstream of the NF-kB sites, 
contains binding sites for numerous factors, including CCAAT/enhancer binding 
protein (C/EBP) factors (Henderson et al., 1995), activating transcription factor/cyclic 
AMP response element binding (ATF/CREB) factors (Krebs et al., 1997), lymphocyte 
enhancer factor (LEF-1), nuclear factor of activated T cells (NFAT) (Shaw et al., 
1988), CD28 responsive element (CD28RE) (Duverger et al., 2013) (Fig. 4) . Since 
the proviral reservoir is established within resting memory CD4+T cell in which the 
important cellular transcription factors such as NF-κB and NFAT are sequestered in 
the cytoplasm and not active, the transcription initiation is inhibited (Colin and Van 
Lint, 2009). Upon T-cell activation by external stimulants, the transcription factors are 
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freed from their inhibitors and are transported into the nucleus where they bind to 
their respective binding sites in the enhancer region of 5’LTR, resulting in provirus 
expression.  
 
Fig. 4. HIV-1 LTR promoter contains multiple binding sites for several key 
transcription factors. (Image source: Colin and Van Lint, 2009) 
 Even though the host transcription factors binding to 5’LTR can initiate latent 
virus transcription, the expression level is very low. The basal transcription is 
boosted by a viral trans-activating protein Tat. Tat interacts with the cis-acting RNA 
element TAR (Transactivation response element) that forms a RNA stem loop 
structure, present at the 5'end of each newly formed viral transcripts (Berkhout et al., 
1989). Tat plays a pivotal role in HIV transcription through the number of protein-
protein and protein-RNA interactions that pave the way for the transcriptionally active 
complexes to assemble at the LTR. HATs, such as the CREB-binding protein 
(CBP)/p300 complex, are recruited to the HIV-1 promoter region by Tat. These 
enzymes then acetylate the nucleosomes on the promoter and make the viral LTR 
accessible for transcription initiation (Pumfery et al., 2003). The host transcription 
factor Sp1 is phosphorylated and activated by Tat induced dsDNA-dependent protein 
kinase (DNA-PK) and consequently, Sp1 proteins bind to LTR to upregulate the HIV-
1 promoter (Chun et al., 1998). The tight regulation of Tat by ubiquitination reveals 
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the close interplay between the viral trans-activator and the host cell (Bres et al., 
2003).  
 Together with the above described viral and cellular cis- and trans- factors 
that are necessary for transcription initiation, other factors that contribute to the 
transcription elongation of full length viral mRNA also determine the successful 
prolongation of latency and/or its reversal and gene expression.   
 The HIV-1 proviral DNA is transcribed by cellular RNA polymerase II enzyme 
(RNAPII). Transcription initiated by RNAPII in response to various cell stimulation 
signals produces the early regulatory protein Tat which is essential for the elongation 
phase of HIV-1 transcription (Colin and Van Lint, 2009; Feinberg et al., 1991). Since 
the RNAPII is associated with two negative elongation factors, DRB sensitivity-
inducing factor (DSIF) and negative elongation factor (NELF) that inhibit RNAPII 
processivity,  the progress of transcription initiation to elongation phase is impeded 
(Yamaguchi et al., 2002). The cellular positive transcription elongation factor b (P-
TEFb) complex recruited by Tat helps to overcome this block (Peterlin and Price, 
2006). P-TEFb complex is composed of regulatory subunit cyclin T1 and catalytic 
subunit cyclin-dependent kinase 9 (CDK9) proteins (Price, 2000). P-TEFb complex 
phosphorylates serine residues in the C-terminal domain (CTD) of RNA polymerase 
II and also it releases RNAPII from promoter-proximal pausing by phosphorylating 
NELF and DSIF. These events potentiate RNA polymerase II to synthesize full-
length HIV transcripts (Williams et al., 2006). In activated cells, the P-TEFb is 
associated either with a 7SK RNP complex or with a chromatin-binding 
bromodomain protein BRD4. While the association of 7SK RNP complex inhibits P-
TEFb activity (Yang et al., 2001), the BRD4 activates P-TEFb and stimulates 
transcriptional elongation of a wide range of genes (Yang et al., 2008; Itzen et al., 
2014). 
 Recruitment of P-TEFb to the TAR RNA element by Tat is a crucial step in 
HIV-1 transcriptional activation. TAR hairpin contains a highly conserved 3-
nucleotide (nt) pyrimidine bulge that binds the Tat protein and an apical 6-nt loop to 
which the transcriptional elongation factor P-TEFb binds in a Tat-dependent manner 
(Wei et al., 1998; Rana and Jeang, 1999; Richter et al., 2002). P-TEFb also directs 
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the recruitment of TATA box binding protein to the LTR promoter and thus stimulates 
the assembly of new transcription complexes (Raha et al., 2005). Recent studies 
show that P-TEFb is not a discrete elongation factor, rather it is an integral part of a 
much bigger “super elongation complex” (SEC) where several other proteins such as 
AF4/FMR2 family proteins AFF1 and AFF4 and ELL family of elongation stimulatory 
factors ELL1 or ELL2 are also playing a part in RNAPII elongation (He et al., 2010; 
Sobhian et al., 2010; Chou et al., 2013). 
3.1.5. ‘Shock and Kill’ - Latency reversing agents 
 Combined antiretroviral therapy (cART) can successfully suppress the 
viraemia to undetectable levels and can facilitate the prolongation of the infected 
individual’s lifespan. Nevertheless, it cannot completely cure the infection, due to the 
inaccessible reservoirs of latent HIV-1 (Richman et al., 2009).  If cART is interrupted, 
the persistent latent virus in the reservoirs like the resting CD+T cells would re-
emerge rapidly and produce infectious virions, resulting in new episodes of active 
infection (Wong et al., 1997, Davey et al., 1999, Siliciano and Greene, 2011). Hence, 
the infected person must stay on therapy for the rest of the life, while cART reveals 
many adverse effects associated with metabolic, cardiovascular and renal diseases 
and toxicities (de Gaetano Donati et al., 2010, Fortuny et al., 2015).  
 Dieffenbach and Fauci have defined two types of cures – the sterilizing cure 
and the functional cure. A complete eradication of all replication-competent forms of 
the virus and the viral reservoirs from the infected person means a sterilizing cure, 
whereas a permanent control of virus replication without therapy represents a 
functional cure (Dieffenbach and Fauci, 2011). To achieve a sterilizing cure, the 
“shock and kill” strategy is currently the focus of many research groups. Reactivating 
the latent virus by stimulating the resting CD4+T cells is the “shock”, while “kill” is 
purging the activated reservoir cells as a result of induced viral cytopathic effects, 
immune clearance by cytolytic T lymphocytes (CTL) and cell death. To prevent the 
newly produced viruses from infecting other uninfected cells, the reactivation of 
latent virus must be carried out in conjunction with cART (Deeks et al, 2012; Shan et 
al., 2012).  
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 In the beginning, attempts were made to reactivate the latent HIV-1 through 
activating T cells globally by combination of cytokines like interlukin-6 (IL-6), tumour 
necrosis factor alpha (TNF-α) or immunoregulatory cytokine interlukin-2 (IL-2) in 
conjunction with ART (Chun et al., 1998; Chun et al., 1999a). This strategy was 
termed as immune activation therapy (IAT). This combination of cytokines 
reactivated latent virus ex vivo in resting CD4+T cells obtained from HIV-1 infected 
individuals with or without HAART treatment.  But in vivo, when the treatment was 
interrupted, within 2-3 weeks a detectable plasma viremia re-emerged, suggesting 
an only partial purge of the reservoir (Chun et al., 1999b; Dybul et al., 2002). Also, 
global T cell activation might result in increased number of uninfected target cells 
and increased virus production beyond the controlling threshold of antiretroviral 
therapy. Later strategies harnessed the molecules that selectively reactivate the 
latent provirus with minimal effect on the host cells. The compounds that can 
reactivate the latent virus are termed as ‘latency reversing agents’ (LRA). Blocking or 
activating the factors involved in the establishment of latency, maintenance of 
transcriptional silence, reactivation, initiation and elongation of provirus transcription 
are the targets of LRA.  
(A) HDAC inhibitors 
 Inhibition of HDAC activity, thereby forming euchromatin, and increasing the 
accessibility of transcription factors for proviral DNA to facilitate the transcription is 
the principle of this strategy. All the four classes of HDAC inhibitors (HDACi): short-
chain aliphatic acids, hydroxamic acid, benzamides, and cyclic tetrapeptides and 
despeptides have been showed to reactivate the provirus in latently infected T cell 
lines and in resting CD4+ T cells isolated from HIV-1 infected, cART-treated patients 
(Shang et al., 2015). Valproic acid (VPA), a short chain aliphatic acid and inhibitor of 
HDAC, was shown to induce the expression of quiescent provirus without fully 
activating the resting CD4+T cells of aviremic patients ex vivo (Ylisastigui et al., 
2004). But in vivo, it depleted resting CD4+T cell infection (RCI) only in patients with 
intensified ART (Lehrman et al., 2005) and failed to deplete RCI in patients with 
standard ART (Archin et al., 2008). Later it was found out that inhibition of HDAC1 
isoform alone is not sufficient to induce provirus gene expression and an additional 
inhibition of another isoform HDAC3 is necessary to reactivate the latent virus. In 
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case of valproic acid, its potency to inhibit HDAC3 is weak relative to HDAC1 (Huber 
et al., 2011). Hydroxamic acid HDAC inhibitor vorinostat (suberoylanilide hydroxamic 
acid; SAHA), is another well studied HDAC inhibitor. SAHA has been shown to 
induce provirus expression and to increase the unspliced cellular HIV-1 RNA levels 
in resting CD4+ T cells (Archin et al., 2012), but only a very small percentage 
(0.079%) of proviruses in resting CD4+ T cells were reactivated to produce virions 
(Cillo et al., 2014). Panobinostat is another potent HDACi that showed comparatively 
higher latency reversal activity than many other HDACis (Rasmussen et al., 2013). 
Loss of intestinal T helper 17 cells (Th17) in HIV-1 infection leads to damage in the 
muscosal barrier and to disease progression. In a recent clinical study, it was 
observed that while reactivating the latent provirus, panobinostat also increased 
Th17 cell activity and improved mucosal barrier function (Bjerg Christensen, 2015). 
Many more studies are exploring the potency of various new HDACi’s to reactivate 
the latent HIV-1. To name a few, Oxamflatin (Yin et al., 2011), natural cyclic peptide 
Romidepsin (Istodax) (Wei et al., 2014), thiol-based HDACi ST7612AA1 (Badia et 
al., 2015). 
(B) HMT inhibitors 
 As described earlier, histone methyltransferases like SUV39H1 and G9a 
methyltransferases play a role in transcriptional silencing of latent HIV-1 and 
consequently, the compounds that inhibit these enzymes are actively searched for 
exploiting them as potent latency reversing agents (Kumar et al, 2015). Chaetocin, a 
fungal mycotoxin from Chaetomium minutum belongs to 3–6-epi-dithio-
diketopiperazines, acts as a specific inhibitor of Suv39H1 (Bernhard et al., 2011) has 
been shown to induce latent HIV-1 without producing a T cell response. Another 
molecule BIX-01294, a diazepin-quinazolin-amine derivative, functions as a specific 
inhibitor of G9a (Kubicek et al., 2007) also reactivates the provirus from latency (Imai 
et al., 2010). Later a detailed study reported that chaetocin induced HIV-1 recovery 
in 50% of CD8+-depleted PBMCs cultures and in 86% of resting CD4+ T-cell 
isolated from HIV-1-infected, HAART-treated patients, whereas BIX-01294 
reactivated HIV-1 expression in 80% of resting CD4+ T-cell cultures isolated from 
similar patients. This study also showed that the synergistic action of both these 
compounds with prostratin have even stronger reactivation potential (Bouchat et al., 
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2012). HMT inhibitors and HDAC inhibitors are reported to synergistically induce the 
reactivation of latent HIV-1. An example to this is, enhancer of zeste 2 Polycomb 
repressive complex 2 subunit 1 or 2 EZH1/EZH2 (a HMTi) demethylates H3K27. 
This epigenetic change does not induce provirus gene expression, but a subsequent 
exposure to HDACi SAHA resulted in an increased expression of HIV-1 provirus 
from resting CD4+T cells (Tripathy et al, 2015).  
(C) DNMT inhibitors 
 Along with HDACis and HMTis, DNA methyltransferase inhibitors are also 
considered as epigenetic therapeutics for HIV-1 infection. DNMT inhibitor 5-aza-
2′deoxycytidine (aza-CdR) was shown to inhibit cytosine methylation and abrogate 
recruitment of MBD2 and HDAC2 at the CpG islands flanking the HIV-1 transcription 
start site. The reactivation of latent HIV-1 by aza-CdR was significantly enhanced in 
synergy with the NF-κB activators prostratin or TNF-α (Kauder et al., 2009). 
However, when examining the effect of aza-CdR with TNF-α more closely, a 
syngeristic action was found to be different for different cell lines. In Jurkat T cell-
derived J-Lat cell lines (6.3, 8.4 and 9.2) the aza-CdR plus TNF-α combination 
increased the reactivation of latent HIV-1 at least two fold when compared to TNF- α 
alone. In contrast it decreased the reactivation in J-Lat 10.6, ACH-2, J1.1 and U1 cell 
lines (Fernandez and Zeichner, 2010). Overall, there is a need to explore more new 
DNMTis with synergising compound combinations to develop DNMT inhibitors as a 
possible molecule for HIV-1 latency reversal. 
(D) Protein kinase C activators 
 The protein kinase C (PKC) signal cascade is one of the well known cellular 
signal transduction pathways, affecting most important cellular functions such as cell 
growth, differentiation, maturation and death (Spitaler and Cantrell, 2004). Phorbol 
esters promote activation of monocytes and T cells, through the action of PKC. As 
mentioned in earlier sections, reactivation and expression of latent HIV-1 is highly 
dependent on the availability of host transcription factors, such as NF-κB, NFAT and 
AP1, and transcriptional elongation factor P-TEFb. PKC family serine-threonine 
kinases are important for degradation of IκB-α (an inhibitor of NF-κB) and nuclear 
translocation of the activated NF-κB that is required for latent HIV reactivation.  
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 Phorbol esters such as phorbol-12-myristate 13-acetate (PMA) and prostratin, 
and lactones like bryostatin-1 can act as analogues of DAG (an important second 
messenger molecule in the PKC pathway) and induce latent proviral expression 
(McKernan et al., 2012). Bryostatin-1 showed a significant ex vivo potency to 
revert HIV-1 latency, compared to other LRA, but in a recent phase I trial the drug 
did not show any effect on PKC activity or on the transcription of latent HIV, probably 
due to low plasma concentrations (Gutiérrez et al., 2016). Even though phorbol 
esters and DAG analogue lactones activate PKC family kinases, the PKC isoforms 
they target are different. For example, PMA or prostratin induce latent HIV-1 
transcription by the sequential action of PKC α and PKC θ isoforms (Trushin et al., 
2005), while bryostatin-1 reactivates through PKC α and PKC δ (Mehla, 2010). PMA 
is a known T cell activator and tumor promoting phorbol ester, while prostratin is a 
non-tumorigenic phorbol ester, extracted from the barks of Samoan medicinal plant, 
Homalanthus nutans. Prostratin inhibits HIV-1 infection and viral spread (Gustafson 
et al., 1992) and also reactivates latent provirus from cells (Gulakowski, 1997). The 
anti-HIV-1 effects of prostratin is associated with its ability to down regulate the 
expression of CD4 receptor, the primary receptor for HIV-1, and also it down-
regulates the HIV-1 co-receptors CXCR4 and CCR5. Non-tumorigenic property, 
inhibition of HIV-1 infection and yet reactivation of the latent provirus, all these 
qualities suggest that prostratin may be a potential inductive adjuvant for cART 
(Kulkosky et al., 2001).  
 Ingenol, another PKC inducer, is also a natural compound isolated from the 
succulent plant Euphorbia tirucalli. Derivatives of ingenol inhibit HIV-1 infection by 
down-regulating CD4 and CXCR4 receptors (Hong et al., 2011). Another ingenol 
derivate, 3-caproyl-ingenol (ingenol B, ING B) reactivates the latent HIV-1 gene 
transcription through PKC activation and NF-κB nuclear translocation. Notably, in 
both HIV latency models and HIV infected primary resting cells, ING B induces 
higher levels of reactivation when compared to TNF-α, PMA, SAHA and HMBA (Jose 
et al., 2014). A novel ingenol synthetic derivative (ISD) plays a dual role in HIV-1 
infection, inhibiting the de novo infection while reactivating provirus from latency 
(Abreu, 2014). In general, growing numbers of natural and synthetic PKC inducers 
that exhibit anti-HIV-1 activity, lower toxicity and potent reactivation property, with 
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some of which being dual players in HIV-1 infection, are among the most interesting 
molecules in the realm of functional and sterilizing therapies of HIV-1 infection. 
(E) Other unclassified LRAs 
 BRG-Brahma associated factors (BAF) are ATP-dependent chromatin 
remodelling complexes. Two small molecule inhibitors of BAF (BAFi), caffeic acid 
phenethylester and pyrimethamine, have been shown to reactivate latent HIV-1 
through the removal of a repressive nucleosome nuc-1, without inducing a general T 
cell activation. These BAF inhibitors synergistically enhanced the induction of latency 
reversal with HDAC inhibitor SAHA and with PKC agonist prostratin in latently 
infected T cell lines, ex vivo infected primary cells and cells from aviremic HIV-1 
infected individuals (Stoszko et al., 2016).  
 Disulfiram, an inhibitor of acetaldehyde dehydrogenase used to treat 
alcoholism, has been shown to reactivate latent HIV-1 (Xing et al., 2011) through 
depleting phosphatase and tensin homolog (PTEN) protein (Doyon et al., 2013) . A 
recent pilot study showed that a short-term administration of disulfiram increased 
cell-associated unspliced HIV RNA, consistent with activating HIV latency and the 
study suggested that disulfiram might be suited for future studies of combination and 
prolonged therapy to activate latent HIV (Elliott et al., 2014). 
 Another recent and novel approach to reactivate latent HIV-1 provirus is 
based on exploiting the customizable DNA-binding platforms such as engineered 
zinc-finger, transcription activator-like effector (TALE) proteins, as well as CRISPR-
Cas9. Wang and colleagues, for the first time demonstrated the reactivation of HIV-1 
expression from latently infected cells using engineered zinc finger transcription 
factors. The custom zinc finger transcription factor named as ZF-VP64 is composed 
of designer zinc-finger proteins and the herpes simplex virus-based transcriptional 
activator VP64 domain. The reactivation of HIV-1 by ZF-VP64 occurs through 
specific binding to the 5′-LTR promoter and  without altering cell proliferation or cell 
cycle progression  (Wang et al., 2014). 
 Transcription activator-like effectors (TALEs), originating from Xanthomonas 
plant pathogens, are a class of transcriptional activators (Miller et al., 2011). 
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Artificially designed TALE fusion proteins, containing a DNA-binding domain 
specifically targeting the HIV-1 promoter and the herpes simplex virus-based 
transcriptional activator VP64 domain has been shown to reactivate latent HIV-1 via 
a specific binding to the HIV-LTR promoter. Also, the TALE-VP64 fusion protein did 
not affect cell proliferation or cell cycle distribution while reactivating the latent 
provirus (Wang et al., 2015). Moreover, complementing TALE transcription factors 
with HDAC inhibitors can further enhance TALE-induced activation of latent HIV-1 
expression (Perdigao et al., 2016).  
 RNA-guided CRISPR-Cas9 system comprises single guide RNAs (sgRNAs) 
with a nuclease-deficient Cas9 mutant (dCas9) fused to the VP64 transactivation 
domain (dCas9-VP64). A CRISPR-Cas9 system engineered to target a “hotspot” in 
the enhancer sequence of HIV-1 5’LTR consistently and effectively reactivated latent 
HIV-1 mediated by activator sgRNAs, across multiple different in vitro latency cell 
models (Saayman et al., 2015). Another transcriptional system, dCas9-SunTag-
VP64, with guide RNA (sgRNA) targeting specific sequences upstream of the 
transcription start sites of HIV-1 was also shown to reactive latent HIV-1, without 
exhibiting genotoxicity and global T-cell activation (Ji et al., 2016). These novel 
approaches provide new means for reactivating the virus from the latent reservoirs 
and could contribute to the development of next-generation HIV-1 therapies. 
3.1.6. Model systems to study HIV-1 latency 
 In vitro and in vivo HIV-1 latency model systems have greatly helped in 
understanding the molecular mechanisms underlying latency establishment, 
maintenance and reactivation. Also, primary screening and efficacy evaluation of 
latency reversing drugs are routinely conducted in these in vitro and in vivo models. 
The cell- and animal-based models are the two main model systems to study the 




Fig. 5. Model systems to study HIV-1 latency. Cell based models (a, b and c) and animal 
based models (d, e and f) (Image source: Archin et al., 2014). 
(A) Cell-based latency models 
 Immortalised T cell and monocyte cell lines that contain either a complete 
HIV-1 DNA or a minimal HIV-1 DNA promoter with a reporter gene for readout, 
integrated into the cellular chromosomes are widely used to study the HIV-1 latency 
and reactivation. ACH-2 cells derived from parental A3.01 T cell line containing one 
integrated HIV-1 proviral copy (Clouse et al., 1989, Folks et al., 1989), J-Lat cells 
derived from Jurkat T cell clones containing full length HIV-1 without nef and env 
(Jordan et al., 2003), U1 cell line, a sub clone of pro-monocytic cell line U937 that 
has been chronically infected with HIV-1 (Folks, et al., 1987), several Jurkat cell 
clones that harbour HIV-1 “mini-virus” (containing EGFP reporter cloned under HIV-1 
LTR) (Jordan et al.,  2001) are a few examples of such transformed cell lines that 
serve as HIV-1 latency models. Despite of the usefulness in basic and applied 
studies, none of these model system could fully recapitulate the in vivo latency 
environment of an infected person. In a study where a panel of thirteen molecules 
known to reactivate HIV-1 were tested across different latent cell models including 
five primary T cell models, four J-Lat cell models and resting CD4+ T cells from 
aviremic patients, to compare the responsive properties of these different cell models 
to latency reactivating drugs. The results indicated that no single in vitro cell model 
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alone was able to recapitulate accurately the ex vivo response characteristics of 
latently infected T cells from patients. Also, it made clear that the latency reactivation 
by most drugs is not uniform across the different cell models (Spina et al., 2013).  
 Despite the fact that the frequency of latent CD4+ memory T cells is very low 
(1 in 106 memory CD4+ T cells), isolating resting CD4+ T cells from HIV-1  infected, 
cART-treated aviraemic patients is a valuable method to study HIV latency or the 
effect of putative LRAs ex vivo (Archin et al, 2014). To mimic the resting stage of 
latent CD4+ T cells, active CD4+ T cells isolated from uninfected healthy donors are 
infected with HIV or HIV-derived vectors, followed by the induction of a resting state. 
This in vitro generation of memory T cells is a tedious process and only few cells 
transform to quiescent stage (MacLeod et al., 2010). Direct infection of resting CD4+ 
T cells in the absence of any stimuli (Swiggard et al., 2005) ; transducing active 
CD4+ T cells isolated from uninfected donors with Bcl-2, to increase the lifespan of 
the cells in culture and to allow them to return back to the resting stage and to 
establish latency by infecting with HIV-1 vector (Yang et al., 2009) are other ways to 
study latency in primary cell models. 
(B) Animal models of latency 
 SCID (severe combined immune deficiency) mice are the base for the 
development of many humanised mouse models to study HIV-1 pathogenesis. scid-
hu-Thy/Liv mice are generated by transplanting human foetus thymus and liver cells 
into scid mice. They produce human haematopoietic progenitor stem cells (CD34+) 
and mature human lymphocytes and HIV-1 latency could be established during 
thymopoiesis (Brooks et al., 2001). A novel variant of scid-hu-Thy/Liv mouse named 
NSG-hu-Thy/Liv (TOM, T cell only mice) has been developed and shown to be a 
promising tool in studying HIV-1 latency establishment, with no graft-versus-host 
disease (Honeycutt et al., 2013). BLT mice generated by transplanting human bone 
marrow-liver-thymus are superior model over scid-hu-Thy/Liv mice, as they can 
provide peripheral reconstitution with multiple haematopoietic lineages. HIV-1 
latency has been established in BLT mice with integrated, activation-inducible, 
replication-competent virus infection (Marsden et al., 2012). 
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 Recent advances in HAART that made possible a successful control of SIV  in 
non-human primates have open the doors to study HIV-1 latency in these system 
(North et al., 2010). The possibility of studying different organs in non-human 
primates makes them more advantageous models to study virus latency. Non-human 
primates have immune responses that resemble human immune response but the 
HIV-1 latency in human lasts for many years while latency in non-human primates is 
only few months (Pace et al., 2011). 
3.1.7. Assays to quantify latent reservoir 
 Quantifying the latent reservoir is important to evaluate the efficacy of latency 
reversal-based strategies to eradicate the reservoir. Quantitative viral outgrowth 
assay (Q-VOA) (Finzi et al, 1997; Siliciano and Siliciano, 2005, Laird et al., 2013) is 
considered as a golden standard to quantify the number of latently infected cells 
carrying replication competent virus. In this method highly purified latently infected 
resting CD4+ T cells isolated from an HIV patient are serially diluted and maximally 
stimulated to reactivate the latent provirus. To expand the virus produced from the 
reactivated latent reservoirs, activated PBMCs from healthy donors are added. After 
the incubation, HIV-1 p24 is quantified by ELISA or PCR to estimate the number of 
original latently infected cells. However, Q-VOA is laborious, expensive, requiring 
large volume of blood, highly time consuming and possibly underestimating the size 
of the latent reservoir (Ho et al., 2013). qPCR-based methods are being developed 
as an alternative to Q-VOA. However, qPCR-based assays could overestimate the 
latent reservoir as they measure all cell-associated DNA or different RNA species, 
including both functional and abortive transcription (Pasternak et al., 2013). Prime 
Flow RNA is a latest development in quantification of latency reservoirs. It combines 
cell-based detection of proteins with antibodies and detection of intracellular RNA 
with specific probes. It was reported to detect 1 infected cell/104-105 (Romerio and 
Zapata, 2015). 
3.2 Heme Arginate 
 Hematin, used in the treatment of acute hepatic porphyrias is highly unstable. 
Consequently, a search for a stable heme preparation led to the development of 
heme arginate by Tenhunen and his colleagues in 1987 (Tenhunen et al., 1987). 
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Heme arginate is a product of pure hemin isolated from human blood complexed 
with amino acid L-arginine (Fig.6). The stability of heme arginate is better than 
hematin, the degradation rates in 4 hours is 1% for heme arginate, whereas it is 61% 
for hematin. Due to the increased stability, heme arginate has lesser side effects in 
homeostasis than hematin (Volin et al., 1988). It is an approved drug (Normosang, 
Orphan Europe) used to treat acute hepatic porphyrias and available outside the 
USA.  In addition several positive effects of heme arginate has been reported, for 
example, HA decreases the blood pressure in spontaneously hypertensive rats 
(Levere et al., 1990), ameliorates murine type 2 diabetes (Choudhary et al., 2013), 
improves reperfusion patterns after ischemia (Andreas et al., 2012). 
 
Fig. 6. Two dimensional structure of heme arginate (Image source: PubChem) 
3.2.1 Heme catabolism 
 Heme is catabolised by heme oxygenases (HO-1,2), leading to formation of 
equimolar amounts of biliverdin, free iron (Fe2+)  and carbon monoxide. The formed 
biliverdin is rapidly reduced to bilirubin by biliverdin reductase (Tenhunen et al., 
1968). There are three isoforms of heme oxygenase, heme oxygenase-1 (HO-1) 
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which is inducible and heme oxygenase-2 that is expressed constitutively. HO-1 is 
inducible by its natural substrate heme and a large number of structurally unrelated 
agents and variety of circumstances like oxidative stress, hypoxia, heat shock, 
reactive oxygen species (ROS), nitric oxide (NO) etc., (Fig. 7) (Abraham and 
Kappas, 2008). HO is considered as an important antioxidant enzyme and its 
cytoprotective effects are defined by the antioxidant potencies of CO and bilirubin 
(Parfenova et al., 2006). There are many research articles reporting a therapeutic 
role of HO in metabolic diseases (Son et al., 2013), cardiovascular diseases 
(Immenschuh and Schroder, 2006), lung diseases (Raval and Lee, 2010), renal 
diseases (Jarmi and Agarwal, 2009), cancer (Chau, 2015), neurodegenerative 
diseases (Cuadrado and Rojo, 2008), diabetes (Tiwari and Ndisang, 2014). 
 In vitro, heme (Fe2+, ferroprotoporphyrin IX) has been demonstrated as very 
efficient in inhibiting HIV-1 reverse transcription (Argyris et al., 2001; Levere et al., 
1991). Further, hemin (Fe3+, ferriprotoporphyrin IX) ameliorated HIV-1 infection in 
humanized mice, and heme oxygenase-1 (HO-1) was suggested to be responsible 
for the inhibitory effect (Devadas and Dhawan, 2006). 
 
Fig. 7. Heme degradation by heme oxygenase. HO-1 and HO-2 degrades heme to yield 
Biliverdin, iron and CO. Biliverdin is reduced immediately by biliverdin reductase to bilirubin. 
HO-1 is inducible by variety of stress including heat shock, oxidative stress, ROS, UV light 
etc., (Image source: Abraham and Kappas, 2008) 
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3.2.1.1 Iron  
 Iron is an essential trace element present in biological systems in either 
ferrous (Fe2+) or ferric (Fe3+) state.  Iron is also an essential co-factor for many 
important biological activities, including transport of oxygen via red blood cells 
(Galaris and Pantopoulos, 2008). Iron generated by HO-catalysed degradation of 
heme is sequestered by ferritin protein and ferritin expression is induced by 
increased iron concentration (Paller and Jacob, 1994). Free iron (Fe2+) produced 
from heme degradation is pro-oxidative and was shown to generate ROS. Iron and 
ROS are recognised as initiators and mediators of cell death in a variety of 
pathological situations (Dixon and Stockwell, 2014).  
 Iron metabolism plays a central role in HIV-1 replication. The decline in iron 
stores due to poor adsorption in early HIV-1 infection may however increase later 
due to iron accumulation in macrophages and other cells as the disease progress 
(Drakesmith and Prentice, 2008). There are many reports correlating the high iron 
status with increased HIV-1 infection and replication (McDermid et al., 2007; Rawat 
et al., 2009; Chang et al., 2014). Four different clinical observations have shown the 
possibility that high iron status may adversely affect the outcome of HIV-1 infection 
(Gordeuk et al., 2001). In addition, plasma iron burden has been shown to increase 
due to release of a bound iron from the apoproteins as a result of increased oxidative 
stress (Award, 2006). Anaemia or iron deficiency (ID) is common in chronic HIV-1 
infection (Redig and Berliner, 2013). The liver produced hormone hepcidin regulates 
systemic iron homeostasis by inhibiting ferroportin. Increased hepcidin and 
decreased plasma iron levels has been observed in HIV-1 acute infection, also 
hepcidin remained elevated in untreated or cART-treated persons with chronic HIV-1 
infection (Armitage et al., 2014). Anaemia is a clinical problem in HIV-infected 
patients in both pre- and post- cART era. This suggests that HIV infection could 
result in a fundamental change in the regulation of erythropoiesis. Several studies 
have also reported a decrease in CD34+ progenitor cells and serum erythropoietin 
levels in HIV infected patients when compared to uninfected persons, demonstrating 
a direct effect of HIV infection on haematopoietic progenitor cells and erythropoietin 
responsiveness (Costantini et al., 2009; Calis et al., 2010).  
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3.2.1.2 Carbon monoxide 
  Evidence for a vital role of carbon monoxide (CO) in a number of biological 
and physiological functions have changed the evil image of CO as a pollutant and 
intoxicant (Wu and Wang, 2005). CO can mimic certain effects of nitric oxide (NO); 
the action of certain neurotransmitters and muscle relaxants can be regulated by 
both molecules (Abraham and Kappas, 2008). Carbon monoxide is an odourless, 
colourless, tasteless gas and the major source of endogenous CO in animals is 
heme degradation by HO (Abraham et al., 1983). CO can bind to ferrous (Fe II) 
heme and inhibit heme proteins, for example cytochrome p450 (Dulak and 
Jozkowicz, 2003). CO has been shown to inhibit cytochrome-c oxidase in 
mitochondria by competing with oxygen for binding to the reduced form of the 
enzyme (Alonso et al., 2003). CO acts as a vasodilator and the CO-induced vascular 
relaxation is ubiquitous (Wang, 1998). CO has been showed to protect against 
ischemia-reperfusion injury in vitro via its antioxidant properties (Berne et al., 2012). 
Several CO-releasing molecules (CORM) are being evaluated for their therapeutic 
potential for cardiovascular disease, inflammatory disorders and organ 
transplantation (Motterlini, 2007; Motterlini and Otterbein, 2010). 
3.2.1.3 Biliverdin-Bilirubin 
 Biliverdin, a bile pigment, is also one of end the products of heme catabolism 
by HO. Biliverdin is rapidly reduced to bilirubin by biliverdin reductase (BVR). 
Bilirubin is a major physiologic antioxidant and cytoprotectant (Baranano et al., 
2002). Bilirubin is oxidized by ROS to biliverdin that is then reduced back to bilirubin 
by the action of BVR in a process known as ‘BVR-amplified redox cycle’ (Maghzal et 
al., 2009). Biliverdin reductase A (BVR-A) is also a serine/threonine/tyrosine kinase 
involved in regulation of glucose metabolism and cell growth (Kapitulnik and Maines, 
2009). In addition, BVR-A is a leucine zipper-like DNA binding protein and acts as a 
transcription factor for activator protein 1 (AP-1)-regulated genes such as HO-1 
(Kravets et al., 2004). Due to all these properties (cytoprotective BVR-amplified 
redox cycle, kinase and transcription factor activity) BVR becomes a vital enzyme in 
the heme degradation pathway. Biiliverdin and bilirubin have been shown to inhibit 
HIV-1, HIV-2 and SIV protease (McPhee, 1996). Biliverdin has been shown to induce 
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tolerance to cardiac allograft by inhibiting the activation of ROS-sensitive 
transcription factors NFAT and NF-kB (Yamashita et al., 2004; Gibbs and Maines, 
2007). 
3.3 HIV infection and oxidative stress  
 Oxidative stress, defined as a disturbance in the balance between the 
production of reactive oxygen species (free radicals) and antioxidant defences 
(Betteridge, 2000).  Oxidative stress can cause harm to the biological system by 
damaging biomolecules such as lipids, proteins and DNA, but at the same time they 
can play a useful role in physiologic adaptation and also in the regulation of 
intracellular signal transduction (Yoshikawa and Naito, 2002). The most important 
reactive oxygen species are superoxide radical (O2
.-
), hydrogen peroxide (H2O2), 
hydroxyl radical (·OH), singlet oxygen (1O2), hydroperoxyl radical (HOO), 
alkylhydroperoxide (LOOH), alkylperoxyl radical (LOO·), alkoxyl radical (LO·), 
hypochlorite ion (CIO
-
), ferryl ion (Fe4+O), periferryl ion (Fe5+O) and nitric oxide (NO). 
Superoxide anion is considered as a ‘primary’ ROS, because it can form ‘secondary’ 
ROS via enzyme or metal-catalysed reactions. Superoxide dismutase (SOD) 
reduces O2
.-
 to hydrogen peroxide (H2O2) that can be converted to hydroxyl radical 
(·OH) through the Fenton reaction (Juarez et al., 2008). Inflammatory cells 
(neutrophils, eosinophils and macrophages), peroxisomes and complex I and III of 
mitochondrial respiratory chain are sources of endogenous cellular ROS generation 
(Sandalio et al., 2013; Sabharwal and Schumacker, 2014).  
 Oxidative stress appears to affect the HIV-1 infection in two ways: HIV-1 
infection generates oxidative stress in the cells and oxidative stress drives HIV-1 
disease progression. Oxidative stress may contribute to several aspects of HIV 
disease pathogenesis, including viral replication, inflammatory response, decreased 
immune cell proliferation, loss of immune function, apoptosis, chronic weight loss, 
and increased sensitivity to drug toxicities (Pace and Leaf, 1995). Oxidative stress 
due to a persistent immune activation associated with uncontrolled HIV-1 replication 
leads to excessive ROS generation and metabolic acidosis (Salmen and Berrueta, 
2012, Gil del Valle, 2011). HIV-1 increases oxidative stress in the infected patients 
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by disturbing the cellular antioxidant defense system and progressively depleting the 
antioxidant system (Pasupathi et al., 2009). The low CD4+ T cell count in HIV 
positive patients is also attributed to the HIV-1 induced oxidative stress. The ROS 
produced in the cell due to HIV-1 replication triggers apoptosis that leads to cell 
death (Patki et al., 1997; Aires et al., 1995). Also in an astrocytoma cell line, HIV-1 
induced oxidative stress resulted in telomere shortening and apoptosis (Pollicita et 
al., 2009). HIV-1 Tat has been shown to induce enterocyte apoptosis through a 
redox-mediated mechanism (Buccigrossi et al., 2011). HIV-1 Nef, another regulatory 
protein also increases oxidative stress in primary human astrocytes and led to their 
rapid cell death (Masanetz and Lehman, 2011). 
 Oxidative stress affects the intracellular redox status that results in the 
activation of protein kinases, including a series of receptor and non-receptor tyrosine 
kinases, protein kinase C  and the MAP kinase cascade (Chen et al, 2016; Son et 
al., 2011; Serras, 2016) leading to the induction of various cellular responses. NF-kB 
is an important transcription factor that regulates the expression of hundreds of 
genes that are involved in regulating most functions at all stages of the cell growth is 
affected by the inhibitory/stimulatory effects of ROS. Genes regulated by NF-kB in 
turn play a role in regulating ROS levels in the cell (Morgan and Liu, 2011). The ‘bad’ 
and ‘good’ effects of ROS are determined by their concentration. A high 
concentration of ROS may lead to tissue damage or cell death, whereas a low 
concentration of ROS would lead to a cytoprotective response such as activating the 









4. Aims of the study 
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The overall aim of the thesis has been to evaluate heme arginate as a possible 
HIV-1 latency reversing agent. The specifics objectives were: 
1. To assess the effect of heme arginate on HIV-1 acute infection. 
2. To study the effect of heme arginate on HIV-1 latency reversal. 
3. To find the effect of heme degradation compounds on HIV-1 latency reversal. 















 All the media and growth supplements were purchased from Thermo 
Scientific, USA, Invitrogen Corporation (Carlsbad, CA) or PAA Laboratories GmbH 
(Pasching, Austria).  Other chemicals used, including phorbol myristate acetate 
(PMA), ferric nitrate, ascorbic acid, carbon monoxide releasing molecule-A1 (CORM-
A1), bilirubin, desferrioxamine mesylate salt (DFO) and N-Acetyl cysteine (NAC) 
were purchased from Sigma-Aldrich (Germany) unless otherwise specified. Heme 
arginate (Normosang) was purchased from Orphan Europe (Paris, France), tin 
protoporphyrin IX (SnPP) from Frontier Scientific (Logan, UT), TNF-a from Peprotech 
(London, United Kingdom), and RETRO-TEK HIV-1 p24 Antigen ELISA from 
ZeptoMetrix Corp. (Buffalo, NY). The chemicals for RNA and DNA isolation, PCR 
and real-time PCR were purchased from Top-Bio (Czech Republic), for ddPCR from 
Bio-Rad (Hercules, USA), primers and probes from IDT (Belgium) and Life 
Technologies (Carlsbad, CA, USA). TURBO DNA-free kit, Ambion, was from Life 
Technologies (Carlsbad, CA, USA). 
5.2. Cell lines 
 Human T-cell lines A3.01 and Jurkat (a clone with high expression of CD4), 
ACH-2 cells harboring an integrated HIV-1 provirus (clone #4; Clouse et al., 1989), 
and A2 and H12 clones of Jurkat cells latently infected with a ‘‘mini-virus’’ containing 
the HIV-1 LTR-Tat-IRES-EGFP-LTR (Blazkova et al., 2009; Jordan et al., 2001) 
were grown in RPMI 1640 supplemented with 10% fetal bovine serum, 2 mM 
glutamine, 12.5 mM Hepes, and antibiotics (penicillin 1X105 U/l, streptomycin 100 
mg/l; 10% FBS-RPMI). The cells were treated with increasing concentrations of HA 
(1.25 and 2.5 µl/ml of HA correspond to 31.25 and 62.5 µg/ml of hemin or 48 and 96 
µM hemin, respectively). ACH-2, A2 and H12 cells were stimulated with phorbol 
myristate acetate (PMA; final concentration 0.5 ng/ml was used throughout the 
experiments) to express HIV-1 or EGFP, respectively. The cells were also treated 
with N-acetyl cysteine (final concentration 5 and 10 mM), SnPP (final concentration 
6.25 µM), TNF-a (final concentration 1 and 10 U/ml), PHA (final concentration 0.5 
and 1 µg/ml) Stock solutions of PMA and bilirubin were prepared in DMSO and 
freshly diluted in culture medium to 20x working solutions. Other working solutions 
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were freshly prepared as follows: 100x Fe3+ (1 mM FeNO3 in 50 mM Hepes pH=8 
and  20 mM EDTA), 100x ascorbate (25 mM ascorbic acid in H2O), 100x CORM-A1 
(5 mM CORM-A1 in H2O), 20x NAC (100mM in RPMI), 100x DFO (12.5 mM in H2O). 
The compounds were added at final concentrations specified in each experiment. 
5.3. Primary cells 
 Peripheral blood mononuclear cells (PBMCs) of HIV-infected patients on a 
combined anti-retroviral therapy (cART) with viremia < 50 copies/ml were isolated by 
Ficoll gradient centrifugation (Histopaq, Sigma-Aldrich, Germany), differential blood 
count was determined by Advia 60 Hematology System (Bayer Healthcare, country) 
and PBMC’s were resuspended at final concentration of 5 x 106 lymphocytes/ml in 
10% FBS-RPMI. PBMC’s were plated at 1 ml/well in a 24-well plate and subjected to 
treatment with 2.5 µl of HA/ml and different concentrations of PMA for 18 h. 
5.4. Viruses and infection 
 The stock of HIV-1 was prepared using a transient transfection of Jurkat cells 
with pNL4–3 (Adachi et al., 1986). The culture supernatant was collected at day 7 
after transfection and virus titer was estimated as 4.8 X1010 TU/ml (transducing 
units/ml) based on levels of p24 antigen determined by RETRO-TEK HIV-1 p24 
antigen ELISA according to the manufacturer’s protocol. For time course 
experiments, 0.2X 106 cells in 0.2 ml of 10% FBS-RPMI were infected with 2 µl of the 
stock; after 4 h of adsorption of inoculum, 0.8 ml of 10% FBS-RPMI was added and 
supplemented with HA (final concentration 1.25 and 2.5 µl/ml). The cells were split 
1:4 at the indicated times after infection and the media was supplemented with HA to 
keep the final concentrations as indicated. The growth of HIV-1 was characterized by 
levels of p24 antigen in culture supernatants. For detection of HIV-1 reverse 
transcripts, virus stock was treated with RNAse-free DNase I (Sigma, Germany; final 
concentration 300 U/100 µl of virus stock) and incubated at room temperature for 45 
min to remove plasmid and cellular DNA present in the inoculum. 0.5 x 106 A3.01 
and Jurkat cells in 0.2 ml of 10% FBS-RPMI were infected with 100 µl of the DNase 
I-treated virus stock, and after 4 h of adsorption of inoculum, 0.8 ml of 10% FBS-
RPMI was added and supplemented with HA (final concentration 2.5 µl/ml) or 
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Azidothymidine (AZT; final concentration 10 µM) as a control. Forty eight hours after 
infection, the cells were collected in PBS, trypsinized and used for DNA isolation. 
5.5. Western blot analysis 
 Samples from all experiments that were analysed by western blot, were 
performed by seeding an initial concentration of 0.5x106 cells/ml (ACH-2, A2 and 
H12 Jurkat cells) unless otherwise specified. Cells were collected and lysed in 
Laemmli reducing sample buffer, boiled and analyzed by SDS–PAGE and western 
blotting as previously described (Harlow and Lane, 1988; Laemmli, 1970), using 
chemiluminescence (West Femto, Thermo Fisher Scientific –Pierce, Rockford, IL). 
For p24 antigen, the cell lysates were resolved on a 14% SDS–PAGE and detected 
using a monoclonal antibody ND-1 (dilution 1:500; Exbio, Prague, Czech Republic) 
and a peroxidise conjugated goat anti-mouse IgG (dilution 1:20,000; Sigma Co., 
St.Louis, MO). EGFP was detected using a 12% SDS–PAGE, a rabbit polyclonal 
antibody (dilution 1:1000; Exbio, Prague, Czech Republic) and a peroxidase-
conjugated goat anti-rabbit IgG (dilution 1:20,000; MP Biomedicals – Cappel, Solon, 
OH), HO-1 was detected using a 10% SDS–PAGE, a rabbit polyclonal antibody 
(dilution 1:20,000; Abcam, Cambridge, United Kingdom) and a peroxidise-
conjugated goat anti-rabbit IgG (dilution 1:20,000). β-Actin was detected on a 10% 
gel, using either a goat polyclonal antibody (dilution 1:200; Santa Cruz 
Biotechnology, Santa Cruz, CA) and a peroxidase-conjugated donkey anti-goat IgG 
(dilution 1:20,000; Jackson ImmunoResearch Laboratories, West Grove, PA) or 
using a rabbit polyclonal antibody (dilution 1:7500; Abcam, Cambridge, United 
Kingdom) and a peroxidase-conjugated goat anti-rabbit IgG (dilution 1:20,000). 
Wherever indicated, the chemiluminescence was recorded using ChemiDoc MP 
system (BioRad, Hercules, USA) and the densitometry analysis was performed with 
ImageLab software version 5.0 (BioRad, Hercules, USA). 
5.6. ELISA for HIV-1 p24 quantification 
 Samples from all experiments that were analysed by p24 ELISA, were 
performed by seeding an initial concentration of 0.5x106 cells/ml of ACH-2 cells 
unless otherwise specified.  HIV-1 capsid protein p24 accumulation in the culture 
supernatant was quantified using RETRO-TEK HIV-1 p24 Antigen ELISA 
54 
 
(ZeptoMetrix Corp. Buffalo, NY) according to the manufacturer’s protocol. Cell 
culture supernatant was lysed in lysis buffer, diluted and incubated in HIV-1 p24 
antibody coated microplate for 2 hours at 37ºC. Followed by subsequent incubation 
with HIV-1 p24 detector antibody, streptavidin-peroxidase, substrate (containing 
tetramenthylbenzidine (TMB), and dimethyl sulfoxide (DMSO)) in the order 
respectively with intermittent washings between each step. Finally, optical density of 
the colour produced by enzyme-substrate reaction was measured at 450nm using a 
microplate reader (Victor, PerkinElmer, USA) and the concentration of HIV-1 p24 
(pg/ml) is calculated by interpolating the OD values of samples from the standard 
curve plotted with antigen standard. 
5.7. Flow cytometry analysis 
 Flow cytometer Canto II (Becton Dickinson) equipped with 3 lasers emitting at 
488, 405 and 633 nm, and with 8 detectors was used. Flow cytometry 
measurements were performed using the Diva 6 software (Becton Dickinson, 
Franklin Lakes, NJ). Subsequent analyses of the flow cytometric data were 
performed using Diva 6 and/or FlowJo (Tree Star, Inc., Ashland, OR). At each time 
point, cells were collected, stained with a fluorochrome, and used for further analysis 
in the appropriate detecting channel. Ten thousand cells were collected upon gating 
on a FSC-A x SSC-A dot plot. The region used for further analysis contained live 
cells, as well as their apoptotic counterparts (Fig. 8). Discrimination of apoptotic cells 
was performed on a FSC-A x SSC-A dot plot and/or using staining with Hoechst 
33342 (Intergen; final concentration 0.1µg/ml; Kalbacova et al., 2002; Lizard et al., 
1996) and 7-AAD (final concentration (1µg/ml) followed by flow cytometry analysis in 
FL5 (detecting at 474–496 nm) and FL4 (detecting at 750–810 nm), respectively. 
Percentage of apoptotic cells determined on a FSC-A x SSC-A dot plot correlated 
with the percentage of apoptotic cells determined on a Hoechst 33342 x 7-AAD dot 
plot. For assessment of cell viability of the infected cells during the time course 
experiment, the cells were first fixed with 1% paraformaldehyde, and then analyzed 
as described above. EGFP fluorescence was characterized by a flow cytometry 
analysis in FL1 (detecting at 515–545 nm). EGFP expression was assessed as the 
arithmetic mean of green fluorescence of green cell population x percentage of all 
EGFP-positive cells. EGFP fluorescence intensity was characterized by the median 
55 
 
fluorescence of live green cells. Detection of CD69 expression was performed using 
a mouse monoclonal antibody against human CD69 labelled with Alexa Fluor-700 
(dilution 1:50; Exbio, Prague, Czech Republic) followed by flow cytometry analysis in 
FL7 (detecting at 700–720 nm). 
 In all the experiments were EGFP expression in A2 and H12 cells were 
analysed by flow cytometry, an initial concentration of 0.1x106/200 µl cells was 
seeded, except for the experiments with iron and ascorbate (Fig. 23), where it was 
0.5x106/ml. Also, in all the experiments with A3.01 cells were the cell viability and 
apoptotic cell percentage were analysed by FACS, an intital concentration of  
0.5x106/ml cells was seeded, unless otherwise specified. 





Fig. 8. Example of a flow cytometric analysis. Gating was done based on size and 
granularity of the cells. Cell populations in Regions 1 and 2 were used for further analysis; 
the two regions contained live and apoptotic cells, respectively. The samples were collected, 
incubated with individual fluorescent indicators as indicated, and analyzed using flow 
cytometry and Diva 6 or FlowJo software. 
5.8. Cytotoxicity assays and determination of CC50 
 Cytotoxicity of heme arginate was characterized by determination of induction 
of apoptosis using flow cytometry (see above) and by the effects on cell viability and 
growth using a protocol adapted according to TOX-1 kit (Sigma Co., St. Louis, MO). 
Briefly, A3.01 and Jurkat cells were diluted with fresh culture medium and 24 h later, 
they were plated in 24-well plates at a density of 0.06 x106/ml/well in culture medium 
containing increasing concentrations of HA. In parallel, wells with culture medium 
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and HA were incubated to be used as individual blanks for each particular 
concentration of HA. After 2 days of incubation, cell growth and viability were 
characterized by activity of mitochondrial dehydrogenases using the MTT assay. The 
conversion of MTT to formazan was determined photometrically at 540 nm after 
dissolving the product in the acidified isopropanol. The cytotoxic concentration was 
expressed as CC50, the concentration of the tested compound that reduced cell 
growth to 50% compared to vehiculum-treated controls. 
5.9. DNA and RNA isolation and quantification 
 Total cellular DNA was isolated using a modified method of Miller’s salting-out 
procedure, without proteinase K and with addition of a chloroform extraction phase 
(Olerup and Zetterquist, 1992). Ethanol-precipitated DNA was dissolved in TE buffer 
and quantified by measuring the absorbance at 260 nm using UV spectrophotometer 
BioPhotometer (Eppendorff AG, Germany). 
 RNA was isolated using RNA Blue reagent by precipitation of the aqueous 
phase according to the manufacturer’s protocol (Top-Bio, Czech Republic); RNA was 
solubilized in nuclease- and protease-free molecular biology grade water (Sigma-
Aldrich, Germany) with the addition of RiboLock RNase inhibitor (Thermo Scientific, 
USA; final concentration 1 U/µl) and stored in -80ºC for further use. The 
concentration and purity of RNA was determined by measuring the absorbance at 
260 and 280 nm using UV spectrophotometer Eppendorf BioSpectrometer 
(Eppendorff AG, Germany). The isolated RNA was then treated with TURBO DNase 
(TURBO DNA-free kit, Ambion, Life Technologies) to remove contaminant genomic 
DNA according to the manufacturer’s protocol.  
5.10. PCR detection of HIV-1 reverse transcripts 
 HIV-1 reverse transcripts were determined by PCR using primers specific for 
LTR/gag (Schmidtmayerova et al., 1998) and for GAPDH (sense 5’-TTC TGT CTT 
CCA CTC ACT CC-3’, antisense 5’-GTA TTC CCC CAG GTT TAC ATG-3’) in a 50 
µl reaction volume containing 1U of Taq DNA polymerase (Top-Bio, Czech 
Republic), 1x PCR buffer (10 mM Tris–HCl, pH 8.8; 50 mM KCl; 0.1% Triton X-100), 
200 nM each primer, 200 lM dNTPs, MgCl2 (1 mM for LTR/gag; 0.75 mM for 
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GAPDH) and sample DNA (1000 ng for LTR/gag; 200 ng for GAPDH. PCR 
conditions: initial denaturation 94ºC/4 min and 35 cycles of 94ºC/30 s, 52ºC/30 s for 
LTR/gag or 57ºC/30 s for GAPDH, 72ºC/60 s, with final extension 72ºC/10 min in a 
Mastercycler Gradient thermocycler (Eppendorf AG, Hamburg, Germany) . The PCR 
products were resolved using a 1.5% agarose gel electrophoresis in 1x TBE buffer 
and 0.5 µg/ml ethidium bromide, and visualized under UV transilluminator. 
5.11. Quantification of HIV-1 RNA by droplet digital PCR 
 Absolute quantification of the HIV-1 RNA expressed in ACH-2 cells was 
performed using the QX100 droplet digital PCR system (Bio Rad, Hercules, USA) 
and One-Step RT ddPCR kit for probes (Bio Rad, Hercules, USA) according to 
manufacturer’s protocol. Twenty µl of the reaction mixture consisted of 10 µl of 2x 
one-step RT ddPCR super mix, 0.8 µl of 25 mM manganese acetate, 0.5 or 5 ng of 
DNase treated RNA and primers and probes for HIV Gag or human GAPDH. Primers 
and probes used: HIV-1 Gag – forward primer GAG1 (5’-
TCAGCCCAGAAGTAATACCCATGT-3’) and and reverse primer GAG2 (5’-
CACTGTGTTTAGCATGGTGTTT-3’),           final concentration 200 nM each, probe 
GAG3 (FAM-5’-ATTATCAGAAGGAGCCACCCCACAAGA-3’-BHQ1), final 
concentration 250 nM (Pasternak et al., 2008; Kiselinova et al., 2014); human 
GAPDH – 1x primer-probe Hs02758991_g1 VIC-MGB labelled (Life Technologies, 
Calsbard, CA, USA). The droplets were generated using the QX100 droplet 
generator (Bio Rad, Hercules, USA) by mixing 70µl of droplet generating oil (Bio 
Rad, Hercules, USA) with 20 µl of ddPCR reaction mixture and PCR amplification 
was performed on a T100 thermal cycler (Bio Rad, Hercules, USA). The thermal 
cycling conditions were as follows: reverse transcription at 60ºC for 30 minutes, 95ºC 
for 5 min, 40 cycles consisting of denaturation at 94ºC for 30 s and 
annealing/extension at 60ºC for 60 s, followed by a terminal extension at 98ºC for 10 
min. The amplified droplets were read by the QX100 droplet reader (Bio Rad, 
Hercules, USA) and the data were analysed by QuantaSoft analysis software 
1.6.6.0320 (Bio Rad, Hercules, USA). Copies of Gag RNA were standardized to 
human GAPDH as a reference gene. 
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5.12. Quantification of HIV-1 RNA by real-time PCR 
 RNA isolated from cultured and stimulated PBMC’s of HIV-infected patients 
treated with cART (viremia < 50 copies/ml) was used for detection of cell-associated 
HIV-1 RNA using semi-nested 2-step RT-qPCR adapted from (Kiselinova et al., 
2014; Pasternak et al., 2008). Sixteen µl of DNase-treated RNA was used for 
reverse transcription in a final volume of 40 µl using random hexamer primers 
(Premium Reverse Transcriptase, Thermo Scientific). Then, 20 µl of cDNA was 
amplified in a total volume of 100 µl using GAG1 and SK431 primers (final 
concentration 250 nM each; SK431 sequence: 5’-
TGCTATGTCAGTTCCCCTTGGTTCTCT-3’; (Pasternak et al., 2008)) and 0.05 U/µl 
of Blood Taq DNA polymerase (Top-Bio, Czech Republic) in 1x PCR Blue buffer 
(Top-Bio, Czech Republic) containing 2 mM MgCl2. The thermal cycling conditions 
were as follows: initial denaturation at 95ºC for 5 min, 15 cycles consisting of 
denaturation at 94ºC for 30 s, annealing at 55ºC for 30 s,  and extension at 72ºC for 
60 s, followed by terminal extension at 72ºC for 10 min using the Mastercycler 
Gradient (Eppendorf AG, Hamburg, Germany). Finally, 10 µl of the first PCR product 
was used in duplicate for real-time PCR in a total volume of 50 µl containing GAG1 
and GAG2 primers, GAG3 probe (final concentration 200 nM each; GAG3 sequence: 
FAM-5’-ATTATCAGAAGGAGCCACCCCACAAGA-3’-TAMRA; (Pasternak et al., 
2008)), and 1x qPCR Blue buffer (Top-Bio, Czech Republic) using the Applied 
Biosystems 7300 Real-time PCR System (Applied Biosystems, Foster City, CA) and 
the universal cycling conditions. Four µl of the first PCR product was used for 
quantification of a reference gene in a 20 µl reaction also in duplicate. Levels of HIV 
Gag RNA were standardized to GAPDH. Four µl of DNase-treated RNA was used for 
a no-RT control and further processed in the way analogous to cDNA. The mean of 
technical duplicates was used for relative quantification of HIV Gag compared to 
GAPDH. Changes in expression of 10 additional house-keeping genes in healthy 
donors PBMCs after the individual treatments were determined using Real-time PCR 
kit for Human Reference Genes (Generi Biotech, Czech Republic). 
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5.13. Statistical analysis 
 Results are presented as means ± SD (standard deviation) or SEM (standard 
error of mean). The data were analysed and graphically represented using 
GraphPad Prism 5.04 software. Statistical differences between each group and 
control or between two groups were determined using a two-sample two-tailed 
Student’s t-test for either equal or unequal variances. Equality of variances was 












6.1 Heme arginate inhibited HIV-1 acute infection  
Based on preliminary experiments and on the estimated distribution volume of 
heme arginate in vivo, 1.25 and 2.5 µl/ml of HA (31.25 and 62.5 µg/ml of hemin or 48 
and 96 µM hemin, respectively) were selected and used to assess the effect of HA 
on HIV-1 acute infection. In a time course experiment, T-cell lines A3.01 and Jurkat 
were acutely infected with HIV-1 or mock infected in the presence of HA. Aliquots of 
culture supernatant were collected at three days interval (days 4, 7, 10 and 13 p.i.), 
to determine the HIV-1 p24 by ELISA. Throughout the incubation period, HA strongly 
inhibited the growth of HIV-1 in both cell lines and the levels of the p24 antigen in the 
culture supernatants were significantly decreased when compared to levels of the 
untreated controls in both cell lines (Fig. 9). In untreated cells, the HIV-1 replication 
and p24 levels kept increasing during the experiment period and were found to reach 
a maximum on day 10, with a decrease on day 13 as there remained only few cells 
alive (Fig. 10A). Treatment with HA 1.25 µl/ml decreased the levels of the p24 
antigen several folds in comparison with untreated cells, while HA 2.5 µl/ml was even 
more effective in inhibiting HIV-1 infection and kept the levels of p24 antigen very 
low, close to the detection limit of the assay.  
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Fig. 9. Heme arginate inhibits HIV-1 acute infection. A3.01 and Jurkat cells were infected 
with HIV-1 and treated with HA 1.25 and 2.5 µl/ml. HIV-1 p24 levels in the culture 
supernatant were quantified by ELISA at indicated days after infection (p.i.). Graph 
represents the results of two independent experiments performed in duplicates. 
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6.2 Effect of HA on T cell viability 
In a parallel time course experiment with the same setup as above, the cells 
collected at different times p.i. were fixed with 1% paraformaldehyde and analysed 
by flow cytometry to determine the viability. The apoptotic and live cells were 
determined based on the size and granulosity of the cells as analysed by FSC-A X 
SSC-A. Viability of the HIV-infected, untreated cells sharply decreased during the 
incubation period. In contrast, viability of both HA-treated infected and mock-infected 
cells were comparable to untreated mock-infected cells up to the 13 days p.i. (Fig. 
10A). 
Additionally, uninfected A3.01 and Jurkat cells were treated with increasing 
concentrations of HA for 48 h to characterize the effects of HA on T-cell viability, 
growth, and cytotoxicity (Table 10B). Percentage of apoptotic cells was analysed by 
flow cytometry based on cell size and granulosity (FSC-A X SSC-A).  HA 1.25 and 
2.5 µl/ml that inhibited HIV-1 growth did not induce any increased apoptosis of A3.01 
cells, while 2.5 µl/ml of HA increased apoptosis of Jurkat cells slightly. The live and 
apoptotic cells analyzed by flow cytometry with Hoechst 33342 and 7-AAD labelling, 
yielded similar results (data not shown). The cytotoxicity and growth inhibitory 
properties of HA were further characterized by the activity of mitochondrial 
dehydrogenases using the MTT assay. The results indicated that 1.25 µl/ml of HA 
did not induce any significant decrease of this activity, while 2.5 µl/ml of HA 
somewhat decreased it in both cell lines.  
The CC50 of HA in A3.01 and Jurkat cells was determined by both flow 
cytometry and MTT assay. Based on flow cytometry assays, CC50 was determined 
as 42 and 17 µl/ml of HA (1612 and 636 µM hemin) in A3.01 and Jurkat cells, 
respectively, while it was 10.7 and 6.4 µl/ml of HA (412 and 244 µM hemin) in A3.01 








































































Apoptosis (%) 7.40  0.84 8.24  1.09 9.55  1.09 11.90    1.11 15.00  1.32
MTT (%) 100.00  0.00 97.04  4.12 92.00  7.27 82.48  13.66 62.54  9.45







Apoptosis (%) 9.95  2.59 10.32  2.71 13.47  2.93 21.18  0.85 27.57  1.42
MTT (%) 100.00  0.00 96.08  3.75 81.02  9.02 67.83  7.37 36.18  4.22




Fig. 10. Effect of HA on T cell viability. (A) Viability of HIV-1-infected, untreated and HA-
treated A3.01 and Jurkat cells as characterized by flow cytometry. Graphs represent the 
results of two independent experiments performed in duplicate. (B) Apoptosis and 
cytotoxicity of HA in A3.01 and Jurkat cells as determined by flow cytometry and MTT assay. 
The results represent means of three (A3.01) or two experiments (Jurkat) performed in 
duplicates ±SD.  
 
6.3. Heme arginate inhibited reverse transcription of HIV-1  
Inhibiton of reverse transcriptase by heme has been demonstrated previously 
(Levere et al., 1991; Staudinger et al., 1996; Argyris et al., 2001). To test the effects 
of HA on HIV-1 reverse transcription in A3.01 and Jurkat cells, the cells were 
infected with DNase-treated inocula of HIV-1 or mock-infected and treated with HA 
2.5 µl/ml. Treatment with a nucleoside analogue inhibitor of reverse transcriptase, 
64 
 
azidothymidine (AZT, was included as a control for RT inhibition. After 48 h 
incubation, cellular DNA was isolated and PCR was performed using primers specific 
for HIV LTR/gag (Fig. 11). The results showed a decrease in HIV-1 DNA 
demonstrating the inhibitory effects of HA on levels of reverse transcripts that were 
comparable to those of AZT. On the other hand, levels of a house-keeping gene 










































Fig. 11. HA inhibits reverse transcription of HIV-1. HIV-1 LTR/Gag specific PCR in DNA 
isolated from HIV-1 infected, HA2.5 µl/ml treated A3.01 and Jurkat cells demonstrated the 
inhibitory activity of heme arginate on HIV-1 RT. Representative results of two independent 
experiments performed in triplicates. 
 
 
6.4. Determination of PMA concentration 
 To determine the minimum concentration of PMA required to activate the T 
cell lines, 0.5x106/ml A3.01 cells were treated with different concentrations of PMA 
(0.05, 0.1, 0.5 and 1 ng/ml) for 24 h. After incubation, cells were collected and the 
expression of CD69 on the cell surface was analysed by flow cytometry using anti-
CD69 antibody labelled with AlexaFluor 700. PMA 0.5 ng/ml was found as the lowest 
concentration to activate A3.01 cells as determined by the expression of CD69 
molecule – a marker of activated T cells (Fig.12). The stimulatory effect of PMA 
















Fig. 12. PMA 0.5 ng/ml was the lowest concentration required to activate T cell lines. 
A3.01 cells were treated with increasing concentrations (0.05, 0.1, 0.5 and 1 ng/ml) of PMA 
for 24 and analysed by flow cytometry to detect the expression of CD69 molecule.  
Representative results of two independent experiments. 
 
 
6.5. Effect of HA on reactivation of HIV-1 provirus  
Reactivation of the latent HIV-1 is a hot topic in HIV therapy research. The 
effects of heme or hemin on reactivation of the HIV-1 provirus has not been 
previously studied. Therefore, we decided to study the effect of HA treatment in HIV-
1 latency reversal.  ACH-2 cells, harboring an integrated HIV-1 provirus, were pre-
treated with different concentration of HA (2.5, 5.0 and 7.5 µl/ml) for 24 h and 
stimulated with PMA. The cells and culture supernatants were collected 24 h after 
PMA stimulation and analysed for HIV-1 p24 antigen determined by western blot 
analysis and ELISA, respectively. Interestingly, the results showed that HA dose-
dependently increased reactivation of the provirus in PMA-stimulated ACH-2 cells. 
The levels of the p24 antigen and its precursor p55 were found increased both in 
cells (Fig. 13A), and culture supernatants (Fig. 13B). It was clear from the 
quantitative ELISA results that the basal induction of HIV-1 reactivation by PMA was 
strongly potentiated by HA and as a result p24 production was increased by several 
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hundred-folds. These results indicated that HA dose-dependently reactivated HIV-1 
provirus in PMA-stimulated ACH-2 cells. On the other hand, HA alone was not found 
to stimulate reactivation of the HIV-1 provirus at any concentration tested (data not 
shown).  
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Fig. 13. Effects of HA on reactivation of the latent HIV-1 provirus in ACH-2 cells.  ACH-
2 cells were pretreated with increasing concentrations of HA for 24 h, and then stimulated 
with (PMA; final concentration 0.5 ng/ml) for 24 h. (A) Western blot analysis of p24 antigen in 
the cells. Representative results of two independent experiments. (B) p24 antigen in culture 
supernatants. Levels of p24 antigen were determined by ELISA. Graphs represent mean of 
two independent experiments performed in duplicates ± SD. 
 
 
6.6. Effect of HA on reactivation of the latent HIV-1 ‘‘mini-virus’’  
 A2 and H12 clones of Jurkat cells that harbour a HIV-1 ‘‘mini-virus’’ containing 
EGFP reporter gene cloned under the HIV-1 LTR promoter serve as an in vitro 
model of reversible latency.  Reactivation and EGFP expression in these Jurkat 
clones differs based on the site of HIV-1 “mini-virus” integration (Jordan et al., 2001) 
and modifications in the promoter/enhancer region (Blazkova et al., 2009). To study 
and confirm further the effect of HA on reactivation of the latent provirus, we treated 
these Jurkat clones with increasing concentrations of HA either for 48 h or pretreated 
the cells with HA for 24 h and stimulated them with PMA for another 24 h.  The cells 
were collected after the incubation and the EGFP expression was analyzed by 
western blot and flow cytometry. HA induced the PMA-stimulated reactivation of 
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latent HIV-1 mini-virus and EGFP expression in A2 and H12 Jurkat cells (Fig. 14A 
and B) and the result was in agreement with the results obtained in ACH-2 cells. 
Interestingly, EGFP expression also revealed a stimulatory effect of HA-alone, but 
the effect was weaker than that in combination with PMA (Fig. 14A and B). Though, 
H12 cells revealed a higher background expression of EGFP than A2 cells, while 
EGFP expression upon treatment with HA alone or with PMA was somewhat higher 
in A2 cells than H12 cells. 
  The concentrations of HA 2.5 µl of HA/ml and higher were cytotoxic in A2 and 
H12 cells, as indicated by decreased levels of the house-keeping gene b-actin    
(Fig. 14A). Also, the increased expression of EGFP inversely correlated with cell 
viability, with a significant increase of apoptosis at concentrations of HA 2.5 µl/ml and 
higher (Table 14C). The stimulatory effects of HA-alone and in combination with 
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EGFP+ Cells                                                    
(%)     
Fluorescence Intensity              
(EGFP+ Live Cells Median)    
Cell Viability                                 
(% of Live Cells) 
HA A2   H12  HA A2   H12  HA A2   H12 
  0 PMA   0 PMA    0 PMA   0 PMA    0 PMA   0 PMA 
                          
0 2.68 10.33   4.90 22.04  0 386 1,917   411 2,132  0 87.53 88.32   90.18 83.56 
0.63 2.13 13.02   4.15 21.02  0.63 432 2,644   435 2,062  0.63 87.80 87.55   88.70 84.83 
1.25 3.13 24.85   4.75 25.42  1.25 464 4,145   454 2,611  1.25 83.75 83.57   85.10 78.47 
2.5 11.87 49.38   9.08 42.33  2.5 1,035 9,405   657 7,008  2.5 72.67 55.53   73.13 33.90 
5 31.60 11.90   22.73 8.78  5 3,722 23,493   1,438 16,351  5 18.15 0.70   15.55 0.25 
7.5 14.33  -     12.40  -    7.5 5,933  -     2,533  -    7.5 3.43  -     16.03  -   
  SD   SD    SD   SD    SD   SD 
0 0.57 2.77   0.29 6.59  0 73 437   22 790  0 4.10 4.33   2.70 9.15 
0.63 0.51 2.81   0.13 6.22  0.63 58 303   22 870  0.63 3.06 5.05   2.43 5.70 
1.25 0.43 11.01   0.29 4.98  1.25 79 628   24 996  1.25 4.92 8.44   2.90 4.73 
2.5 2.38 5.29   1.27 7.20  2.5 280 3,130   70 1,184  2.5 5.14 28.13   4.34 15.95 
5 4.41 9.03   2.03 3.56  5 1,659 8,909   622 9,638  5 14.23 0.57   10.90 0.13 
7.5 14.34  -     11.04  -    7.5 3,887  -     1,971  -    7.5 3.99  -     27.04  -   
 
 
Fig. 14. Effect of HA on reactivation of the latent HIV-1 ‘‘mini-virus’’. Pretreatment 
with increasing concentrations of HA alone or in combination with PMA (final concentration 
0.5 ng/ml) reactivated latent HIV-1 “mini-virus”. (A) Western blot analysis of EGFP 
expression from 0.5x106/ml cultured. Representative results of two independent 
experiments. (B) FACS analysis of EGFP from 0.1x106/200 µl cells cultured. The graphs 
show a quantification of EGFP expression calculated as the arithmetic mean of green 
fluorescence of green cell population x percentage of all EGFP-positive cells. *Increase in 
EGFP expression is statistically significant when compared to HA 0 in each treatment (p < 
0.05). x, Increase in EGFP expression in the presence of PMA is statistically significant 
when compared to the same concentration of HA without PMA (p < 0.05). (C)Table 
summarize percentage of all EGFP+ cells, fluorescence intensity of EGFP+ live cells 
(median of green fluorescence), and cell viability (% of live cells) presented in Fig. 14B. Live 
and apoptotic cells were distinguished based on their size and granulosity (FSC-A x SSC-A; 
see Fig. 8). The results represent means of two independent experiments performed in 






6.7. Induction of HO-1 expression by HA with PMA in ACH-2 cells 
Heme oxygenase-1 (HO-1) is an inducible isoform of Heme oxygenase 
enzyme family that catabolise heme into carbon monoxide, biliverdin and Fe2+ 
(Tenhunen et al., 1969). Heme is a natural substrate of heme oxygenases, and it 
induces the expression of the HO-1 (Maines et al., 1986; Wu and Wang, 2005). 
Reactive oxygen species produced by the Fe2+ released by heme degradation 
(Kruszewski, 2003) could mediate reactivation HIV-1 provirus through the activation 
of transcription factor NF-kB. Hence, we first determined the expression of HO-1 in 
ACH-2 cells pre-treated with increasing concentration of heme arginate (1.25, 2.5, 
5.0 and 7.5 µl/ml) for 24 h and then stimulated with PMA (final concentration 0.5 
ng/ml) for another 24 hours. The cells were collected and analysed by western 
blotting for the expression of HO-1 enzyme using specific primary antibody against 
HO-1. We observed an increase in HO-1 levels with increasing HA concentrations in 
the presence of PMA i.e. under the conditions leading to the reactivation of HIV-1 
provirus (Fig. 15). The low background level of HO-1 expression was not increased 
by treatment with PMA alone.  
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Fig. 15. HA with PMA stimulate expression of heme oxygenase-1. ACH-2 cells were 
pretreated with increasing concentrations of HA (24 h) and stimulated with PMA for another 
24 h. Cell lysates were used to detect the HO-1 by western blotting. Representative result of 
two independent experiments performed in duplicates. 
 
 
6.8 Anti-oxidant NAC decreased HA- and PMA-induced reactivation of HIV-1 
In order to examine the involvement of heme arginate-mediated ROS 
production in reactivating the latent HIV-1, we pre-treated the cells with an anti-
oxidant agent N-acetyl cysteine (NAC; final concentration 5mM), precursor of the 
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reduced glutathione (GSH) for 4 h and then treated with HA (2.5 µl/ml) for 24 h and 
another 24 h with PMA (0.5 ng/ml). HIV-1 p24 detected from the cell lysates by 
western blot analysis showed a decrease in reactivation of the provirus in HA-pre-
treated, PMA-stimulated ACH-2 cells by the addition of NAC (Fig. 16A). In addition, 
PMA-alone stimulated expression of p24 was also decreased by NAC. On the other 
hand, ELISA analysis of culture supernatants (Fig. 16B) revealed that pre-treatment 
with NAC decreased the levels of p24 antigen released by PMA-stimulated ACH-2 
cells, while it was not sufficient to decrease significantly the p24 release in HA-pre-
treated, PMA-stimulated cells. 
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Fig. 16. N-acetyl cysteine decreased HA- and PMA-induced reactivation of HIV-1.  
ACH-2 cells were pretreated with anti-oxidant NAC and treated with HA for 24h and then 
with PMA. (A) Levels of p24 and b-actin were characterized by western blot.  Representative 
result from two independent experiments performed in duplicate, (B) Levels of p24 antigen in 




6.9. HA did not induce expression of HO-1 in A2 and H12 cells  
A2 and H12 Jurkat cells were treated with different concentrations of HA 
(1.25, 2.5 and 5.0 µl/ml) and incubated for 48 h. Expression of HO-1 was analysed 
by western blotting. In contrast to the dose-dependent increase in HO-1 expression 
by HA with PMA in ACH-2 cells (Fig. 15), the background HO-1 expression in A2 and 
H12 Jurkat cells was quite high already in untreated cells and there was no further 
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increase induced by HA (Fig. 17). HA and PMA treatment did not increase HO-1 
levels in A2 and H12 cells either (data not shown). Also, HA at higher concentrations 
decreased HO-1 levels and was cytotoxic to A2 and H12 cells as evidenced by the 
decrease in β-actin level.  
HA 48 h














Fig. 17. HA did not induce the expression of HO-1 in A2 and H12 Jurkat cells. HO-1 
was found expressed already in untreated cells and treatment with increasing concentrations 
(1.25, 2.5 and 5.0 µl/ml) of HA for 48 h did not increase HO-1 in A2 and H12 cells. 
 
 
6.10. Effect of NAC and HO-1 inhibitor SnPP IX in A2 and H12 cells 
Following the inhibitory effect of anti-oxidant NAC observed in HA- and PMA- 
stimulated reactivation of HIV-1 provirus in ACH-2 cells (Fig. 16), a similar 
experiment was performed to explore the involvement of HA-mediated ROS 
production in HIV-1 “mini-virus” reactivation in A2 and H12 Jurkat clones. A2 and 
H12 cells were pre-treated with two different concentrations of NAC (10 and 5 mM) 
and treated with HA (2.5 µl/ml) for 24 h and stimulated with PMA (0.5 ng/ml) for 
another 24 h. Expression of EGFP in the cells was analysed by western blotting and 
flow cytometry. Anti-oxidant NAC, similar to the effects observed in  ACH-2 cells, 
prevented the HIV-1 “mini-virus” reactivation, demonstrated by the decreased levels 
of EGFP in A2 and H12 cells treated with both HA and PMA, as well as in cells 
treated with PMA only (Fig. 18A, EGFP induced by HA only could be observed in 
longer exposures).   
Tin protoporphyrin IX (SnPP) is an inhibitor of HO-1 activity. Therefore, the 
effects of SnPP on reactivation of HIV-1 in ACH-2 cells and on reactivation of HIV-1 
“mini-virus” in Jurkat clones were studied. In short, either SnPP (6.25 µM) was added 
to untreated cells or after 4 h pretreatment with NAC (5 mM). Consequently, the cells 
were treated with HA and PMA as described above. The results of western blot 
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analysis revealed that inhibition of HO-1 activity by SnPP led to a strong increase in 
EGFP expression in A2 and H12 cells treated with HA alone (Fig. 18B), whereas the 
increase in EGFP levels in HA- and PMA-treated cells was not significant. SnPP did 
not affect or somewhat decreased the levels of EGFP in PMA-stimulated cells. SnPP 
alone did not stimulate any expression of EGFP in untreated cells. NAC pretreatment 
decreased the stimulation of EGFP expression in all combinations of SnPP, HA- and 
PMA-treated cells (Fig. 18C) suggesting that these effects were mediated by an 
increased redox stress. Interestingly, while decreasing the EGFP expression, NAC 
restored the cell viability in all treatments. EGFP expression analysed using flow 
cytometry from a same experimental set-up was comparable to the pattern of results 
obtained by western blot analysis (Fig. 18C, Table 18D).  
The background expression of EGFP in untreated H12 cells was higher than 
in A2 cells, and in general, the response was lower than in A2 cells. In untreated 
control A2 cells the basal EGFP expression was apparently decreased by SnPP but 
it was not affected by NAC. In contrast, the basal EGFP expression in untreated 
control H12 cells was not affected by SnPP, whereas it was decreased by NAC.  The 
stimulatory effects of SnPP observed in A2 and H12 cells were confirmed also in 
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A2                                      EGFP+ Cells (%)   H12                                      EGFP+ Cells (%)  
  0 NAC SnPP 
NAC  
SnPP PMA 




PMA           
NAC 
SnPP    0 NAC SnPP 
NAC  
SnPP PMA 




PMA           
NAC 
SnPP 
                     
HA 0 2.65 2.97 1.46 1.30 12.38 8.37 12.60 6.92  HA 0 7.03 5.33 6.40 4.38 18.70 15.93 19.00 16.25 
HA 1.25 1.75 3.35 6.77 2.72 16.58 8.70 34.12 8.97  HA 1.25 6.83 6.80 8.75 6.20 17.18 17.03 20.45 17.12 
HA 2.5 3.03 3.78 23.67 3.38 24.43 10.68 50.98 11.18  HA 2.5 7.25 7.48 13.05 7.40 17.77 17.65 25.30 17.60 
  SD    SD 
HA 0 0.67 0.93 0.30 0.39 3.96 2.72 4.49 2.51  HA 0 0.21 0.05 0.47 0.33 1.46 1.83 0.30 2.78 
HA 1.25 0.58 0.77 2.25 0.31 6.31 1.90 6.13 2.76  HA 1.25 0.71 0.39 0.81 0.22 1.08 1.89 0.81 2.00 
HA 2.5 0.84 0.50 3.51 0.36 8.64 3.82 4.79 3.17  HA 2.5 0.42 0.53 1.91 0.60 2.14 3.26 1.23 2.10 
                   
A2            Fluorescence Intensity (EGFP+ Live Cells Median)  H12            Fluorescence Intensity (EGFP+ Live Cells Median) 
  0 NAC SnPP 
NAC  
SnPP PMA 




PMA           
NAC 
SnPP    0 NAC SnPP 
NAC  
SnPP PMA 




PMA           
NAC 
SnPP 
                     
HA 0 1,143 996 1,206 1,058 2,482 2,116 2,626 2,315  HA 0 1,070 914 1,035 899 2,002 1,598 2,183 1,786 
HA 1.25 1,279 857 2,227 824 3,459 1,808 5,758 2,062  HA 1.25 1,060 905 1,218 905 2,136 1,698 2,533 1,734 
HA 2.5 1,665 763 5,122 729 4,488 1,774 9,812 1,951  HA 2.5 1,141 886 1,744 876 2,286 1,627 3,445 1,788 
  SD    SD 
HA 0 279 93 176 192 307 231 396 215  HA 0 118 55 56 88 255 75 145 277 
HA 1.25 158 118 388 100 772 179 681 316  HA 1.25 117 79 78 56 186 87 173 103 
HA 2.5 193 77 826 25 965 462 1,170 496  HA 2.5 89 47 304 82 190 117 253 92 
                   
A2                           Cell Viability (% of Live Cells)  H12                           Cell Viability (% of Live Cells) 
  0 NAC SnPP 
NAC  
SnPP PMA 




PMA           
NAC 
SnPP    0 NAC SnPP 
NAC  
SnPP PMA 




PMA           
NAC 
SnPP 
                     
HA 0 84.63 89.97 83.70 89.68 87.07 90.85 87.28 91.20  HA 0 86.60 94.33 84.18 93.68 88.85 93.45 88.43 93.50 
HA 1.25 82.47 88.83 76.30 87.20 84.23 90.17 79.32 90.33  HA 1.25 83.35 91.68 80.10 91.50 88.30 92.65 87.48 93.10 
HA 2.5 78.37 87.60 68.23 87.10 81.33 89.80 67.55 89.50  HA 2.5 80.00 91.98 74.73 91.10 87.37 92.58 84.60 92.18 
  SD    SD 
HA 0 0.54 1.44 0.56 1.56 1.51 2.28 2.07 1.92  HA 0 1.63 0.43 1.60 0.68 1.40 2.44 2.32 2.74 
HA 1.25 2.08 1.22 1.14 2.60 2.28 2.19 1.17 1.25  HA 1.25 2.25 1.58 2.15 1.45 2.16 2.73 2.39 2.27 
HA 2.5 0.85 1.33 1.65 1.21 2.23 1.73 3.58 1.61  HA 2.5 3.70 1.36 4.19 0.82 2.27 2.58 2.81 2.51 
 
 
Fig. 18. Effect of NAC and HO-1 inhibitor SnPP IX in A2 and H12 cells. (A) N-acetyl 
cysteine prevented the reactivation of HIV-1 ‘mini-virus’. Pretreatment of NAC (10 and 5 mM) 
decreased EGFP expression in HA (2.5 µl/ml) and PMA (0.5 ng/ml) stimulated cells as 
detected by western blot analysis. Representative results of two independent experiments 
performed in duplicates. (B) HO-1 inhibitor SnPP (6.25 µM) strongly stimulated HIV-1 mini-
virus reactivation and EGFP expression in HA-alone treated A2 and H12 cells and the 
stimulation was not significant enough in HA and PMA treated cells. EGFP was detected by 
western blot. Representative results of two independent experiments performed in duplicate. 
(C) NAC decreased the stimulation of EGFP expression in A2 and H12 cells treated with HA-
alone, PMA-alone, HA and PMA, and +/- SnPP treatments.  The cells were analyzed by flow 
cytometry in FL1. The graphs show a quantification of EGFP expression calculated as the 
arithmetic mean of green fluorescence of green cell population X percentage of all EGFP-
positive cells. *Increase in EGFP expression is statistically significant when compared to HA 
0 in each treatment (p < 0.05). X, Increase in EGFP expression in the presence of SnPP is 
statistically significant when compared to the same treatment without SnPP (p < 0.05).  
§Decrease in EGFP expression in the presence of NAC is statistically significant when 
compared to the same treatment without NAC (p < 0.05). (D) Tables summarize percentage 
of all EGFP-positive cells, fluorescence intensity of EGFP+ live cells (median of green 
fluorescence), and cell viability (% of life cells) presented in Fig. 18C. The results represent 
means of two independent experiments performed in duplicates ± S.D. 
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6.11. Effect of Iron and ascorbate on PMA-stimulated reactivation of the latent 
HIV-1  
 As described earlier, heme is catabolized by heme oxygenases to release 
Iron (Fe2+), CO and biliverdin. Free iron (Fe2+) is pro-oxidative and was shown to 
generate ROS. ROS mediated reactivation of HIV-1 provirus from latency through 
the activation of transcription factor NF-kB has been previously demonstrated (Pyo 
et al., 2008). Since our experiments clearly demonstrated the potentiation by heme 
arginate in PMA-stimulated HIV-1 provirus reactivation, we decided to explore the 
effects individual products of heme degradation to understand the HA mediated 
reactivation of latent HIV-1 in more detail.  
 ACH-2 cells were treated for 24 h with ferric nitrate ( Fe(NO3)3 ) (10 μM), 
ascorbate (0.25 mM) and PMA (0.5 ng) either alone or in combinations as labelled in 
Fig.6.10A and B. Fe2+ is unstable and readily oxidized to Fe3+ in aqueous 
environment.  Ferric nitrate used in the experiments served as a source of Fe3+ and 
the ascorbate was added to reduce Fe3+ to Fe2+ (Hermes-Lima et al., 2000; Zhang et 
al., 2008).  Reactivation of HIV-1 provirus and p24 expression was analyzed by 
western blotting and chemiluminescence, recorded and analyzed digitally by the 
ChemiDoc system. Without PMA stimulation, none of the treatment namely, Fe3+-
alone, ascorbate-alone or Fe3+ and ascorbate together – showed any effect on p24 
expression in ACH-2 cells. Interestingly, the low levels of p24 expression induced by 
PMA stimulation were increased by ascorbate by several folds. Unexpectedly, Fe3+ 
decreased both the PMA-alone stimulated and PMA and ascorbate together 
stimulated reactivation of HIV-1 and p24 expression (Fig. 19A and B).   
 Total cellular RNA was isolated from the ACH-2 cells treated in the same way 
as above, and HIV-1 Gag mRNA was quantified using 1-step RT-ddPCR to 
characterize the mechanism of iron and ascorbate action in ACH-2 cells at gene 
expression level. A house-keeping gene (human GAPDH) was also quantified to 
normalize the HIV-1 Gag mRNA expression. In general, the mRNA expression 
pattern was similar to the trend observed in digital quantification of the p24 protein 
detected by western blots. As shown in Fig. 19C, the background Gag mRNA levels 
were increased 34-times by PMA-alone, while the addition of ascorbate increased 
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the PMA-stimulated levels about 6-fold and Fe3+ inhibited PMA alone and PMA with 
ascorbate stimulated HIV-1 Gag mRNA expression.  
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Fig. 19. Effect of Fe3+ and ascorbate on PMA-stimulated HIV-1 provirus reactivation in 
ACH-2 cells. ACH-2 cells treated with ferric nitrate (Fe; 10 µM), ascorbate (Asc; 0.25mM) 
and PMA either alone or in combination for 24 h. (A) HIV-1 p24 expression analyzed by 
western blot. Representative result of two independent experiments performed in duplicate 
(B) Densitometric analysis of samples presented in panel (A). Graph presented as mean of 
the values of two experiments performed in duplicate ± SEM. (C) HIV-1 Gag mRNA was 
quantified by 1-step RT-ddPCR and standardised to GAPDH gene. Graph presented as 
mean of the values of two experiments performed in duplicates ± SEM. 
 
 
6.12. NAC and iron chelator DFO decreased PMA- and ascorbate-stimulated 
HIV-1 provirus reactivation 
 To determine the involvement of iron and ROS in PMA and ascorbate 
stimulated reactivation of latent HIV-1, ACH-2 cells were pretreated with either NAC 
(5 mM) or with iron chelator, desferrioxamine (DFO; 125 or 62.5 μM ) for 4 h and 
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then treated with ferric nitrate (10 μM), ascorbate (0.25 mM) and PMA (0.5 ng) either 
alone or in combinations for 24 h, as above.  
 Western blot analysis of p24 in cell lysates demonstrated the stimulatory 
effects of PMA alone or with ascorbate in reactivation, while the expression of latent 
HIV-1 was decreased by both NAC and DFO (Fig. 20A and B), suggesting the 
involvement of iron and/or free radicals in the reactivation of the latent HIV-1 by 
these compounds. Fe3+ reduced the HIV-1 reactivation characterized by p24 
expression by PMA-alone or with ascorbate in a way similar to NAC pointing that 
Fe3+ could act as an antioxidant in this system. 
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Fig. 20. NAC and iron chelator DFO decreased PMA and ascorbate stimulated HIV-1 
provirus reactivation. ACH-2 cells pre-treated with either NAC (5 mM) or DFO (125 or 62.5 
µM) for 4 h and treated with ferric nitrate (Fe; 10 µM), ascorbate (Asc; 0.25mM) and PMA 
either alone or in combination for 24 h. (A) HIV-1 p24 expression analyzed by western blot. 
Representative result of two independent experiments performed in duplicates (B) 
Densitometric analysis of samples presented in panel (A). Graph presented as mean of the 
values of two experiments performed in duplicates ± SEM.  
 
 
6.13. Effect of iron and ascorbate on cell viability  
 A3.01 cells, the parental T cell line of ACH-2, were treated with ferric nitrate 
(Fe; 10 μM), ascorbate (2, 1, 0.5 and 0.25 mM) with or without PMA (0.5 ng) either 
alone or in combinations for 48 h.  Induction of apoptosis by the effects of individual 
treatments was determined by analyzing the cell size and granulosity using flow 
cytometry (Fig. 21). Apoptosis in PMA-treated cells was found to increase in 
comparison with cells without PMA addition.  Ascorbate 2 and 1 mM alone and with 
iron increased percentage of apoptosis 2-4-times when compared to the basal 
apoptosis percentage in cells with or without PMA treatment. Importantly, 0.25 mM 


















Fe       - +    -     -     - - +    +    +    +
Asc     -     - 2 1 .5 .25 2 1 .5 .25


















Fe       - +    -     -     - - +    +    +    +




Fig. 21. Effect of iron and ascorbate on cell viability. A3.01 cells were treated with 10 μM 
ferric nitrate, 2, 1, 0.5 or 0.25 mM ascorbate with or without 0.5 ng/ml PMA for 48 h. Cell size 
and granulosity were analysed by flow cytometry. Graph presented as mean of three 
independent experiments performed in duplicates ± SEM.  * Increase is statistically 
significant when compared to 0 in each treatment (p<0.05). The experiments were 
performed with a kind help of Michaela Madlenakova. 
 
 
6.14. Effect of CO and bilirubin on PMA-stimulated reactivation of the latent 
HIV-1 
 Biliverdin formed as a result of heme degradation is unstable and is 
immediately reduced to bilirubin by biliverdin reductase. Both bilirubin and the carbon 
monoxide released from heme degradation are strong anti-oxidants. To elucidate the 
role of CO and bilirubin in latent HIV-1 reactivation stimulated by PMA, ACH-2 cells 
were treated with increasing concentrations of either a CO-donor CORM-A1 (2, 10 
and 50 µM) for 5 minutes or with bilirubin (0.01, 0.1 and 1 µM) for 6 h, and treated 
with 0.5 ng/ml PMA for 24 h. Additionally, the effect of CORM-A1 was tested in PMA 
stimulated ACH-2 cells treated with ferric nitrate (Fe; 10 µM) and ascorbate (0.25 
µM) for 24 h. HIV-1 p24 expression was analysed by western blotting and digital 
quantification was performed with ImageLab software (BioRad). The results revealed 
that CO (CORM-A1) dose dependently inhibited the reactivation of latent HIV-1 as 
indicated by the decreased levels of p24 in PMA-stimulated ACH-2 cells (Fig. 22A 
and B) as well as in PMA-stimulated ACH-2 cells treated with iron and ascorbate 
(Fig. 22C and D). Biliverdin also showed the same pattern of dose-dependent 
decrease in p24 levels in PMA-treated ACH-2 cells (Fig. 22E and F). The effects of 
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biliverdin in PMA-stimulated p24 expression in ACH-2 was tested, but it did not 
reveal any appreciable effects (data not included). 
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Fig. 22. Effect of CO and bilirubin on PMA-stimulated reactivation of the latent HIV-1. 
ACH-2 cells pre-treated with CORM-A1 (2, 10 and 50 µM) for 5 min or with bilirubin (0.01, 
0.1 and 1 µM) for 6 h, and treated with 0.5 ng/ml PMA for 24 h. (ferric nitrate (Fe; 10 µM) 
and ascorbate (0.25 µM) were added extra, only to experiments with CORM-A1 treated 
cells) (A, C, E) Western blot detection of HIV-1 p24 expression. Representative results of 
two independent experiments performed in duplicates. (B, D, F) Quantification of the 
western blots presented in panel (A, C, E) respectively. The graphs represents densitometric 
analysis of 4 western blots ± S.E.M. 
 
 
6.15. Effect of Iron and ascorbate on latent HIV-1 ‘‘mini-virus’’ reactivation and 
cell viability in H12 clone of Jurkat cells 
 In our previous experiments, the HA- and PMA-stimulated HIV-1 provirus 
reactivation in ACH-2 cells was reproducible in Jurkat clones. In addition, HA-alone 
treated for 48 h was also shown to induce the expression of EGFP in the Jurkat 
clones (Fig. 14). Therefore, we decided to determine the effect of iron and ascorbate 
on reactivation of HIV-1 “mini-virus” in H12 Jurkat cells. H12 cells were treated with 
ferric nitrate (Fe; 10 μM), ascorbate (2, 1, 0.5 and 0.25 mM) with or without PMA (0.5 
ng/ml) either alone or in combinations for 48 h. The cells were collected and EGFP 
expression was analysed by flow cytometry. The combination of iron with different 
concentrations of ascorbate induced the expression of EGFP in     H12 cells 
unstimulated or stimulated with PMA (Fig. 23A). Additionally, ascorbate 1 and 2 mM 
alone significantly increased the EGFP expression in unstimulated cells. 
Concentrations of ascorbate lower than 1 mM in combination with iron did not reveal 
any appreciable effect on EGFP expression.  
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 In addition, apoptosis of the cells was determined by flow cytometry to assess 
the effect of iron and ascorbate on H12 cell viability (Fig. 23B). In general, the 
apoptosis induced by iron and ascorbate alone or in combination was proportional to 
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Fig. 23. Effect of Iron and ascorbate on reactivation of the latent HIV-1 ‘‘mini-virus’’  
and cell viability in H12 clone of Jurkat cells. H12 cells treated with 10 µM ferric nitrate 
(Fe), 2, 1, 0.5 or 0.25 mM ascorbate (Asc), and 0.5 ng/ml PMA for 48 h. (A) Flow cytometric 
analysis of EGFP expression. The graphs show a quantification of EGFP expression 
calculated as the arithmetic mean of green fluorescence of green cell population X 
percentage of green cells. The graphs represent mean and standard error of mean (S.E.M.) 
of 3-8 experiments (B) Percentage of apoptosis -based on the size and granulosity as 
analysed by FACS (FSC-A x SSC-A).  x, * Increase is statistically significant when compared 
to 0 in each treatment (p<0.1, 0.05 respectively). The experiments were performed with a 





cells. A 5-fold increase in apoptotic cell percentage was observed in PMA-alone 
treatment, when compared to unstimulated H12 cells. 
6.16. Role of iron in HA-mediated and PMA-stimulated reactivation of the latent 
HIV-1 
 In order to confirm the role of iron also in the HA-mediated, PMA-induced 
reactivation of HIV-1 provirus, the ACH-2 cells were pretreated with DFO (125 and 
62.5 µM) for 4 h and treated with HA (2.5 µl) for 24 h, followed by additional 24 h  
treatment with PMA (0.5 ng/ml). HIV-1 p24 expression in cell lysates was detected 
by western blot analysis and HIV-1 Gag mRNA expression was quantified by 1-step 
RT-ddPCR. Both p24 protein levels (Fig. 24A and B) and Gag mRNA expression 
levels (Fig. 24C) are dose dependently decreased by DFO in HA and PMA 
stimulated induction of HIV-1 provirus reactivation in ACH-2 cells. The results 
confirmed the possibility of role of iron in HA-mediated PMA stimulated latent HIV-1 
reactivation. Of note, DFO decreased also the levels of control β-actin in the 
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Fig. 24. Role of iron in HA-mediated and PMA-stimulated reactivation of the latent HIV-
1. ACH-2 cells pre-treated with 125 and 62.5 µM DFO for 4 h, and treated with 2.5 ul of 
heme arginate/ml for 24 h and additional 24 h with PMA (0.5 ng/ml) (A) Western blot 
analysis of HIV-1 p24 antigen. Representative results of two independent experiments 
performed in duplicates. (b) Quantification of the western blots presented in panel (A). The 
graph represents densitometric analysis of 4 western blots ± S.E.M. (C) Analysis of HIV-1 
Gag RNA using 1-step RT-ddPCR. The Gag mRNA quantified was standardised to human 




6.17. Heme arginate stimulates HIV-1 expression in human HIV+ PBMC’s ex 
vivo 
 Demonstrating the stimulatory effects of HA and PMA on latent HIV-1 
reactivation directly in primary cell cultures would be more appropriate in reflecting 
the real situation in vivo, as the latency models used in previous experiments are 
known to reveal different mutations and clonal bias. For example, ACH-2 cells 
possess a mutation in TAR region, affecting Tat-mediated transactivation of latent 
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HIV-1 provirus transcription ( Venkatachari et al., 2015). Also in the Jurkat clones, 
the HIV “mini-virus” genome integration site and differential methylation pattern 
influences the rate of transactivation (Jordan et al., 2001, Blazkova et al., 2009). 
Thus, in order to validate the effects of HA and PMA on reactivation of the latent 
HIV-1, PBMCs isolated from four HIV-1 infected patients on cART were treated with 
HA (2.5 ul) and PMA (0.5 or 2.5 ng/ml) for 18 h. In the first approach, we intentionally 
used PBMC’s instead of purified CD4+ T-cells because the heterogenic cell 
population is closer to the situation in vivo. The HIV-1 Gag mRNA was detected in 
the total RNA isolated from the PBMCs cultured ex vivo by two step semi-nested 
qPCR. Gag mRNA quantified was standardised to human GAPDH mRNA. As shown 
in Fig. 25, the cell-associated HIV-1 Gag RNA detected in all the samples at the time 
of isolation, went down during the 18 h-incubation ex vivo (based on relative 
quantification to GAPDH). PMA-alone and HA-alone increased the levels of HIV-1 
RNA compared to untreated samples. On the other hand, HA synergized with PMA 
to induce a 2-12-fold increase in HIV-1 Gag RNA expression when compared to 
untreated samples. HIV-1 RNA levels were quantified relatively to human GAPDH. 
Additionally in a different series of experiments testing 10 house-keeping genes, we 
found GAPDH and β-2 microglobulin genes to be affected the least by individual 
treatments. Nevertheless, PMA treatment increased their expression also, affecting 




Fig. 25. Heme arginate stimulates HIV-1 expression in human HIV+ PBMC’s ex vivo.  5 
x 106/ml of human PBMC’s were treated with HA 2.5 μl/ml with or without addition of 0.5 or 
2.5 ng/ml PMA for 18 h. HIV-1 Gag RNA was analysed using semi-nested 2-step RT-qPCR 
and standardized to GAPDH mRNA. Results of 4 different HIV+ patients on cART are 
presented as fold-increase (A, B, C, D). T0 – time 0, 0 – no treatment, HA – heme arginate 
2.5 μl/ml, PMA 0.5 or 2.5 ng/ml, NP – not performed. The experiments were performed with 
a kind help of Zora Melkova. 
 
6.18. Comparison of HIV-1 reactivation by HA and other T cell activating agents 
Tumor necrosis factor-α (TNF-α), phytohemagglutinin (PHA) and phorbol 
myristate acetate (PMA) are some of the well-known and routinely used T cell 
activators. The PMA concentration (0.5 ng/ml) used in our experiments was selected 
based on a preliminary screening as the lowest concentration of PMA required to 
detect p24 expression by western blot analysis. The weak stimulation and 
reactivation of HIV-1 provirus by this low concentration of PMA allows to detect a 
several hundred-fold increase in reactivation when potentiated by pre-treatment with 
HA (Fig. 13B). To assess the efficiency of HA-potentiated, PMA-stimulated HIV-1 
provirus reactivation and to compare it with other cell stimulators, ACH-2 cells were 
treated with 5 µl/ml of HA, PMA (final concentration 0.5 ng/ml), HA and PMA, TNF-α 
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(final concentration 1 and 10 U/ml) or phytohemagglutinin (PHA; final concentration 
0.5 and 1 µg/ml) for 48 h. HIV-1 provirus reactivation was characterized as p24 
expression detected in cell lysate by western blot analysis and in culture supernatant 
by ELISA. 
The results revealed that treatment with HA-alone as high as 5 µl/ml did not 
stimulate reactivation of HIV-1 in ACH-2 cells. p24 expression levels in PMA-alone 
treatment were increased comparably as in combination with HA for 48h. TNF-α 1 
U/ml induced a relatively smaller expression of p24 Ag, whereas 10 U/ml of TNF-α 
led to maximum expression of p24 Ag of all the compounds.  On the other hand, all 
the concentrations of phytohemagglutinin A tested (PHA; 0.5, 2.5; 5 µg/ml) alone or 
in combination with 1 µM ionomycin failed to yield a positive signal of p24 Ag in 
western blot analysis (Fig. 26A and data not shown). 
The HIV-1 provirus reactivation and p24 expression in culture supernatants 
quantified by ELISA analysis revealed similar changes as the western blot analysis 
(Fig. 26B). It was clear that a 24 h pre-treatment with HA and followed by a 
stimulation with PMA for additional 24 hours increased p24 expression in ACH-2 
cells several folds more than a 24 h stimulation with PMA alone (Fig. 13A and B). 
However, at 48 h, stimulation of ACH-2 cells by PMA-alone resulted in a stronger 
expression of p24 than by the combined action HA and PMA. This effect was 
possibly due to the death of the HA-and PMA-stimulated cells at 48 h - as indicated 
by the decreased β-actin levels (Fig. 26A) or due to the inhibitory effects of heme 
degradation end products CO and bilirubin (Fig. 22). 
HA mediated reactivation of HIV-1 “mini-virus” in A2 and H12 cells was 
compared using the same stimulatory agents and experimental settings for 48 h. As 
observed previously (Fig. 14) the weak expression of EGFP in A2 and H12 cells by 
HA-alone treatment was increased strongly with PMA-alone and even more strongly 
with PMA and HA. The stimulation with 10 U/ml of TNF-α or 0.5–1 µg/ml PHA was 
comparable to the effect of PMA, while the stimulation with 1U/ml TNF-α induced a 
relatively weaker expression of EGFP. The effect of 1 U/ml TNF-α was comparable 
to the effect of HA (2.5 µl/ml) in H12 cells, while it was stronger in A2 cells. 
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EGFP expression by individual cell-stimulating agents was also determined 
using flow cytometry (Fig. 26D, Table 26E). As expected, the EGFP expression 
pattern was similar to the trend observed in western blot analysis. Also, as 
mentioned above, H12 cells reveal a higher background expression of EGFP in 
untreated cells than A2 cells, and in general respond with a smaller fold-increase 
than A2 cells. Based on various criteria used in this analysis, it can be concluded 
that A2 cells are more responsive to TNF-α than H12 cells. When analyzing the cell 
viability, neither PMA nor TNF-α alone or in combination with HA were found to 
decrease it. On the other hand, PHA reduced cell viability relatively strongly.  
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A2 EGFP+ Cells (%)   H12 EGFP+ Cells (%)  
  0 PMA PHA 0.5 TNF 1 TNF 10    0 PMA PHA 0.5 TNF 1 TNF 10 
               
HA 0 2.74 8.10 13.57 14.68 72.55  HA 0 9.46 18.30 30.84 15.08 43.75 
HA 1.25 1.76 11.97 14.33 15.93 73.73  HA 1.25 9.29 16.49 29.25 14.83 43.20 
HA 2.5 2.81 17.75 15.33 20.90 75.40  HA 2.5 9.88 19.58 28.00 16.30 43.30 
  SD    SD 
HA 0 0.57 2.78 2.09 1.92 3.20  HA 0 2.33 3.96 5.48 3.11 1.55 
HA 1.25 0.91 1.70 1.98 2.68 2.23  HA 1.25 1.93 2.58 2.06 2.57 0.98 
HA 2.5 0.26 1.01 1.43 1.74 1.91  HA 2.5 2.34 2.33 1.62 2.76 0.74 
             
A2 Fluoresc. Intensity (EGFP+ Live Cells Median)  H12 Fluoresc. Intensity (EGFP+ Live Cells Median) 
  0 PMA PHA 0.5 TNF 1 TNF 10    0 PMA PHA 0.5 TNF 1 TNF 10 
               
HA 0 979 1,897 5,342 1,367 4,556  HA 0 1,098 1,813 4,319 1,217 2,836 
HA 1.25 1,187 2,607 6,462 1,625 5,853  HA 1.25 1,167 1,951 5,388 1,335 3,325 
HA 2.5 1,597 4,189 7,702 2,074 7,891  HA 2.5 1,207 2,373 6,045 1,459 3,969 
  SD    SD 
HA 0 251 242 615 148 441  HA 0 94 204 969 61 135 
HA 1.25 214 659 854 212 653  HA 1.25 101 241 154 84 152 
HA 2.5 212 338 796 165 661  HA 2.5 69 31 406 84 98 
             
A2 Cell Viability (% of Live Cells)  H12 Cell Viability (% of Live Cells) 
  0 PMA PHA 0.5 TNF 1 TNF 10    0 PMA PHA 0.5 TNF 1 TNF 10 
               
HA 0 83.35 87.44 70.69 85.93 85.98  HA 0 86.78 86.75 61.63 88.10 87.45 
HA 1.25 80.77 83.74 68.20 82.85 82.50  HA 1.25 84.45 85.33 69.85 85.63 85.03 
HA 2.5 76.56 79.68 61.33 80.10 79.35  HA 2.5 81.43 86.58 67.83 83.13 81.43 
  SD    SD 
HA 0 2.05 1.55 3.72 1.20 1.27  HA 0 1.08 3.75 16.59 0.75 1.10 
HA 1.25 1.68 2.35 1.64 1.54 1.22  HA 1.25 1.58 5.20 5.20 0.85 0.40 
HA 2.5 1.99 2.67 3.25 1.30 1.13  HA 2.5 0.90 4.17 4.51 0.76 1.25 
  
 
Fig. 26. Comparison of HIV-1 reactivation by HA and other T cell activating agents. 
ACH-2 cells were treated with 5 µl/ml of HA, PMA (final concentration 0.5 ng/ml), HA and 
PMA, TNF-α (final concentration 1 and 10 U/ml) or phytohemagglutinin (PHA; final 
concentration 0.5 and 1 µg/ml) for 48 h. (A) Levels of p24 and b-actin were characterized by 
western blot analysis and chemiluminescence. (B) p24 antigen in culture supernatants were 
determined by ELISA. Results of two independent experiments ±SD.     (C and D) A2 and 
H12 cells were treated as above except the HA concentration used (HA 1.25 µl/ml or 2.5 
µl/ml) for 48 h (C) Western blot analysis of EGFP in the cells. Representative results of two 
independent experiments. (D) Flow cytometric analysis of EGFP expression. The graphs 
show a quantification of EGFP expression calculated as the arithmetic mean of green 
fluorescence of green cell population X percentage of all EGFP-positive cells.  
*Increase in EGFP expression is statistically significant when compared to HA 0 in each 
treatment (p < 0.05).  x, Increase in EGFP expression in the presence of the stimulatory 
agent is statistically significant when compared to the same concentration of HA without the 
agent (p < 0.05). (E) Flow cytometric analysis of EGFP expression. Tables summarize 
percentage of all EGFP-positive cells, fluorescence intensity of EGFP+ live cells (median of 
green fluorescence), and cell viability (% of life cells) presented in Fig. 26D. Live and 
apoptotic cells were distinguished based on their size and granulosity (FSC-A x SSC-A; Fig. 
8). The results represent means of two independent experiments performed in duplicates 
± S.D. The experiments involving flow cytometry were performed with a kind help of Zora 
Melkova and Jana Liskova. 
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6.19. HA neither stimulated nor interfered with activation of T cell  
CD69 is expressed on the activated T cells, and thus it is used as a surface 
marker for the identification of T cell activation. To determine whether HA-alone 
activates the T cells or whether it might interfere with PMA-stimulated T cell 
activation, the A3.01 cells were stimulated with PMA (0.5 ng/ml) with or without HA 
(1.25 and 2.5 µl/ml) for 24 h. Expression of CD69 on the cell surface was determined 
by using anti-CD69 antibody labelled with AlexaFluor 700 and flow cytometry. The 
results revealed that HA did not exhibit any effects on T-cell activation characterized 
by this activation marker at any concentration of PMA tested (1 and 10 ng/ml; data 
not shown), especially not even at the lowest concentration used throughout the 
experiments (0.5 ng/ml; Fig. 27). Importantly, HA alone did not activate the T cells 
when used alone. 
      




















Fig. 27. HA neither stimulated nor interfered with activation of T cells.  A3.01 cells were 
treated with increasing concentrations of HA in the presence or absence of PMA (final 
concentration 0.5 ng/ml) for 24 h. Flow cytometry detection of T cell activation marker CD69. 
Representative results of two independent experiments performed in duplicates. 
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6.20. Selected compounds potentiate reactivation of the HIV-1 provirus in ACH-
2 cells stimulated by different cell inducers. 
 In order to identify new promising molecules that could possibly be developed 
and used as latency reversing agents, we screened several compounds and 
selected three among them for further evaluation of their effect on reactivation of 
latent HIV-1 in synergy with different activation inducers. The selected compounds 
(A, B and C) alone do not reveal any stimulatory effects, but they potentiate the 
reactivation of transcriptionally silent HIV-1 provirus induced by threshold levels of 
different inducers (1, 2 and 3). Therefore, they can be considered as sensitizers. The 
level of synergy is different for different inducer-compound combinations. In general, 
all three compounds increases the reactivation of HIV-1 by several folds when 
compared to the inducers alone (Fig. 28A and B), but compound A is the most 
efficient one among the compounds tested. More information about the compounds 
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Fig. 28. Selected compounds potentiates reactivation of the HIV-1 provirus in ACH-2 
cells stimulated by different cell inducers.  0.5 x 106/ml of ACH-2 cells were incubated 
without any inducer or with an inducer (inducer 1, 2, 3), additionally in combination with 
compounds A, B and C (5, 10 μM). (A) After 24 hours, the cells were collected and lysed, the 
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proteins were resolved by 14% SDS-PAGE, and HIV protein p24 was detected by western 
blot analysis using chemiluminescence. (B) The parallel samples were incubated for 48 
hours, and then the levels of p24 Ag in the supernatant were determined by ELISA. The 
inducer alone = 100%. The experiments involving ELISA assay were performed with a kind 









7. Discussion  
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Global HIV-AIDS epidemic reached the peak in 1997 when new infection 
rates started to be efficiently curbed down by highly active antiretroviral therapy 
(HAART). Out of 36.7 million people who are currently living with HIV (as of 2015) 
only 17 million people are having access to antiretroviral therapy yet. Despite this still 
unsufficient coverage, AIDS-related deaths have fallen by 45% since the peak in 
2005 (http://www.unaids.org/en/resources/fact-sheet). The introduction of even more 
efficient combined antiretroviral therapy (cART) has significantly improved the clinical 
outcome and life expectancy of HIV infected patients. Despite the clinical benefits of 
the drug therapy, cART alone is not able to eliminate the virus from the organism, as 
the virus persists in reservoirs that are thought to be the source for viral re-
emergence after treatment interruption (Chun et al., 2010 and Chun et al., 1997). 
Therefore, developing novel therapeutics targeting the latent reservoirs becomes 
crucial. Latently infected CD4+ T cells constitute one reservoir of replication-
competent HIV that needs to be eliminated to completely purge the virus from 
antiretroviral drug-treated patients. For the realization of a sterilizing cure, strategies 
to eradicate the latent virus reservoirs including the “shock and kill” method of 
therapeutic reactivation are being actively explored by researchers. Latency 
reversing agents often target the factors involved in establishing viral latency and 
reactivation and expression of transcriptionally silent latent virus. HDAC inhibitors, 
HMT inhibitors, DNMT inhibitors, protein kinase C activators and several unclassified 
molecules are examples of molecules being explored and developed as possible 
latency reversing agents (Ylisastigui et al., 2004, Archin et al., 2012, Bjerg 
Christensen, 2015, Kumar et al, 2015, Bernhard et al., 2011, Kauder et al., 2009, 
McKernan et al., 2012, Trushin et al., 2005, Gulakowski, 1997, Jose et al., 2014). 
Since increased redox stress plays an important role in HIV-1 replication (Pace and 
Leaf, 1995) our aim was to employ the effects of redox stress induced by redox 
modulators and to reactivate the latent HIV-1. 
 Heme arginate is consists of heme and L-arginine.One of its degradation 
products is ferrous iron (Fe2+). Heme- and iron-mediated Fenton reaction generates 
reactive oxygen species (ROS) and creates an oxidative stress. Heme arginate is 
more stable and has less or no side effects on homeostasis when compared to its 
equivalent hematin (Volin et al., 1988). Heme has been previously shown to inhibit 
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replication of HIV-1 (Levere et al., 1991), specifically reverse transcriptase (Argyris et 
al., 2001). Further, heme derivative hemin has been demonstrated to inhibit HIV-1 
growth in human PBMC-reconstituted NOD-SCID mice and to induce a dose-
dependent inhibition of HIV-1 replication in tissue culture during a 7-day long 
infection (Devadas and Dhawan, 2006).  Though the RT inhibition by heme or 
hematin has been demonstrated by different groups as stated above, there is a gap 
in the research exploring the effect of heme or hematin in HIV-1 latency reversal and 
there are no reports available in the literature about this. Hence, we sought to 
explore and evaluate the effect of heme arginate on HIV-1 replication and 
reactivation from latency. 
 In accordance with previous publications, our results revealed the inhibitory 
effects of HA on HIV-1 replication and reverse transcription in acutely infected cells, 
characterized by levels of p24 and reverse transcripts, respectively. Devadas and 
Dhawan (2006), also found hemin to induce expression of HO-1, and the inhibitory 
effects of hemin on HIV-1 replication could be reversed by certain concentrations of 
SnPP, the inhibitor of HO-1. Based on these results, they had concluded that the 
inhibition of HIV-1 growth was mediated by the action of HO-1. We also observed a 
HA-induced expression of HO-1 in ACH-2 cells, while its levels were already 
increased in untreated A2 and H12 cells. However simultaneously, we observed HA-
induced stimulatory effects on HIV-1 provirus and ‘‘mini-virus’’ reactivation in ACH-2 
and A2, H12 cells, respectively. 
 HA stimulated HIV-1 provirus reactivation in synergy with PMA or TNF-α, in 
ACH-2 cells while it acted alone and/or in synergy with the two agents in A2 and H12 
cells. Further, the effects of HA in both ACH-2 cells and Jurkat clones A2 and H12 
were increased by the addition of SnPP, the inhibitor of HO-1, and all the stimulatory 
effects could be inhibited by antioxidant NAC and iron chelator DFO. Thus based on 
our results, it can be suggested that in the experiments of Devadas and Dhawan 
(2006), the inhibitory effects of hemin on HIV-1 replication were in fact over-ridden by 
the increased redox stress due to inhibition of HO-1 by SnPP and the resulting 
increase in expression of the provirus. 
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 Heme and hemin differ in the oxidation state of iron in the two compounds; 
they contain Fe2+ and Fe3+, respectively. In the organism, heme is mostly bound as 
a prosthetic group in various heme proteins. In the presence of various oxidizing 
agents, the heme moiety is oxidized to hemin, while the oxidized heme proteins as 
well as the free hemin readily undergo reduction driven by CO, both in biological 
systems and in vitro (Bickar et al., 1984). Changes in the oxidation state of iron in 
heme moiety are also mediated by another ubiquitously present gas signaling agent, 
nitric oxide (Ascenzi et al., 2010; Kilbourn et al., 1994). It is thus impossible to strictly 
separate the effects of heme and hemin as their mutual balance is dynamically 
regulated. On the other hand, only heme can serve as a substrate of HO-1. As a 
hydrophobic compound, hemin inserts into plasma membranes and translocates 
inside the cells. Inside the cells, the free iron is released namely by the action of 
heme oxygenases, hydrogen peroxide or other non-specific degradation (Belcher et 
al., 2010), leading to the generation of the hydroxyl radical (Kruszewski, 2003) and 
activation of the redox sensitive transcription factor NF-κB (Lander et al., 1993; 
Pantano et al., 2006). Heme also regulates levels of key enzymes involved in heme 
synthesis and degradation, non-specific synthase of 5-aminolevulinic acid (ALAS1), 
HO-1, and of oxidative stress response genes (Furuyama et al., 2007; Igarashi and 
Sun, 2006; Mense and Zhang, 2006).  
 In the time-course experiments (Fig. 9), HA inhibited HIV-1 replication 
characterized by levels of p24 Ag. In similar time-course experiments (Fig. 10), 
viability of the mock-infected and infected cells in the presence of HA was found 
comparable to the untreated mock-infected cells, while untreated infected cells 
succumbed to apoptosis. A long-term culture of the cells in the presence of HA in 
concentrations that inhibited HIV-1 replication did not therefore negatively affect cell 
growth and viability; on the contrary, HA protected the infected cells from dying. We 
cannot, though, exclude a possibility that a selection of HA-resistant cells could take 
place. 
 In contrast to the acutely infected cells, HA revealed stimulatory effects on 
HIV-1 provirus and ‘‘mini-virus’’ reactivation in ACH-2 and A2, H12 cells, 
respectively. In A2 and H12 cells, HA stimulated ‘‘mini-virus’’ reactivation even by 
itself, but its effects were much weaker than those of PMA, PHA, or TNF-α alone or 
100 
 
in combination with HA. The overall EGFP expression as well as percentage of 
EGFP-positive cells were dose-dependent for all agents. During a 48 h-incubation 
period, stimulatory effects of HA and TNF-α were more or less comparable to HA 
and PMA in H12 cells, while A2 cells appeared to be more responsive to TNF-α (Fig. 
26D). Both cell lines seemed to respond similarly to PHA. H12 cells revealed a 
higher background fluorescence of untreated cells than A2 cells, similarly to the 
published data (Blazkova et al., 2009), but in general, they responded to the 
individual inducers with a smaller fold-increase than A2 cells. Perhaps, the lower 
responsiveness of H12 cells might be due to a somewhat higher CpG methylation of 
the 50 LTR region compared to A2 cells (Blazkova et al., 2009). 
 The observed effects of PMA on the HIV-1 provirus reactivation in ACH-2 
cells were biphasic, possibly due to a low concentration of PMA used. During a 24 h-
treatment, PMA stimulated the provirus reactivation only weakly, while a 48 h-
treatment induced a 10-fold increase in the levels of p24 compared to a 24 h-
treatment. 
 Apparently, PMA was inducing the provirus reactivation indirectly. It seems to 
induce expression and/or activity of certain factors that in turn mediate reactivation of 
the provirus. Phorbol esters mimic the action of diacyl glycerols (DAG), activators of 
protein kinase C family proteins (PKC) and of several non-PKC targets. In addition to 
DAG or phorbolester, the full activation of PKC’s requires also Ca2+  and acidic 
phospholipids, leading to a synergistic activation of two different ligand binding 
domains and to the appropriate membrane targeting (Brose and Rosenmund, 2002; 
Goel et al., 2007). PKC was also found to mediate expression of HO-1 stimulated by 
PMA or LPS (Devadas et al., 2010; Naidu et al., 2008). Also, PMA is known to 
generate ROS (primarily superoxides) (Swindle et al., 2002).The effects of PMA in 
ACH-2 cells could be greatly potentiated with HA during a 24 h-treatment (Figs. 13 
and 15).  Possibly, HA could synergize with PMA by changing levels of cytoplasmic 
Ca2+, membrane targeting of PKC’s or by increasing the redox stress and changing 
the properties of zinc-finger-like repeats in C1 domain involved in PMA binding to its 
targets. Heme and PMA were independently shown to affect also other signal 
transduction pathways, e.g. Ras and MAPK, increasing chances for their synergistic 
action (Mense and Zhang, 2006; Sacks, 2006). The exact mechanism of stimulation 
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of HIV-1 reactivation by HA remains to be established, but a mechanism involving 
induction and/or activity of HO-1 along a with release of Fe2+, increased redox stress 
and activation of the redox-sensitive transcription factor NF-κB can be suggested 
(Belcher et al., 2010; Devadas and Dhawan, 2006; Kruszewski, 2003; Lander et al., 
1993; Morse et al., 2009; Pantano et al., 2006). Therefore, we propose a model in 
which heme arginate induces a redox stress leading to chromatin remodeling, 
binding of specific transcription factors to HIV-LTR and potentiation of HIV-1 
expression induced by a PKC inducer.  
 Our results indicate a HA-induced expression of HO-1 in ACH-2 cells, while 
HO-1 was found present already in untreated A2 and H12 cells. In all cell lines, LTR-
driven expression could be inhibited by pretreatment of the cells with antioxidant 
NAC, precursor of the potent anti-oxidant, GSH, and by iron chelator DFO, 
suggesting that the effect of HA involved an increased redox stress mediated by iron. 
In fact, we have also detected increased production of free radicals by A3.01 and 
Jurkat cells in the presence of HA or PMA (unpublished results). Additionally, we 
tested the effect of the inhibitor of HO-1, SnPP, in both ACH-2 and Jurkat clones A2 
and H12. While SnPP was not found to affect basal expression of EGFP in either cell 
line, it strongly stimulated this expression in the presence of HA in both A2 and H12 
cells. Most probably, EGFP expression could be stimulated by an increased redox 
stress imposed by HA that could not be counteracted by the anti-oxidative effects of 
HO-1 because of its inhibition by SnPP. Alternatively, electron transfer between the 
two porphyrin species and generation of ROS could take place. Again, the 
stimulatory effects of SnPP and HA on LTR-driven expression were inhibited by 
NAC. 
 The other two products of heme oxygenases, CO and biliverdin, further 
converted to bilirubin, reveal strong antioxidant and cytoprotective properties (Morse 
et al., 2009). The effect of HA addition thus can be shortly pro-oxidative and then 
anti-oxidative for a prolonged period of time. Thus, upon a massive induction of 
expression of HO-1 stimulated by HA and PMA in ACH-2 cells, the anti-oxidative 
effects could eventually prevail, and inhibit provirus reactivation during a longer 
incubation in the presence of HA. The situation seems to be different in A2 and H12 
cells in which HO-1 was found expressed already in untreated cells and its levels 
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were not further increased by any treatment; HO-1 thus could start to effectively 
degrade HA immediately after its addition. Apparently, the kinetics and balance 
between the pro-oxidative and anti-oxidative effects of HO-1 products might be 
different in these cells. 
 We used A2 and H12 cells (Blazkova et al., 2009; Jordan et al., 2001) to 
characterize the effects of HA on LTR-driven expression, comparing western blot 
analysis detecting levels of EGFP and flow cytometry detecting fluorescence of 
EGFP. The flow cytometry results underestimate the numbers of EGFP-positive cells 
and/or levels of EGFP expressed, as high levels of EGFP are cytotoxic and dead 
cells loose EGFP fluorescence. Nevertheless, we assessed the overall expression   
of EGFP by the number of all EGFP-positive cells x arithmetic mean of green 
fluorescence of the green cell population. Using this approximation, the levels of 
EGFP expression were found increased even by treatment with 1.25 µl/ml of HA in 
most experiments, corresponding to the results of western blot analysis. The 
percentage of green (EGFP-positive) cells in samples treated with 1.25 µl/ml of HA 
used to be lower than in untreated cells, while the arithmetic mean and median of 
green fluorescence of all green and live green cells, respectively, were always 
higher. In higher concentrations of HA, as well as in other stimulatory treatments, all 
values were higher than in controls. 
 In general, in A2 and H12 cells, HA alone or in combination with other 
stimulatory agents increased LTR-driven EGFP expression as well as cell death. 
These tendencies seemed to be similar in ACH-2 cells. However, a long term 
incubation of A3.01 and Jurkat cells with HA did not significantly increase cell death. 
It is thus possible that the cytotoxicity of HA might be further increased due to 
expression of HIV or EGFP. In fact, it would be of advantage if latently infected cells 
were more prone to cell death induced by HA alone or in combinations. There might 
be several mechanisms involved in cell death induced by HA: first, a direct increase 
in ROS production due to a higher availability of heme and iron; second, an indirect 
cytotoxicity of HA that would further increase ROS production and HIV reactivation; 
third, the resulting increase in HIV reactivation would lead to the cell death. The 
excess of oxygen free radicals induces oxidation of proteins, lipids, lipoproteins, 
nucleic acids, carbohydrates and other cellular or viral targets. Thus, HA might not 
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only stimulate expression of the provirus, but also affect the viability and infectivity of 
the released virions. A similar inhibition of HIV-1 by reactive oxygen species was 
indeed shown in the case of bleomycin (Georgiou et al., 2004). 
 Heme oxygenase has been suggested to exert various immunoregulatory 
effects on innate and adaptive immune cells, and to inhibit pathogenesis of several 
immune-mediated inflammatory diseases (Soares et al., 2009). Further, analysis of 
HO-1 promoter polymorphism revealed that Caucasian HIV-1-infected patients who 
maintain low levels of immune activation and control HIV-1 viral loads to 
undetectable levels are more likely to possess a specific microsatellite (GT)n repeat 
and two single nucleotide polymorphisms in HO-1 promoter region that favour 
enhanced HO-1 gene expression (Seu et al., 2009). 
 With these findings of the effect of heme arginate on HIV-1 provirus 
reactivation, we then stepped further to decipher the role of individual heme 
degradation products- iron, carbon monoxide and  bilirubin (reduced from biliverdin 
by biliverdin reductase) on HIV-1 latency reversal.   Previously published results 
indicated that a longer pre-treatment with ascorbate suppressed the induction of 
HIV-1 reactivation in latently infected T-cell lines (Harakeh et al., 1990). However, in 
our experiments, ascorbate added shortly before PMA stimulated latent HIV-1 
reactivation in both ACH-2 and H12 cells; these effects could be attributed to the 
double faced character of ascorbate that can act as an anti- or pro-oxidant, 
depending on its high or low concentrations (Atanassova and Tzatchev, 2008). Pro-
oxidant character of ascorbate has been observed in a recent study where ascorbate 
induced necrosis of Hep2 cells via ROS generation and PKC induction, while the 
antioxidant NAC inhibited the effects of ascorbate (Beak et al., 2016). Methylation of 
DNA at the 5-position of cytosine (5mC) is an important epigenetic modification that 
repress gene transcription. In contrast, demethylation makes DNA accessible for 
active gene transcription. Interestingly, Fe(II) and ascorbate function as co-factors for 
enzymes that are involved in demethylation (Ponnaluri et al., 2013; Minor et al., 
2013; Dickson et al., 2013). Ascorbate mediated increase in latent HIV-1 gene 
expression could also be explain in this light. 
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 Further, the stimulatory effects of ascorbate but also those of PMA were 
inhibited by DFO, suggesting involvement of iron in these processes. In addition to 
direct effects of DFO on iron chelation, this inhibition might be explained also by 
previously described inhibitory effects of DFO on activation of NF-κB, the redox-
sensitive transcription factor involved in both PMA signaling and HIV-1 reactivation 
(Sappey et al., 1995). On the other hand, addition of Fe3+, similarly to NAC, was 
inhibitory to PMA- and ascorbate-stimulated latent HIV-1 reactivation; Fe3+ alone 
thus appears to reveal final antioxidant effects in this system, possibly due to its 
complex with EDTA. Evidently, the final outcome of chemical reactions and 
annihilations of individual compounds and free radicals, respectively, depends on 
many variables and can dynamically change in a biological system. Importantly, the 
concentrations of heme-degradation products used in our experiments were 
comparable or lower than effective concentrations of heme arginate. On the other 
hand, effective concentrations of heme arginate are achievable in vivo (Tokola et al., 
1986).   
 In ACH-2 cells, the effect of ascorbate or iron with ascorbate on induction of 
latent HIV expression was relatively lower at both RNA and protein levels than the 
effect of HA. Indeed, HA serves as a source of both iron and hemin. Heme similarly 
to iron, generates ROS by Fenton reaction (Shibahara, 2003), while hemin is known 
to regulate expression of various genes (Furuyama et al., 2007; Mense and Zhang, 
2006).  On the other hand, pretreatment with a CO-donor or bilirubin dose-
dependently decreased p24 levels in ACH-2 cells, while the CO donor increased 
EGFP expression and bilirubin was ineffective in H12 cells. These differences may 
be attributable to a different intracellular redox milieu, possibly affected by a 
constitutive expression of heme oxygenase-1 (Shankaran et al., 2011). In addition to 
its anti-oxidant property, bilirubin is also a PKC inhibitor (Sano et al., 1985), and thus 
can directly inhibit HIV-1 transcription stimulated by PMA (a PKC inducer). These 
results also suggest that the contribution of the individual heme-degradation 
products may vary in different cell types in vivo. In the first approach, we intentionally 
used PBMC’s to verify the stimulatory effects of heme arginate as they are closer to 
the situation in vivo. Nevertheless, additional experiments on individual cell types, 
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namely on isolated total and resting CD4+ cells, will better assess the magnitude of 
HA-stimulatory effects and help to delineate the underlying mechanisms. 
 HIV-1 replication and spread is closely connected to the induction of cell 
death and can be modulated by its onset (Cummins and Badley, 2013; Wang et al., 
2016; Wang et al., 2011). While the general apoptosis due to toxicity of latency 
reversing agents is not desirable, elimination of the infected cells is a goal of all 
approaches aiming at curing HIV-1. Increased redox stress characterized by 
decreased levels of reduced glutathione is associated with HIV-1 replication (Pace 
and Leaf, 1995), while it was suggested as an approach to reactivate and kill latently 
infected cells by several authors (Iordanskiy and Kashanchi, 2016; Lewis et al., 
2011; Shankaran et al., 2011).   Importantly, central memory and transition memory 
T-cells, the main reservoir cells containing the latent HIV-1, were shown to be more 
susceptible to the redox stress and apoptosis (Chirullo et al., 2013). 
 HIV/AIDS, similarly to other chronic infections, has been reported to lead to 
immune-mediated anemia of chronic disease, iron deficiency anemia or their 
combination (Kerkhoff and Lawn, 2015; Minchella et al., 2015), in which differential 
expression of hepcidin, hemojuvelin, ferroportin and other factors plays an important 
role (Drakesmith and Prentice, 2012; Krijt et al., 2004; Theurl et al., 2011; Xu et al., 
2010). Consequently, iron supplements have often been administered. However, this 
can result in an increased labile iron pool (LIP) and reactivation, expression and 
dissemination of HIV-1. In fact, it has been recognized that iron plays a critical role in 
several steps of HIV-1 replication (Nekhai et al., 2013) and its levels are modulated 
by most nonpathogenic SIV (Koppensteiner et al., 2014). Several clinical studies 
also suggest that iron supplementation or hereditary defects leading to increased 
intracellular iron stores can fasten progression of HIV infection to AIDS in untreated 
patients (Gordeuk et al., 2001; McDermid et al., 2007; Rawat et al., 2009).  
 In vivo, HIV-1 infection can coincide with several conditions that lead to acute 
or chronic hemolysis that could cause a similar exposure to extracellular heme as 
the administration of HA. These conditions include genetically determined glucose-6-
phosphate dehydrogenase deficiencies, sickle cell anemia, thalasemia or other 
hemoglobinopathies as well as various other diseases involving hemolytic episodes 
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or chronic hemolysis, especially malaria (Lopez et al., 2010; Pamplona et al., 2009). 
It would be worthwhile to determine a possible correlation of HIV-1/AIDS progression 
with these conditions. However, the situation is complex and therapeutic 
interventions, namely iron supplementation, could strongly affect the fine balance of 
pro-oxidative and anti-oxidative agents. 
 In clinics, HA is used to treat acute attacks of hepatic porphyrias. The mean 
maximum plasma levels of heme after a single dose of HA 3 mg/kg body weight was 
determined as 60 µg/ml (corresponds to 2.4 µl/ml of HA), with a plasma half-life of 
10.8 h and a distribution volume of 3.4 L (Tokola et al., 1986). The concentrations of 
HA used throughout this research work are thus very close to the levels achieved in 
clinics. Additionally, 24–48 h after administration of the same dose of hemin, but in 
the form of Panhematin, plasma levels of HO-1 were increased 5-times, while its 
activity in venous leukocytes increased 15-times (Bharucha et al., 2010). 
 Heme mediates a feedback inhibition of the rate-limiting enzyme in the heme 
synthetic pathway, synthase of 5-aminolevulinic acid. It also reconstitutes heme 
stores and function of various hemoproteins, namely hemoglobin, cytochrome P450, 
guanylate synthase, nitric oxide synthases, tryptophan dioxygenase, catalase and 
peroxidase. However, neither the exact pathogenesis of the neurovisceral symptoms 
in acute porphyrias, nor the precise mechanism of action of heme arginate are 
understood (http://www.porphyria.uct.ac.za/professional/prof-haem-therapy.htm; 
Herrick and McColl, 2005; Siegesmund et al., 2010). Nevertheless since HA has 
been approved for human use, it can be suggested that HA could be tested as a 
supplement of HAART in selected cases. For example its administration could be 
suggested as an additional measure in early stages of HIV/AIDS disease to release 
the virus from the existing latent pool, while inhibiting its dissemination to the new 
viral reservoirs. Since the levels of TNF-α and other cytokines are increased and/or 
dysregulated in HIV/AIDS, HA might synergize with these cytokines in provirus 
reactivation also in vivo. The suggestion of HA use in HIV/AIDS is further supported 
by a case of an HIV-positive individual that was administered one infusion of 
Normosang because of anemia. This patient then remained p24 negative for several 
months (Pavel Martasek, General Faculty Hospital in Prague, personal 
communication). Obviously, the use of HA should be tested first in animal models of 
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retrovirus infection to assess its therapeutic potential against retroviruses more 
closely. 
 Also, the administration of HA can be complicated by its adverse side effects. 
Vascular side effects of HA, especially on hemostasis, can occur, but they are 
reported to be much weaker than after administration of hematin (Panhaematin). 
Additionally, since hemin decreased HIV growth in humanized mice even when 
administered intraperitoneally (Devadas and Dhawan, 2006), it is possible that the 
i.p. or some other way of administration of HA would be also effective against HIV in 
humans. Repeated administrations of HA could lead to an iron overload. However, 
HIV/AIDS disease is often accompanied by the anaemia due to a chronic immune 
activation, altered porphyrin metabolism caused by iron deficiency (Adetifa and 
Okomo, 2009; Fuchs et al., 1990) as well as by treatment with antiretrovirals (Bozzi 
et al., 2004; Fox et al., 1999). All these conditions would be improved by the 
administration of heme, while iron overload might not develop. 
 The ability of cells to become activated remained unaffected by HA as 
demonstrated by expression of the early activation marker CD69, characterized by 
flow cytometry. Since the activation of T cells constitutes an essential component of 
immune responses to the virus itself as well as to other infections, we consider the 
finding that HA does not seem to generally decrease the activation of T cells as 
important. Moreover, HA did not induce any global activation of T-cells either; this 
finding is significant as well, since a nonspecific T-cell activation and release of pro-
inflammatory cytokines should be avoided. The effect of HA thus could be compared 
to the effect of 5-hydroxynaphthalene-1,4-dione, a compound described to reactivate 
the latent provirus without cellular activation (Yang et al., 2009).  
 In addition to the experiments studying a role of HA and heme degradation 
products in HIV-1 latency reversal, we selected additional three compounds and 
assessed their potency to reactivate HIV-1 provirus in ACH-2 cells either alone or in 
combination with three different inducers. None of the selected compounds alone 
could induce the latent HIV-1 expression, while they all stimulated the reactivation of 
HIV-1 provirus induced by the three inducers and increased p24 expression several 
folds. Thus, they could be rather called sensitizers. The final effect of the 
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combination of the two agents is higher than the sum of the effects of the two agents 
used individually (“1+1 > 2”); therefore, it can be classified as a true synergy. 
Understandably, different concentrations of compounds and their combination with 
different inducers resulted in varying levels of reactivation of latent HIV-1. The best 
working compound-inducer combinations we found in our experiments were filed for 
Czech and International patent right protection. In fact very recently, an approach 
towards using a combination of compounds to reactivate HIV-1 provirus and 
reservoir clearance has been eagerly explored. For example, the combination of 
romidepsin (HDAC inhibitor) and bryostatin-1 (PKC agonist) has been shown to be 
very effective in latency reversal in primary CD4+ T cells. Our HA+PMA-mediated 
stimulation and compounds combinations also follow this new approach of HIV-1 
therapeutic reactivation and reservoir clearance. 
 To our knowledge, this is the first work demonstrating the stimulatory 
effect of heme on reactivation of the latent provirus. HA seems to possess a 
combination of two unique properties: it can help to reactivate the provirus from 
latent pools, and simultaneously prevent HIV-1 dissemination into new cells and/or 
expansion of the latent pool. On the whole, these results suggest a possibility of an 













 Despite the successful suppression of HIV-1 viraemia by cART, the 
transcriptionally silent provirus and the inaccessible reservoirs of latent virus are the 
main hurdles to eradicate the HIV-1 infection. “Shock and kill” strategy aiming to 
reactivate the latent virus and wipe out the latent reservoirs, is currently a hot topic in 
HIV-1 therapy research. Our original work focussed at exploring the effects of heme 
arginate on HIV-1 acute infection and reactivation of the latent provirus. The key 
findings and contributions of our research could be summarised as follows: 
1. Heme arginate (HA) inhibited HIV-1 replication in acute infection. 
2. The effective concentrations of HA (2.5 µl/ml and 1.25 µl/ml) that inhibited the 
HIV-1 acute infection did not reveal any significant cytotoxicity. 
3. HA synergized with PMA in reactivating latent HIV-1 in ACH-2 cells and HIV-1 
“mini-virus” in Jurkat clones A2 and H12. 
4. HA alone reactivated HIV-1 “mini-virus” in Jurkat clones A2 and H12. 
5. HO-1 enzyme expression was induced by HA in PMA-stimulated ACH-2 cells, 
but not in A2 and H12 clones, in which the enzyme was found expressed 
constitutively even in untreated cells. 
6. Ascorbate added to generate Fe2+, one of heme degradation products, 
increased the reactivation of HIV-1 provirus in PMA-stimulated ACH-2 and 
H12 cells. In contrast, Fe3+ revealed a final anti-oxidant effect and decreased 
HIV-1 reactivation stimulated by PMA alone and in combination with 
ascorbate. 
7. Carbon monooxide and bilirubin, other two heme degradation products, 
inhibited HIV-1 reactivation stimulated by PMA alone and in combination with 
ascorbate. 
8. Anti-oxidant N-acetyl cysteine inhibited the reactivation of latent HIV-1 by 
PMA alone and in combination with HA or ascorbate, suggesting that the 
stimulatory effects ware mediated by reactive oxygen species. 
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9. Iron chelator desferrioxamine (DFO) prevented latent HIV-1 reactivation by 
PMA alone or in combination with HA or ascorbate, indicating a causal role of 
iron.  
10. HA and PMA stimulated HIV-1 expression also in primary PBMCs of HIV-1 
infected cART-treated patients during ex vivo culture. 
11. HA did not activate nor inhibit activation of T cells. 
12. Our results suggest that HA could be used as a safe HIV-1 latency reversing 
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HIV-1 infection can be currently controlled by combined antiretroviral therapy, but a 
sterilizing cure is impossible as this therapy does not target persistent HIV-1 in latent 
reservoirs. Therefore, different latency reversing agents are intensively explored in 
various models. 
We have previously observed that heme arginate, a drug approved for human use, 
reveals a strong synergism with PKC inducers in reactivation of the latent provirus. 
Heme is physiologically decomposed by heme oxygenases into 3 degradation 
products: iron (Fe2+), carbon monoxide (CO) and biliverdin which is further converted 
to bilirubin by biliverdin reductase.  
In this paper, we have studied the effects of individual heme-degradation products 
on latent HIV-1 reactivation in ACH-2 cells harboring integrated HIV-1 provirus and in 
H12 clone of Jurkat cells harboring HIV-minivirus expressing EGFP. We employed 
addition of ascorbate to generate Fe2+, resulting in increased expression of both HIV-
1 p24 Ag and EGFP in PMA-stimulated ACH-2 and H12 cells, respectively, as 
characterized on RNA and protein levels. On the other hand, addition of a CO-donor 
or bilirubin decreased the p24 expression. The reactivation of latent HIV-1 by iron or 
heme arginate was inhibited by antioxidant N-acetyl cysteine, or by an iron chelator 
desferrioxamine, suggesting that the effects were mediated by iron- or heme-induced 
redox stress. Finally, we demonstrated the synergistic effects of heme arginate and 
PMA on HIV-1 expression in peripheral blood mononuclear cells of HIV-infected 
patients cultured ex vivo. These results may constitute a new direction in the latent 
HIV-1 reactivation and therapy. 
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AIDS = acquired immune deficiency syndrome; cART = combined anti-retroviral 
therapy; CO = carbon monoxide; CORM-A1 = carbon monoxide releasing molecule-
A1; DFO = desferrioxamine; EGFP = enhanced green fluorescent protein; FBS = 
fetal bovine serum; GAPDH = glyceraldehyde 3-phosphate dehydrogenase; GSH = 
glutathione; HA = heme arginate; HIV-1 = human immunodeficiency virus-1; HO-1 = 
heme oxygenase-1; LTR = long terminal repeat; NAC = N-acetyl cysteine; PBMC’s = 
peripheral blood mononuclear cells; PKC = protein kinase C; PMA = phorbol 
myristate acetate; RNS = reactive nitrogen species; ROS = reactive oxygen species; 




HIV/AIDS pathogenesis inherently involves increased generation of reactive oxygen 
and nitrogen species (ROS, RNS) mediated by pro-inflammatory cytokines. An 
increased redox stress with decreased levels of GSH were found already in early 
stages of HIV infection (Pace and Leaf, 1995). Redox stress regulates signal 
transduction by activating redox-sensitive transcription factors like NF-kB and NFAT, 
as well as chromatin remodeling, namely by inhibiting histone deacetylases 
(Kennedy et al., 2012; Pantano et al., 2006; Rahman et al., 2004). HIV-1 LTR 
includes multiple upstream DNA regulatory elements that serve as binding sites for 
cellular transcription initiation factors and facilitate NF-kB and NFAT binding. ROS 
are involved in the reactivation of HIV from latent reservoirs through post-
translational activation of NF-kB (Pyo et al., 2008). While activated, NF-kB facilitates 
HIV gene expression by directing recruitment of the histone acetyltransferases to the 
HIV-1 LTR (Gatignol, 2007). Iron and ascorbate-mediated redox stress affects 
methylation status of  the promoters of genes involved in the redox stress response 
(Yara et al., 2013). 
We have previously demonstrated in human T-cell lines that Normosang (heme 
arginate; HA), a hemin derivative approved for human use in treatment of acute 
porphyria, reactivated the latent provirus by itself or in synergy with PKC inducers 
like phorbol myristate acetate (PMA), TNF-alpha, prostratin or bryostatin-1 
(Shankaran et al., 2011), and unpublished data). HA also induced expression of 
heme oxygenase-1 (HO-1) and inhibition of this enzyme increased the provirus 
reactivation. Antioxidant N-acetyl cysteine (NAC), precursor of GSH, inhibited the 
provirus reactivation, suggesting that the reactivation was mediated by ROS 
(Shankaran et al., 2011). 
Heme is an efficient inhibitor of reverse transcriptase (Argyris et al., 2001; Levere et 
al., 1991; Shankaran et al., 2011), while its derivative hemin stimulates expression of 
various genes, especially HO-1 (Mense and Zhang, 2006). Free heme is toxic due to 
its ability to catalyze Fenton reaction generating hydroxyl radicals, highly reactive 
ROS (Shibahara, 2003). Heme from hemoglobin of aged erythrocytes is 
physiologically degraded by HO-1 in spleen, but the excess of heme and its 
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derivatives stimulates HO-1 expression ubiquitously (Sheftel et al., 2007; Soe-Lin et 
al., 2008). HO-1 breaks down heme into iron (Fe2+), carbon monoxide (CO), and 
biliverdin that is consequently reduced to bilirubin by the action of biliverdin 
reductase. Fe2+ might induce a short-term pro-oxidative state, while CO and 
especially the redox cycle bilirubin/biliverdin/biliverdin reductase act as antioxidants. 
In general, HO-1 is considered an antioxidant enzyme with immunomodulatory 
properties (Otterbein et al., 2003). 
In this paper, we have studied the effects of heme degradation products on PMA-
induced reactivation of latent HIV-1 when added individually to latently infected T-cell 
lines. Further, we assessed the effects of antioxidant NAC and iron chelator 
desferrioxamine (DFO) and verified the synergistic effects of heme arginate and 




All the media and growth supplements were purchased from Thermo Scientific, USA, 
Invitrogen Corporation (Carlsbad, CA) or PAA Laboratories GmbH (Pasching, 
Austria).  Other chemicals used, including phorbol myristate acetate, ferric nitrate, 
ascorbic acid, carbon monoxide releasing molecule-A1 (CORM-A1), bilirubin, 
desferrioxamine mesylate salt (DFO) and N-Acetyl cysteine were purchased from 
Sigma-Aldrich (Germany) unless otherwise specified. Heme arginate (Normosang) 
was purchased from Orphan Europe (Paris, France). The chemicals for RNA and 
DNA isolation, PCR and real-time PCR were purchased from Top-Bio (Czech 
Republic), for ddPCR from Bio-Rad (Hercules, USA), primers and probes from IDT 
(Belgium) and Life Technologies (Carlsbad, CA, USA). TURBO DNA-free kit, 
Ambion, was from Life Technologies (Carlsbad, CA, USA). 
Cell lines and primary cells and their treatment 
Human T-cell line ACH-2 harboring an integrated HIV-1 provirus (clone #4; (Clouse 
et al., 1989)), their parental cell line A3.01, and the H12 clone of Jurkat cells latently 
infected with a ‘‘mini-virus’’ containing the HIV-1 LTR-Tat-IRES-EGFP-LTR 
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(Blazkova et al., 2009; Jordan et al., 2003; Shankaran et al., 2011), were grown in 
RPMI 1640 supplemented with 10% fetal bovine serum, 2 mM glutamine, 12.5 mM 
Hepes, and antibiotics (penicillin 1x105 U/l, streptomycin 100 mg/l; 10% FBS-RPMI). 
The cells were plated at final concentration of 0.5 x 106 cells/ml/well in 10% FBS-
RPMI and then treated with iron (10 μM) and ascorbate (0.25 mM in ACH-2 cells; 
0.25, 0.5, 1 and 2 mM in A3.01 and H12 cells; (Hermes-Lima et al., 2000; Zhang et 
al., 2008)) or with heme arginate (2.5 μl/ml), followed by PMA (0.5 ng/ml); in certain 
experiments, the cells were pre-treated with additional compounds as specified. The 
cells were collected after 24 h (ACH-2 cells) or 48 h (A3.01 and H12 cells).  
Stock solutions of PMA and bilirubin were prepared in DMSO and freshly diluted in 
culture medium to 20x working solutions. Other working solutions were freshly 
prepared as follows: 100x Fe3+ (1 mM FeNO3 in 50 mM Hepes pH=8 and 20 mM 
EDTA), 100x ascorbate (25 mM ascorbic acid in H2O), 100x CORM-A1 (5 mM 
CORM-A1 in H2O), 20x NAC (100 mM in RPMI 1640), 100x DFO (12.5 mM in H2O). 
The compounds were added at final concentrations specified in each experiment. 
PBMC’s of HIV-infected patients on cART with undetectable viremia (< 50 copies/ml) 
were isolated by Ficoll gradient centrifugation (Histopaq, Sigma-Aldrich, Germany), 
differential blood count was determined by Advia 60 Hematology System (Bayer 
Healthcare, USA) and PBMC’s were resuspended at final concentration of 5 x 106 
lymphocytes/ml in 10% FBS-RPMI. PBMC’s were plated at 1 ml/well in a 24-well 
plate and subjected to treatment with 2.5 µl of HA/ml and different concentrations of 
PMA for 18 h.  
Western blot analysis 
Cells were collected after 24 h of incubation, lysed in Laemmli reducing sample 
buffer, boiled and analyzed by SDS–PAGE and western blotting as previously 
described (Harlow, 1988; Laemmli, 1970; Shankaran et al., 2011), using 
chemiluminescence (West Femto, Thermo Fisher Scientific – Pierce, Rockford, IL). 
The cell lysates were resolved on a 12% SDS–PAGE and transferred to a PVDF 
membrane (Hybond, Bio-Rad, Hercules, USA). HIV-1 p24 was detected using a 
mouse monoclonal antibody ND-1 (dilution 1:500; Exbio, Prague, Czech Republic) 
and a peroxidase-conjugated goat anti-mouse IgG (dilution 1:20,000; Sigma Co., 
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St.Louis, MO). β-actin was detected using a rabbit polyclonal antibody (dilution 
1:10,000; Abcam, Cambridge, United Kingdom) and a peroxidase-conjugated goat 
anti-rabbit IgG (dilution 1:20,000, MP Biomedicals – Cappel, Solon, OH). The 
chemiluminescence was recorded using ChemiDoc MP system (BioRad, Hercules, 
USA) and the densitometry analysis was performed with ImageLab software version 
5.0 (BioRad, Hercules, USA). 
Flow cytometry analysis 
Flow cytometer Canto II (Becton Dickinson) equipped with 3 lasers emitting at 488, 
405 and 633 nm, and with 8 detectors was used. Flow cytometry measurements and 
subsequent analyses of the data were performed using the Diva 6 software (Becton 
Dickinson, Franklin Lakes, NJ). EGFP fluorescence was determined in FL1 
(detecting at 515–545 nm) and expressed as the arithmetic mean of green 
fluorescence of green cell population x percentage of green cells. The results of 
each experiment performed in duplicate were then normalized to untreated cells 
(100%); the graphs represent mean and standard error of mean (S.E.M.) of 3-8 
experiments. Live and apoptotic cells were distinguished based on their size and 
granulosity (FSC-A x SSC-A) and % of apoptotic cells was calculated (Shankaran et 
al., 2011). 
RNA isolation and quantification 
RNA was isolated using RNA Blue reagent by precipitation of the aqueous phase 
according to the manufacturer’s protocol (Top-Bio, Czech Republic); RNA was 
solubilized in nuclease- and protease-free molecular biology grade water (Sigma-
Aldrich, Germany) with the addition of RiboLock RNase inhibitor (Thermo Scientific, 
USA; final concentration 1 U/µl) and stored in -80ºC for further use. The 
concentration and purity of RNA was determined by measuring the absorbance at 
260 and 280 nm using UV spectrophotometer Eppendorf BioSpectrometer 
(Eppendorff AG, Germany). The RNA isolated from ACH-2 cells was then treated 
with TURBO DNase (TURBO DNA-free kit, Ambion, Life Technologies) to remove 
contaminant genomic DNA according to the manufacturer’s protocol. For HIV+ 
PBMC’s, 18 µl of RNA (out of total 20 µl) were treated with 6 U of TURBO DNase; 
final volume after inactivation was 26 µl. 
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Quantification of HIV-1 RNA by droplet digital PCR 
Absolute quantification of the HIV-1 RNA expressed in ACH-2 cells was performed 
using the QX100 droplet digital PCR system (Bio Rad, Hercules, USA) and One-
Step RT ddPCR kit for probes (Bio Rad, Hercules, USA) according to the 
manufacturer’s protocol. Twenty µl of the reaction mixture consisted of 10 µl of 2x 
one-step RT ddPCR super mix, 0.8 µl of 25 mM manganese acetate, 0.5 or 5 ng of 
DNase-treated RNA and primers and probes for HIV Gag or human GAPDH. 
Primers and probes used: HIV-1 Gag – forward primer GAG1 (5’-
TCAGCCCAGAAGTAATACCCATGT-3’) and reverse primer GAG2 (5’-
CACTGTGTTTAGCATGGTGTTT-3’), final concentration 200 nM each, probe GAG3 
(FAM-5’-ATTATCAGAAGGAGCCACCCCACAAGA-3’-BHQ1), final concentration 
250 nM  (Kiselinova et al., 2014; Pasternak et al., 2008); human GAPDH – 1x 
primer-probe Hs02758991_g1 VIC-MGB labelled (Life Technologies, Calsbard, CA, 
USA). The droplets were generated using the QX100 droplet generator (Bio Rad, 
Hercules, USA) by mixing 70µl of droplet generation oil for probes (Bio Rad, 
Hercules, USA) with 20 µl of ddPCR reaction mixture and PCR amplification was 
performed on the T100 thermal cycler (Bio Rad, Hercules, USA). The thermal cycling 
conditions were as follows: reverse transcription at 60ºC for 30 minutes, 95ºC for 5 
min, 40 cycles consisting of denaturation at 94ºC for 30 s and annealing/extension at 
60ºC for 60 s, followed by 10 min at 98ºC. The amplified droplets were read by the 
QX100 droplet reader (Bio Rad, Hercules, USA) and the data were analysed by 
QuantaSoft analysis software 1.6.6.0320 (Bio Rad, Hercules, USA). Copies of Gag 
RNA were standardized to human GAPDH as a reference gene. 
Quantification of HIV-1 RNA by real-time PCR 
RNA isolated from cultured and stimulated PBMC’s of HIV-infected patients treated 
with cART was used for detection of cell-associated HIV-1 RNA using semi-nested 
2-step RT-qPCR adapted from (Kiselinova et al., 2014; Pasternak et al., 2008). 
Sixteen µl of DNase-treated RNA was used for reverse transcription in a final volume 
of 40 µl using random hexamer primers (Premium Reverse Transcriptase, Thermo 
Scientific). Then, 20 µl of cDNA was amplified in a total volume of 100 µl using 
GAG1 and SK431 primers (final concentration 250 nM each; SK431 sequence: 5’-
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TGCTATGTCAGTTCCCCTTGGTTCTCT-3’; (Pasternak et al., 2008)) and 0.05 U/µl 
of Blood Taq DNA polymerase (Top-Bio, Czech Republic) in 1x PCR Blue buffer 
(Top-Bio, Czech Republic) containing 2 mM MgCl2. The thermal cycling conditions 
were as follows: initial denaturation at 95ºC for 5 min, 15 cycles consisting of 
denaturation at 94ºC for 30 s, annealing at 55ºC for 30 s,  and extension at 72ºC for 
60 s, followed by terminal extension at 72ºC for 10 min using the Mastercycler 
Gradient (Eppendorf AG, Hamburg, Germany). Finally, 10 µl of the first PCR product 
was used in duplicate for real-time PCR in a total volume of 50 µl containing GAG1 
and GAG2 primers, GAG3 probe (final concentration 200 nM each; GAG3 sequence: 
FAM-5’-ATTATCAGAAGGAGCCACCCCACAAGA-3’-TAMRA; (Pasternak et al., 
2008)), and 1x qPCR Blue buffer (Top-Bio, Czech Republic) using the Applied 
Biosystems 7300 Real-time PCR System (Applied Biosystems, Foster City, CA) and 
the universal cycling conditions. Four µl of the first PCR product was used for 
quantification of a reference gene in a 20 µl reaction also in duplicate. Four µl of 
DNase-treated RNA was used for a no-RT control and further processed in the way 
analogous to cDNA. The mean of technical duplicates was used for relative 
quantification of HIV Gag compared to GAPDH. Changes in expression of 10 
additional house-keeping genes in healthy donors PBMCs after the individual 
treatments were determined using Real-time PCR kit for Human Reference Genes 
(Generi Biotech, Czech Republic). 
Statistical analysis 
Results are presented as means ± S.E.M. The data were analysed and graphically 
represented using GraphPad Prism 5.04 software. Statistical significance of 
differences between control and different treatments within each group were 
determined using a two-sample two-tailed unpaired Student’s t-test with Welch’s 
correction. Equality of variances was tested with F-test. 
RESULTS 
First, we aimed to determine the effects of iron-mediated redox stress on reactivation 
of the latent HIV-1 in ACH-2 cells harboring an integrated HIV-1 provirus. Since Fe2+ 
is quickly oxidized to Fe3+ in the aqueous environment, we employed ascorbate to 
generate Fe2+ in our system (Hermes-Lima et al., 2000; Zhang et al., 2008). We 
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have treated unstimulated or PMA-stimulated ACH-2 cells with Fe3+, ascorbate and 
with a combination of Fe3+ and ascorbate. In unstimulated cells, none of the 
treatments induced p24 expression as detected by western blot analysis and 
chemiluminescence, recorded and analyzed digitally by the ChemiDoc system. In the 
PMA-stimulated cells, Fe3+ alone decreased the PMA-stimulated p24 levels, while 
ascorbate alone increased the PMA-stimulated p24 levels and this increase was 
partially inhibited by Fe3+ (Fig. 1 (a, b)). All the stimulatory effects on p24 expression 
were inhibited by pretreatment of the cells with an antioxidant NAC, precursor of 
GSH, or with an iron chelator desferrioxamine. These results suggest involvement of 
free radicals and/or iron in the reactivation of the latent HIV-1 by these compounds, 
including ascorbate. Interestingly, the effect of Fe3+ on PMA- and ascorbate/PMA-
stimulated p24 expression was inhibitory in a way similar to NAC. Thus, Fe3+ alone 
appears to reveal final antioxidant effects in this system. 
In order to further characterize the mechanism of iron and ascorbate action in ACH-2 
cells, we have quantified levels of HIV-1 mRNA using 1-step RT-ddPCR. PMA alone 
increased background Gag mRNA levels 34-times, while addition of ascorbate or 
addition of iron with ascorbate increased the PMA-stimulated levels about 6- and 2-
times more, respectively (Fig. 1 (c)). Again, Fe3+ alone inhibited PMA-stimulated p24 
expression.  
In addition, we have used a parental cell line of ACH-2 cells, A3.01, to determine 
effects of the individual treatments on induction of apoptosis using flow cytometry 
and changes in their size and granulosity (Fig. 1 (d)). PMA treatment increased the 
background apoptosis about twice, while addition of 2 and 1 mM ascorbate alone 
and with iron increased percentage of apoptosis 2-4-times more in both unstimulated 
and PMA-stimulated cells. Importantly, 0.25 mM ascorbate that was used in ACH-2 
cells, did not induce any increase of apoptosis. 
The other two degradation products of heme arginate are CO and biliverdin that is 
converted to bilirubin by the action of biliverdin reductase. We have used a CO-
donor CORM-A1 to characterize the effects of CO and addition of bilirubin to PMA-
stimulated ACH-2 cells. As shown in Fig. 2, increasing concentrations of both 
CORM-A1 and bilirubin dose-dependently decreased the levels of PMA-stimulated 
p24 levels. We have also tested the effects of biliverdin, but it did not reveal any 
appreciable effects (data not shown). 
162 
 
Additionally, we used the H12 clone of Jurkat cells harboring a latent HIV-1 “mini-
virus” expressing EGFP under control of HIV-1 LTR (Shankaran et al., 2011), 
(Jordan et al., 2003). This clone was previously shown to possess an increased 
methylation of the HIV-1 LTR (Blazkova et al., 2009) and revealed similar responses 
to HA administration as ACH-2 cells, except that HA alone, in the absence of PMA, 
induced EGFP expression also (Shankaran et al., 2011). The  combination of iron 
and ascorbate stimulated EGFP expression both with and without PMA, as 
determined by flow cytometry, while higher concentrations of ascorbate alone 
induced EGFP expression also in the unstimulated H12 cells (Fig. 3 (a)). In other 
concentrations, including 0.25 mM that was used in ACH-2 cells, ascorbate did not 
induce any reactivation. Further, we have determined the percentage of apoptosis 
induced by the individual treatments in these cells (Fig. 3 (b)). PMA treatment 
increased the background apoptosis about 5-times, while percentage of apoptosis 
induced by the individual treatments seemed to reveal a similar pattern as EGFP 
expression. Then, we tested the effects of CORM-A1 and bilirubin in H12 cells. 
CORM-A1 increased the levels of EGFP expression in PMA-stimulated H12 cells 
while pretreatment with of bilirubin did not seem to affect EGFP expression (data not 
shown). On the other hand, percentage of apoptosis was not affected either by 
CORM-A1 or bilirubin (around 5 and 25% in unstimulated and PMA-stimulated cells, 
respectively). 
Previously, we have demonstrated a synergistic effect of heme arginate and PMA on 
reactivation of the latent HIV-1 in ACH-2 cells that was inhibited by the antioxidant 
NAC (Shankaran et al., 2011). In order to determine the role of iron in the HA-
mediated effects, we have now pre-treated the ACH-2 cells with DFO before addition 
of HA and PMA. As shown in Fig. 4 (a, b), DFO decreased HA- and PMA-mediated 
reactivation of latent HIV-1 as characterized by levels of p24 antigen and western 
blot analysis. Of note, DFO decreased also the levels of control β-actin in the 
absence of HA in these experiments. Further, we have determined the levels of HIV-
1 mRNA using 1-step RT-ddPCR (Fig. 4 (c)). As expected, DFO also decreased the 
levels of HA- and PMA-stimulated levels of HIV-1 mRNA, indicating the role of iron in 
PMA- and HA-mediated effects. 
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The results presented above were performed in cell lines which reveal different 
mutations and clonal bias. ACH-2 cells are known to have a mutation in the TAR 
region affecting the Tat-mediated transactivation (Emiliani et al., 1996; Venkatachari 
et al., 2015), while the expression of the latent provirus in different Jurkat clones is 
dependent on their integration site (Jordan 2001). Therefore, to validate the effects 
of HA and PMA on reactivation of the latent HIV-1, we decided to determine the 
effects of HA and PMA in primary cells isolated from the peripheral blood of HIV-
infected patients on cART with undetectable plasma virus load. In the first approach, 
we have intentionally used PBMC’s, as the wider spectrum of cell types is closer to 
the situation in vivo. As shown in Fig. 5, cell-associated HIV-1 RNA Gag 
characterized by a semi-nested 2-step RT-qPCR could be detected in all the 
samples at the time of isolation and went down during the 18 h-incubation ex vivo 
(based on relative quantification to GAPDH). PMA added at low concentrations 
somewhat increased the levels of HIV-1 RNA compared to untreated samples. HA 
alone increased the levels of HIV-1 RNA compared to untreated samples (1.7-4.5-
fold), while HA synergized with PMA (2-12-fold increase compared to PMA- 
untreated samples) similarly as in ACH-2 cells. In these experiments, HIV-1 RNA 
levels were quantified relatively to GAPDH. In additional experiments, we have 
determined the effects of these treatments on 10 other house-keeping genes, with 
changes in expression of GAPDH and β-2 microglobulin being the smallest and 
comparable. Nevertheless, their expression was increased by PMA and HA with 
PMA, affecting the relative changes in HIV-1 RNA levels. 
DISCUSSION 
In summary, our results clearly point to the importance of iron and heme metabolism 
and their dysregulation in pathogenesis of HIV/AIDS. Further, the stimulatory effects 
of ascorbate warrant for a cautious use of antioxidants, vitamins and other food 
additives that could affect the redox state of iron. 
Previously published results indicated that a longer pre-treatment with ascorbate 
suppressed the induction of HIV reactivation in latently infected T-cell lines (Clouse 
et al., 1989). However in our experiments, ascorbate added shortly before PMA 
stimulated latent HIV-1 reactivation in both ACH-2 and H12 cells; these effects could 
be attributed to a double faced character of ascorbate that can act as an anti- or pro-
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oxidant, depending on its concentration 
(http://www.benbest.com/nutrceut/AntiOxidants.html#radicals). Further, the 
stimulatory effects of ascorbate but also those of PMA were inhibited by DFO, 
suggesting involvement of iron in these processes. In addition to direct effects of 
DFO on iron chelation, the inhibition by DFO might be explained also by previously 
described inhibitory effects of DFO on activation of NF-κB, the redox-sensitive 
transcription factor involved in both PMA signaling and HIV-1 reactivation (Chirullo et 
al., 2013; Jordan et al., 2003). On the other hand, addition of Fe3+, similarly to NAC, 
was inhibitory to PMA- and ascorbate-stimulated latent HIV-1 reactivation; Fe3+ 
alone thus appears to reveal final antioxidant effects in this system, possibly due to 
its complex with EDTA. Evidently, the final outcome of chemical reactions and 
annihilations of individual compounds and free radicals, respectively, depends on 
many variables and can dynamically change in a biological system. Importantly, the 
concentrations of heme-degradation products used in this paper were comparable or 
lower than effective concentrations of heme arginate. On the other hand, effective 
concentrations of heme arginate are achievable in vivo (Tokola et al., 1986). 
In ACH-2 cells, the effect of ascorbate or iron with ascorbate on induction of latent 
HIV expression was relatively lower at both RNA and protein levels than the effect of 
HA. Indeed, HA serves as a source of both iron and hemin. Heme similarly to iron 
generates ROS by Fenton reaction (Shibahara, 2003), while hemin is known to 
regulate expression of various genes (Furuyama et al., 2007; Mense and Zhang, 
2006). On the other hand, pretreatment with a CO-donor or bilirubin dose-
dependently decreased p24 levels in ACH-2 cells, while the CO donor increased 
EGFP expression and bilirubin was ineffective in H12 cells. These differences may 
be attributable to a different intracellular redox milieu, possibly affected by a 
constitutive expression of HO-1 (Shankaran et al., 2011). These results also suggest 
that the contribution of the individual heme-degradation products may vary in 
different cell types in vivo. In the first approach to verify the stimulatory effects of 
heme arginate we have intentionally used PBMC’s as they are closer to the situation 
in vivo. Nevertheless, additional experiments on individual cell types, namely on 
isolated total and resting CD4+ cells, will better assess the magnitude of HA-
stimulatory effects and help to delineate the underlying mechanisms. 
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HIV-1 replication and spread is closely connected with the induction of cell death and 
can be modulated by its onset (Cummins and Badley, 2013; Wang et al., 2016; 
Wang et al., 2011). While the general apoptosis due to toxicity of latency reversing 
agents is not desirable, elimination of the infected cells is a goal of all approaches 
aiming at curing HIV-1. Increased redox stress characterized by decreased levels of 
reduced glutathione is associated with HIV-1 replication (Pace and Leaf, 1995), while 
it was suggested as an approach to reactivate and kill latently infected cells by 
several authors (Iordanskiy and Kashanchi, 2016; Lewis et al., 2011; Shankaran et 
al., 2011). Importantly, central memory and transition memory T-cells, the main 
reservoir cells containing the latent HIV-1, were shown to be more susceptible to the 
redox stress and apoptosis (Chirullo et al., 2013). 
HIV/AIDS, similarly to other chronic infections, has been reported to lead to immune-
mediated anemia of chronic disease, iron deficiency anemia or their combination 
(Kerkhoff and Lawn, 2015; Minchella et al.), in which differential expression of 
hepcidin, hemojuvelin, ferroportin and other factors plays an important role 
(Drakesmith and Prentice, 2012; Krijt et al., 2004; Theurl et al., 2011; Xu et al., 
2010). Consequently, iron supplements have often been administered. However, this 
can result in an increased labile iron pool (LIP) and reactivation, expression and 
dissemination of HIV-1. In fact, it has been recognized that iron plays a critical role in 
several steps of HIV-1 replication (Nekhai et al., 2013) and its levels are modulated 
by most nonpathogenic SIV (Koppensteiner et al., 2014). Several clinical studies 
also suggest that iron supplementation or hereditary defects leading to increased 
intracellular iron stores can fasten progression of HIV infection to AIDS in untreated 
patients (Gordeuk et al., 2001; McDermid et al., 2007; Rawat et al., 2009).  
In our short-term experimental conditions, the stimulatory effects of heme arginate 
on HIV-expression clearly prevailed in ACH-2 and H12 cells as well as in HIV-
infected PBMC’s (Figs. 4, 5; (Shankaran et al., 2011)). On the other hand, heme 
arginate inhibits the acute HIV infection at the level of reverse transcription (Fig. 6 
(Levere et al., 1991; Shankaran et al., 2011)). Thus, the ability of heme arginate to 
stimulate a short-term reactivation of the latent HIV while inhibiting reverse 
transcription and further replication of the new virus progeny could make it a useful 
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and safe agent in help to eliminate the HIV-1 latent pool in the presence of 
antiretroviral drugs. 
Redox stress can affect epigenetic mechanisms regulating gene expression as well 
as activation of redox-sensitive transcription factors. Therefore, we propose a model 
in which heme arginate induces a redox stress leading to chromatin remodeling, 
binding of specific transcription factors to HIV-LTR and potentiation of HIV-1 
expression induced by a PKC inducer. These results may constitute new direction in 
the latent HIV-1 reactivation and therapy. 
ACKNOWLEDGEMENTS 
We are grateful to Dr. Paula Pitha for kindly providing ACH-2 cells, Dr. Jana 
Blazkova for providing the H12 clone of Jurkat cells, and Dr. Ward De Spiegelaere 
for kind sugestions and protocols for qPCR and ddPCR. We thank Dr. Paula Pitha 
and Dr. Prem Ponka for helpful discussions, and Dr. Emanuel Necas and Dr. Josef 
Bodor for reading the manuscript and comments. We thank Monika Kaplanova for 
technical assistance. The work of P.S. and M.M. was performed in partial fulfillment 
of the requirements for Ph.D. degree at the 1st Medical Faculty, Charles University. 
The work was supported by the Grant Agency of the Ministry of Health of the Czech 
Republic - project No. NT/14135 -3, by Charles University – projects No. PRVOUK-
P24/LF1/3, by the project BIOCEV – “Biotechnology and Biomedicine Centre of the 
Academy of Sciences and Charles University in Vestec” (CZ.1.05/1.1.00/02.0109) 
from the European Regional Development Fund, and by the Ministry of Education of 





Argyris, EG, Vanderkooi, JM, and Paterson, Y (2001): Mutagenesis of key residues identifies 
the connection subdomain of HIV-1 reverse transcriptase as the site of inhibition by 
heme. Eur J Biochem 268, 925-31. 
Blazkova, J, Trejbalova, K, Gondois-Rey, F, Halfon, P, Philibert, P, Guiguen, A, Verdin, E, 
Olive, D, Van Lint, C, Hejnar, J, and Hirsch, I (2009): CpG methylation controls 
reactivation of HIV from latency. PLoS Pathog 5, e1000554. 
Clouse, KA, Powell, D, Washington, I, Poli, G, Strebel, K, Farrar, W, Barstad, P, Kovacs, J, 
Fauci, AS, and Folks, TM (1989): Monokine regulation of human immunodeficiency 
virus-1 expression in a chronically infected human T cell clone. J Immunol 142, 431-
8. 
Cummins, NW, and Badley, AD (2013): Anti-apoptotic mechanisms of HIV: lessons and 
novel approaches to curing HIV. Cell Mol Life Sci 70, 3355-63. 
Drakesmith, H, and Prentice, AM (2012): Hepcidin and the iron-infection axis. Science 338, 
768-72. 
Emiliani, S, Van Lint, C, Fischle, W, Paras, P, Jr., Ott, M, Brady, J, and Verdin, E (1996): A 
point mutation in the HIV-1 Tat responsive element is associated with postintegration 
latency. Proc Natl Acad Sci U S A 93, 6377-81. 
Furuyama, K, Kaneko, K, and Vargas, PD (2007): Heme as a magnificent molecule with 
multiple missions: heme determines its own fate and governs cellular homeostasis. 
Tohoku J Exp Med 213, 1-16. 
Gatignol, A (2007): Transcription of HIV: Tat and cellular chromatin. Adv Pharmacol 55, 137-
59. 
Gordeuk, VR, Delanghe, JR, Langlois, MR, and Boelaert, JR (2001): Iron status and the 
outcome of HIV infection: an overview. J Clin Virol 20, 111-5. 
Harlow, EL, D. (1988): Immunoblotting. In: Harlow, E., Lane, D. (Eds.), Antibodies: A 
Laboratory Manual. Cold Spring Harbor Laboratory Press, New York, 471–510. 
Hermes-Lima, M, Ponka, P, and Schulman, HM (2000): The iron chelator pyridoxal 
isonicotinoyl hydrazone (PIH) and its analogues prevent damage to 2-deoxyribose 
mediated by ferric iron plus ascorbate. Biochim Biophys Acta 1523, 154-60. 
Chirullo, B, Sgarbanti, R, Limongi, D, Shytaj, IL, Alvarez, D, Das, B, Boe, A, DaFonseca, S, 
Chomont, N, Liotta, L, Petricoin, EI, Norelli, S, Pelosi, E, Garaci, E, Savarino, A, and 
Palamara, AT (2013): A candidate anti-HIV reservoir compound, auranofin, exerts a 
selective 'anti-memory' effect by exploiting the baseline oxidative status of 
lymphocytes. Cell Death Dis 4, e944. 
Iordanskiy, S, and Kashanchi, F (2016): Potential of Radiation-Induced Cellular Stress for 
Reactivation of Latent HIV-1 and Killing of Infected Cells. AIDS Res Hum 
Retroviruses 32, 120-4. 
Jordan, A, Bisgrove, D, and Verdin, E (2003): HIV reproducibly establishes a latent infection 
after acute infection of T cells in vitro. EMBO J 22, 1868-77. 
Kennedy, KA, Sandiford, SD, Skerjanc, IS, and Li, SS (2012): Reactive oxygen species and 
the neuronal fate. Cell Mol Life Sci 69, 215-21. 
Kerkhoff, AD, and Lawn, SD (2015): Iron replacement therapy and anemia associated with 
chronic infectious diseases in sub-Saharan Africa. Clin Infect Dis 60, 1438-9. 
168 
 
Kiselinova, M, Pasternak, AO, De Spiegelaere, W, Vogelaers, D, Berkhout, B, and 
Vandekerckhove, L (2014): Comparison of droplet digital PCR and seminested real-
time PCR for quantification of cell-associated HIV-1 RNA. PLoS One 9, e85999. 
Koppensteiner, H, Hohne, K, Gondim, MV, Gobert, FX, Widder, M, Gundlach, S, Heigele, A, 
Kirchhoff, F, Winkler, M, Benaroch, P, and Schindler, M (2014): Lentiviral Nef 
suppresses iron uptake in a strain specific manner through inhibition of Transferrin 
endocytosis. Retrovirology 11, 1. 
Krijt, J, Vokurka, M, Chang, KT, and Necas, E (2004): Expression of Rgmc, the murine 
ortholog of hemojuvelin gene, is modulated by development and inflammation, but 
not by iron status or erythropoietin. Blood 104, 4308-10. 
Laemmli, UK (1970): Cleavage of structural proteins during the assembly of the head of 
bacteriophage T4. Nature 227, 680-5. 
Levere, RD, Gong, YF, Kappas, A, Bucher, DJ, Wormser, GP, and Abraham, NG (1991): 
Heme inhibits human immunodeficiency virus 1 replication in cell cultures and 
enhances the antiviral effect of zidovudine. Proc Natl Acad Sci U S A 88, 1756-9. 
Lewis, MG, DaFonseca, S, Chomont, N, Palamara, AT, Tardugno, M, Mai, A, Collins, M, 
Wagner, WL, Yalley-Ogunro, J, Greenhouse, J, Chirullo, B, Norelli, S, Garaci, E, and 
Savarino, A (2011): Gold drug auranofin restricts the viral reservoir in the monkey 
AIDS model and induces containment of viral load following ART suspension. AIDS 
25, 1347-56. 
McDermid, JM, Jaye, A, Schim van der Loeff, MF, Todd, J, Bates, C, Austin, S, Jeffries, D, 
Awasana, AA, Whittlex, AA, and Prentice, A (2007): Elevated iron status strongly 
predicts mortality in West African adults with HIV infection. J Acquir Immune Defic 
Syndr 46, 498-507. 
Mense, SM, and Zhang, L (2006): Heme: a versatile signaling molecule controlling the 
activities of diverse regulators ranging from transcription factors to MAP kinases. Cell 
Res 16, 681-92. 
Minchella, PA, Armitage, AE, Darboe, B, Jallow, MW, Drakesmith, H, Jaye, A, Prentice, AM, 
and McDermid, JM Elevated Hepcidin Is Part of a Complex Relation That Links 
Mortality with Iron Homeostasis and Anemia in Men and Women with HIV Infection. J 
Nutr 145, 1194-201. 
Nekhai, S, Kumari, N, and Dhawan, S (2013): Role of cellular iron and oxygen in the 
regulation of HIV-1 infection. Future Virol 8, 301-311. 
Otterbein, LE, Soares, MP, Yamashita, K, and Bach, FH (2003): Heme oxygenase-1: 
unleashing the protective properties of heme. Trends Immunol 24, 449-55. 
Pace, GW, and Leaf, CD (1995): The role of oxidative stress in HIV disease. Free Radic Biol 
Med 19, 523-8. 
Pantano, C, Reynaert, NL, van der Vliet, A, and Janssen-Heininger, YM (2006): Redox-
sensitive kinases of the nuclear factor-kappaB signaling pathway. Antioxid Redox 
Signal 8, 1791-806. 
Pasternak, AO, Adema, KW, Bakker, M, Jurriaans, S, Berkhout, B, Cornelissen, M, and 
Lukashov, VV (2008): Highly sensitive methods based on seminested real-time 
reverse transcription-PCR for quantitation of human immunodeficiency virus type 1 
unspliced and multiply spliced RNA and proviral DNA. J Clin Microbiol 46, 2206-11. 
Pyo, CW, Yang, YL, Yoo, NK, and Choi, SY (2008): Reactive oxygen species activate HIV 
long terminal repeat via post-translational control of NF-kappaB. Biochem Biophys 
Res Commun 376, 180-5. 
169 
 
Rahman, I, Marwick, J, and Kirkham, P (2004): Redox modulation of chromatin remodeling: 
impact on histone acetylation and deacetylation, NF-kappaB and pro-inflammatory 
gene expression. Biochem Pharmacol 68, 1255-67. 
Rawat, R, Humphrey, JH, Ntozini, R, Mutasa, K, Iliff, PJ, and Stoltzfus, RJ (2009): Elevated 
iron stores are associated with HIV disease severity and mortality among postpartum 
women in Zimbabwe. Public Health Nutr 12, 1321-9. 
Shankaran, P, Vlkova, L, Liskova, J, and Melkova, Z (2011): Heme arginate potentiates 
latent HIV-1 reactivation while inhibiting the acute infection. Antiviral Res 92, 434-46. 
Sheftel, AD, Kim, SF, and Ponka, P (2007): Non-heme induction of heme oxygenase-1 does 
not alter cellular iron metabolism. J Biol Chem 282, 10480-6. 
Shibahara, S (2003): The heme oxygenase dilemma in cellular homeostasis: new insights 
for the feedback regulation of heme catabolism. Tohoku J Exp Med 200, 167-86. 
Soe-Lin, S, Sheftel, AD, Wasyluk, B, and Ponka, P (2008): Nramp1 equips macrophages for 
efficient iron recycling. Exp Hematol 36, 929-37. 
Theurl, I, Schroll, A, Nairz, M, Seifert, M, Theurl, M, Sonnweber, T, Kulaksiz, H, and Weiss, 
G (2011): Pathways for the regulation of hepcidin expression in anemia of chronic 
disease and iron deficiency anemia in vivo. Haematologica 96, 1761-9. 
Tokola, O, Tenhunen, R, Volin, L, and Mustajoki, P (1986): Pharmacokinetics of 
intravenously administered haem arginate. Br J Clin Pharmacol 22, 331-5. 
Venkatachari, NJ, Zerbato, JM, Jain, S, Mancini, AE, Chattopadhyay, A, Sluis-Cremer, N, 
Bar-Joseph, Z, and Ayyavoo, V (2015): Temporal transcriptional response to latency 
reversing agents identifies specific factors regulating HIV-1 viral transcriptional 
switch. Retrovirology 12, 85. 
Wang, X, Mbondji-Wonje, C, Zhao, J, and Hewlett, I (2016): IL-1beta and IL-18 inhibition of 
HIV-1 replication in Jurkat cells and PBMCs. Biochem Biophys Res Commun 473, 
926-30. 
Wang, X, Ragupathy, V, Zhao, J, and Hewlett, I (2011): Molecules from apoptotic pathways 
modulate HIV-1 replication in Jurkat cells. Biochem Biophys Res Commun 414, 20-4. 
Xu, M, Kashanchi, F, Foster, A, Rotimi, J, Turner, W, Gordeuk, VR, and Nekhai, S (2010): 
Hepcidin induces HIV-1 transcription inhibited by ferroportin. Retrovirology 7, 104. 
Yara, S, Lavoie, JC, Beaulieu, JF, Delvin, E, Amre, D, Marcil, V, Seidman, E, and Levy, E 
(2013): Iron-ascorbate-mediated lipid peroxidation causes epigenetic changes in the 
antioxidant defense in intestinal epithelial cells: impact on inflammation. PLoS One 8, 
e63456. 
Zhang, AS, Canonne-Hergaux, F, Gruenheid, S, Gros, P, and Ponka, P (2008): Use of 
Nramp2-transfected Chinese hamster ovary cells and reticulocytes from mk/mk mice 





Fig. 1 Effect of iron and ascorbate on PMA-stimulated reactivation of the latent 
HIV-1. ACH-2 cells pre-treated with 5 mM N-Acetyl cysteine (NAC) or with 125 and 
62.5 µM desferrioxamine (DFO) for 4 h, and treated with 10 µM ferric nitrate (Fe), 
0.25 mM ascorbate (Asc), and 0.5 ng/ml PMA for 24 h. (a) Western blot analysis of 
HIV-1 p24 antigen. (b) Digital quantification of the western blots presented in panel 
(a). (c) Droplet digital PCR (ddPCR) analysis of HIV-1 RNA. (d) Flow cytometric 
analysis of apoptosis in A3.01 cells, the parental cell line of ACH-2 cells. * Increase 
is statistically significant when compared to control in each group (p<0.05). 
Fig. 2. Carbon monoxide and bilirubin dose-dependently inhibit PMA-
stimulated reactivation of the latent HIV-1. ACH-2 cells pre-treated with CORM-
A1 (2, 10 and 50 µM) for 5 min or with bilirubin (0.01, 0.1 and 1 µM) for 6 h, and 
treated with 0.5 ng/ml PMA for 24 h (a, c) Western blot analysis of HIV-1 p24 
antigen. (b, d) Quantification of the western blots presented in panel (a, c), 
respectively. 
Fig. 3. Flow cytometric analysis of EGFP expression. H12 cells treated with 10 
µM ferric nitrate (Fe), 0.25 mM ascorbate (Asc), and 0.5 ng/ml PMA for 48 h. (a) 
Flow cytometric analysis of EGFP expression. (b) Percentage of apoptosis. x, * 
Increase is statistically significant when compared to control in each group (p<0.1, 
0.05 respectively). 
Fig. 4. Iron chelator prevents hem arginate- and PMA-stimulated reactivation of 
the latent HIV-1. ACH-2 cells pre-treated with 125 and 62.5 µM DFO for 4 h, and 
treated with 2.5 ul of heme arginate/ml and 0.5 ng/ml PMA for 24 h (a) Western blot 
analysis of HIV-1 p24 antigen. (b) Quantification of the western blots presented in 
panel (a). (c) ddPCR analysis of HIV-1 RNA.  
Fig. 5. Heme arginate stimulates HIV-1 expression in human HIV+ PBMC’s ex 
vivo. HIV+ human PBMC’s treated with 2.5 ul of heme arginate/ml and 0.5 or 2.5 
ng/ml PMA for 18 h. T0 – time 0, 0 – no treatment, HA – heme arginate 2.5 µl/ml, 
PMA 0.5 or 2.5 ng/ml, NP – not performed. 
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Fig. 6. Scheme of action of heme arginate in ACH-2 cells. Heme inhibits reverse 
transcription, leading to HIV-1 inhibition. Heme is decomposed by the action of HO-1 
into Fe2+, CO and biliverdin that is further converted to bilirubin by biliverdin 
reductase. Heme- and iron-mediated Fenton reaction generates reactive oxygen 
species (ROS), leading to reactivation of the latent HIV-1; these processes can be 
inhibited by the antioxidant N-Acetyl cysteine or iron chelator Desferrioxamine. CO 
and bilirubin inhibit reactivation of the latent HIV-1. 
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HIV-1 infection cannot be cured as it persists in latently infected cells that are 
not targeted by the immune system nor by available therapeutic approaches. 
Consequently, a lifelong therapy suppressing only the actively replicating virus is 
necessary. The latent reservoir has been defined and characterized in various 
experimental models and in human patients, allowing research and development of 
approaches targeting individual steps critical for HIV-1 latency establishment, 
maintenance, and reactivation. However, additional mechanisms and processes 
driving the remaining low-level HIV-1 replication in the presence of the suppressive 
therapy still remain to be identified and targeted.  
 
Current approaches towards HIV-1 cure involve namely attempts to reactivate 
and purge HIV-latently infected cells (so called “shock and kill” strategy), as well as 
approaches involving gene therapy and/or gene editing and stem cell transplantation 
aiming at generation of cells resistant to HIV-1.  
 
This review summarizes current views and concepts underlying different 
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HIV/AIDS infection can be successfully treated and controlled with the 
combined antiretroviral therapy (cART) affecting different steps of HIV-1 replication 
cycle. Thus, HIV-1 infection could be viewed as a chronic disease with a relatively 
long life expectancy. However cART, which is still not available to all in need, cannot 
cure HIV infection due to the presence of latently infected reservoir cells. The latent 
proviral DNA cannot be recognized by the immune system nor targeted by cART. 
Consequently, a lifelong therapy is necessary, which is expensive and leads to 
various complications and treatment failures. Therefore, new approaches towards 
functional or sterilizing cure are intensively explored - namely attempts to reactivate 
and purge HIV-1 latently infected cells (so called “shock and kill” strategy), as well as 
approaches involving gene therapy and/or gene editing and stem cell transplantation 
aiming at generation of cells resistant to HIV-1. Ongoing research focuses especially 
on the mechanisms of establishment and maintenance of the latent reservoir, 
assessment of its size and composition, as well as on stimulation of the innate and 




Retrovirus replication cycle is specific by a step of reverse transcription and a 
consequent stable integration of the proviral DNA into the host cell genome. 
Depending on the activation status of the host cell, the HIV-1 provirus can be either 
immediately expressed and the virus replication cycle can proceed further or the 
provirus can become dormant and wait until the latently infected cell encounters the 
right stimulus (often a specific, possibly rare antigen) and becomes activated (Fig. 1). 
It is the very presence of the latently infected cells that makes HIV-1 infection 
incurable as these cells serve as a source of virus rebound after a discontinuation or 
failure of the antiretroviral therapy. After the activation of the host cell or specific 
changes in the epigenetic regulation, the chromatin status and availability of 






HIV persistence during therapy 
HIV-1 infects namely CD4+ T lymphocytes, but also myeloid cells like 
macrophages, microglia, astrocytes and dendritic cells, even though to a lesser 
extent. Acute infection of CD4+ T cells usually leads to cell death, but occasionally, 
these cells survive and revert back to a resting memory state. Alternatively, latency 
may be established directly in resting CD4+ T cells. Resting memory cells, including 
the latently infected ones, then persist and/or are replenished by homeostatic 
proliferation. In contrast, macrophages are resistant to cytopathic effects of HIV-1 
infection, and support virus persistence in various anatomical sanctuaries as tissue 
resident macrophages (Kim and Siliciano 2016; Kumar et al. 2015; McKinstry et al. 
2010).  
 
After initiation of cART, plasma viremia and the level of HIV-1 infected cells in 
peripheral blood decays with a well characterized kinetics based on populations with 
a different turnover contributing to plasma viremia (Hilldorfer et al. 2012) (Fig. 2). A 
rapid decline of plasma viremia during first two phases indicates the efficiency of 
antiretroviral drugs. Phase I represents the turnover of the free virus (half-life from 
minutes to hours) and mainly of productively infected CD4+ T cells (half-life of 1-2 
days; (Ho et al. 1995; Perelson et al. 1997; Perelson et al. 1996; Wei et al. 1995)). 
Consequently, Phase II corresponds to the decay of cells more resistant to HIV-
induced cytopathic effect (partially activated T cells and cells of the monocyte-
macrophage lineage with half-life of 2-4 weeks; (Perelson et al. 1997; Shan and 
Siliciano 2013)). The following Phase III with a very low decay kinetics (half-life of 
273 days) proceeds after several years into Phase IV with a remaining stable low 
level plasma viremia that does not decrease any more (Hilldorfer et al. 2012; 
Maldarelli et al. 2007). Despite the very low plasma viremia below the limit of clinical 
assays (< 50 copies/ml), which is detectable with only ultrasensitive assays (about 3 
copies/ml), cell-associated proviral DNA (prDNA) and RNA (caRNA) is commonly 
detected by PCR-based assays in PBMCs during this phase (Palmer et al. 2008; 
Palmer et al. 2003) (Fig. 2). The presence of the Phase IV indicates the existence of 
additional cell populations that do not succumb to virus-induced cytopathic effects 
and/or are either refractory to cART (proviral DNA or transcription cannot be targeted 
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by cART) or persist in anatomical sanctuaria that are not accessed by cART. 
Reactivation of the latently infected cells, that both persist and are replenished by 
homeostatic proliferation (Chomont et al. 2009; Kim and Siliciano 2016), is viewed as 
the most relevant source of the new HIV RNA (Shan and Siliciano 2013). However, 
lower levels of antiretrovirals (ARV) found in anatomical/immunological sanctuaria 
like brain, genital tract, gut mucosa or lymph nodes can support the ongoing HIV 
replication (Fletcher et al. 2014; Huang et al. 2016; Massanella et al. 2016). Lately, it 
was described that SIV/HIV-1 may continue to replicate within B-cell follicles due to 
follicular exclusion of CD8+ T cells and dysregulated responses of follicular 
regulatory T cells (TFR) and follicular T helper cells (TFH; (Fukazawa et al. 2015; 
Miles et al. 2015; Saison et al. 2014; Tran et al. 2008)). In addition to latently infected 
long-lived memory T-cells and tissue resident macrophages (Avalos et al. 2016) 
(Gludish et al. 2015), an evidence for existence of tissue resident memory T cells 
(TRM) is emerging (Farber 2015; Farber et al. 2014).  
 
Another cause of the residual low-level HIV replication under cART is believed 
to involve the immune hyperactivation induced by various mechanisms. In addition to 
the residual productive infection that is likely to rise some immune responses, there 
is a much more frequent (95%) abortive infection of resting non-permissive CD4+ T 
cells. Due to the cytoplasmic DNA-sensing mechanisms like IFI-16, cGAS, and 
PQBP-1 (Gao et al. 2013; Thompson et al. 2014; Yoh et al. 2015) these cells might 
die by pyroptosis, a very inflammatory type of programmed cell death (Doitsh et al. 
2014; Monroe et al. 2014). Further, HIV-1 replication and disruption of the intestinal 
barrier lead to microbial translocation, stimulation of innate immune responses and 
depletion of CD4 Th17 cells, a defect persisting even after initiation of cART (Chege 
et al. 2011; Schuetz et al. 2014). Finally, the activation and dysregulated functions of 
regulatory T cells (Tregs), critical modulators of immune responses, apparently also 
contribute the immune hyperactivation (Mendez-Lagares et al. 2014; Saison et al. 
2014). The residual low-level HIV replication that leads to an elevated immune 
activation thus further stimulates HIV replication, generating a vicious cycle. 
 
In summary, HIV persistence during cART is supported by homeostatic and 
antigen-induced proliferation of latently infected cells, ongoing replication in the 
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sanctuaries as well as by increased immune activation and inflammation (Chomont 
et al. 2009; Fukazawa et al. 2015; Kim and Siliciano 2016; Van Lint et al. 2013). 
Additionally, the latent reservoir is readily being replenished during episodes of 
viraemia due to a treatment failure or other conditions of incomplete or missing 
pharmaceutical control. 
 
Models of HIV latency 
Our knowledge of the mechanisms, maintenance and reactivation of the latent 
reservoir is based namely on various in vitro and in vivo models as the presence of 
latently infected cells in human body is very low, around 1-10 millions in the whole 
organism, and difficult to study (Crooks et al. 2015; Finzi et al. 1999; Massanella and 
Richman 2016; Siliciano et al. 2003). 
 
Individual models of HIV latency reproduce to some extent certain aspects of 
the complex situation in vivo and allow for studies of certain latently infected 
populations or specific aspects of latently infected cells. Models used to study HIV-1 
latency in vitro include HIV-infected cell lines (immortalized lymphocytic or monocytic 
cells like J-Lat, ACH-2, U1; (Clouse et al. 1989; Folks et al. 1989; Folks et al. 1987; 
Jordan et al. 2003), primary cell models (derived from HIV-1 negative donor PBMCs 
by infection with a particular HIV-1 isolate or recombinant) and resting CD4 cells 
(derived from HIV-1 infected patients; (Spina et al. 2013)). While the cell lines are 
commonly available and easy to handle, they reveal several aspects that often make 
them behave differently from the situation in vivo (namely clonality based on the 
integration site or mutations of specific HIV-1 or host-cell sequences). 
 
Primary cell models might seem to be closer to the situation in vivo while the 
percentage of latently infected cells available for further studies is much higher than 
in vivo. Different primary cell models developed by different laboratories use either 
resting or activated CD4+ T cells that are infected with wild-type (typically NL4-3) or 
recombinant HIV-1 (often expressing a fluorescent reporter gene like EGFP) and 
treated with combinations of several cytokines or chemokines. After establishment of 
the infection, latency is induced by ARVs followed by reactivation by different means. 
The individual models differ in the target cell population, percentage of latently 
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infected cells generated, type and time of readout (Bosque and Planelles 2009; 
Gondois-Rey et al. 2006; Lassen et al. 2012; Saleh et al. 2007; Spina et al. 2013; 
Tyagi et al. 2010; Yang et al. 2009b). Nevertheless, it is questionable how closely 
these models reflect the situation in vivo and how much they are biased due to the 
experimental setup and mode of readout. 
 
Resting CD4 cells derived from HIV-1 infected patients cultured and 
stimulated ex vivo thus seem to be the most relevant in vitro model. However their 
use is limited by a very low presence of latently infected cells, high background rate 
of defective integrated proviruses and difficulties of any analysis due to a very high 
background of uninfected cells (problems with sensitivity and specificity). 
 
\The in vivo models of HIV latency include namely different types of 
humanized mice and macaques infected with HIV, SIV or various recombinants. The 
advantage of humanized mice consists in their relative affordability and ease of 
handling; on the other hand, their preparation is tedious while graft-versus-host 
disease (GvHD) and other differences, namely due to their genetic background, the 
way of immune reconstitution with human tissues, and lineage precursors may limit 
their use and relevance of the results. 
 
Humanized mice used for HIV research were originally based on SCID 
(severe combined immunodeficiency) mice that were irradiated and then 
transplanted with foetal human thymus and liver (SCID-hu Thy/Liv). In this model, 
latent infection is established during thymopoiesis (deactivation phase), leading to 
generation of latently infected naïve CD4+ T-cells. Among other limitations, this 
model does not provide an efficient peripheral reconstitution and human cells are 
found in relatively small numbers (Brooks et al. 2001; Marsden et al. 2012). 
 
Lately, BLT (bone marrow-liver-thymus) mice are considered as a better 
model for complex studies of HIV reservoirs and latency reversing agents (LRA) as 
they provide a robust peripheral reconstitution. These mice are most commonly 
based on irradiated NSG (NOD/SCID-gamma chain null) mice transplanted with 
foetal human thymus and liver and then reconstituted with bone marrow or purified 
CD34+ stem cells (Donahue and Wainberg 2013). This particular combination results 
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in high-level systemic reconstitution of all human leukocyte lineages with improved 
T-cell maturation and selection in a thymic environment and in generation of latently 
infected naïve and resting and CD4+ T-cells (Denton et al. 2012). There are also 
modifications of these mice using reconstitution with only discrete cell types like T 
cells or macrophages (ToM, T-cell only mice; MoM, myeloid-only mice; (Honeycutt et 
al. 2013; Honeycutt et al. 2016)), allowing studies of the role of the individual cell 
types in the establishment of latent reservoir or reactivation.  
 
Although the use of BLT mouse model is valuable for the HIV studies, its 
important limitation consists in the development of GvHD, typically around 6 months 
after engraftment (Karpel et al. 2015). Further, these mice are unable to develop 
proper HIV-specific adaptive immune responses consisting in high levels of hyper-
mutated, class-switched IgG antibodies as human cells of non-haematopoietic origin, 
namely those giving rise to stromal cells, are not transplanted and secondary 
lymphoid organs do not properly develop (Malhotra et al. 2013; Wang et al. 2011).  
 
Yet another BLT model, based on human Rag2−/− −/− mice (Choudhary et 
al. 2012; Traggiai et al. 2004; Zhang et al. 2007) was recently developed and led to 
identification of central memory CD4+ T-cells (TCM) as the main latently infected 
population after suppressive cART similarly as in human (Choudhary et al. 2012; 
Donahue and Wainberg 2013). This model was further improved by generation of 
humanized triple knock-out (TKO) BLT mice on a C57Bl/6 background (C57BL/6 
Rag2−/− −/− CD47-/-) in which the GvDH was much reduced, complement was 
functional and secondary lymphoid organs with a well organized architecture and 
virus-specific immune responses were developed (Lavender et al. 2013). 
 
A model closest to HIV-1 infection in human is infection of non-human 
primates (NHP), namely rhesus macaques, with various SIV strains. It is believed 
that different SIVs crossed the species barrier into humans many times; namely 
SIVsmm naturally infecting sooty mangabeys and SIVcpz infecting chimpanzees 
resulted in HIV-2 and certain clades of HIV-1 (Hirsch et al. 1989; Huet et al. 1990; 
Sharp and Hahn 2011).  
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The NHP models reveal many important features comparable to HIV-1 
infected humans like anatomy, physiology, immune system, infectious agent itself, 
and susceptibility to antiretroviral treatment (Gardner and Luciw 2008; Policicchio et 
al. 2016). The use of NHP models has been essential for understanding 
pathogenesis of HIV/AIDS as well as for studies of different therapeutic and 
vaccination approaches. Many conclusions could be also inferred by comparing 
immune responses to SIV infection in the natural and unnatural hosts, soothy 
mangabeys and rhesus macaques, respectively, in which the SIV infection results in 
non-pathogenic or pathogenic conditions. There is a high viremia in both hosts, but a 
very little loss of CD4+ T cells and preservation of architecture and function of lymph 
nodes in the natural host. In the gut of the natural host, CD4+ T cells are only 
moderately depleted and numbers and functions of Th17 cells remain preserved, 
while microbial translocation is lacking. Further, TFH and TCM are only weakly 
infected (Ploquin et al. 2016).  
 
Additionally, recombinant viruses like RT-SHIV or SHIV containing different 
parts of HIV-1 genome can be used to overcome certain differences between HIV-1 
and SIVs e.g. in studies involving inhibitors specific for human reverse transcriptase 
(Jiang et al. 2009; Ndung'u et al. 2001). One important difference in comparison with 
HIV-1 is that most SIVs (and HIV-2) encode a vpx protein that allows virus infection 
also in non-dividing cells as it targets for degradation cellular SAMHD-1, an enzyme 
that would hydrolyze dNTPs and thus decrease reverse transcription (Hofmann et al. 
2012). Despite many advantages, a major drawback of using macaques consists in 
their cost and ethical and legal regulations of their use. 
 
Obviously, the most relevant approach to study HIV latency and reactivation in 
HIV-infected human patients is in clinical studies. However, performance of clinical 
studies is strictly regulated, expensive and must be preceded by extensive pre-
clinical testing (including animal models). Additionally, human studies never provide 





In summary, the results obtained in various in vitro and in vivo models and in 
human patients indicate that the latent HIV-1 reservoir is represented mainly by 
latently infected resting CD4+ T cells, long-lived central memory CD4+ T cells (TCM 
cells) and  transitional memory CD4+ T cells (TTM cells). In addition to these cells, 
latent reservoir may comprise also other cell populations like CD34+ hematopoietic 
progenitor cells, naïve CD4+ T cells, CD4+ memory stem cells (TSCM cells) or  T 
cells, as well as myeloid cells like macrophages and dendritic cells (Buzon et al. 
2014; Carter et al. 2010; Chomont et al. 2009; Honeycutt et al. 2016; Soriano-
Sarabia et al. 2015; Wightman et al. 2010). The importance of these cells 
constituting the latent reservoir consists in their different survival and stability as well 
as in different requirements for signaling and activation, and thus HIV-1 provirus 
induction (Archin et al. 2014). 
 
Assessment of the size of the latent reservoir 
 
Under suppressive cART, plasma viremia (virion-associated unspliced RNA) 
is undetectable or below the detection limit of common commercial assays (<50 
copies/ml). However, markers of immune hyperactivation persist and cell-associated 
HIV RNA can be readily detected both in peripheral blood and tissues like lymph 
nodes, tonsils, gut or testes. Thus, in order to determine the effect of treatment 
intensification strategies and namely efficiency of LRA explored for therapeutic 
reactivation, availability of specific and sensitive methods allowing an accurate 
assessment of the size of the latent reservoir is crucial (Fig. 3). 
 
The latently infected cells can be defined as cells harboring quiescent, 
replication-competent provirus. A gold standard in determination of latently infected 
cells is a quantitative virus outgrowth assay (qVOA) that is very material-, labor- and 
cost-demanding. It requires large volumes of patients blood to isolate sufficient 
numbers of highly purified latently infected resting CD4+ T cells, and plate them in 
serial dilutions along with activated donor PBMCs (CD8 negative) or with a 
MOLT4/CCR5 cell line. It requires 2-3-week incubation with changes of medium and 
other additives (Finzi et al. 1997; Massanella and Richman 2016; Siliciano and 
Siliciano 2005). However, this assay apparently underestimates the size of the latent 
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pool, as it has been already demonstrated that consecutive rounds of 
stimulation/reactivation of the isolated cells could lead to increased proportion of the 
reactivated proviruses. The replication competent, but non-inducible proviruses bias 
further this assay (Bruner et al. 2015; Ho et al. 2013). An analogue of this assay, 
Mouse virus outgrowth assay (MVOA), allows to determine virus outgrowth in 
humanized mice. It has been recently described to detect latently infected cells with 
higher sensitivity than the standard qVOA as a large number of cells can be used 
and a GvHD promotes HIV-1 reactivation. Nevertheless, it provides only qualitative 
results (Metcalf Pate et al. 2015). 
 
At the other side is a PCR-based determination of the cell-associated DNA, 
which apparently overestimates the size of the latent pool, as most of the integrated 
proviruses are mutated or incapable of reactivation for unknown reasons (Ho et al. 
2013; Sanchez et al. 1997). Depending on the primer/probe sequences, total, 
integrated or 2-LTR DNA can be commonly detected (Murray et al. 2014; Pasternak 
et al. 2013). Finally, determination of cell-associated RNA (caRNA) using various 
combinations of PCR-based techniques like semi-nested RT-qPCR or ddPCR 
(Bullen et al. 2014; Kiselinova et al. 2014) seems to provide a more relevant marker 
of viral persistence and/or reactivation. However, it is important to use approaches 
distinguishing between commonly present prematurely terminated short gag 
transcripts, multiply-spliced transcripts (msRNA) and unspliced RNA (usRNA). 
Levels of usRNA are generally higher, and therefore better detectable than msRNA. 
On the other hand, determination of msRNA (e.g tat/rev; (Pasternak et al. 2008)) or 
correctly terminated viral transcripts (using primers/probe detecting the 
polyadenylated tail; (Shan et al. 2013) better correlate with the ability of the cell to 
produce infectious viruses (Bullen et al. 2014; Pasternak et al. 2013). 
 
Based on the PCR detection of tat/rev spliced transcripts, a new quantitative 
assay allowing single-cell based determination of the inducible viral reservoir called 
TILDA (Tat/rev Induced Limiting Dilution Assay) was recently presented. The 
advantage of this assay is use of only 10 ml of blood, serial limiting dilutions allowing 




A disadvantage of all PCR-based assays is their inability to differentiate 
between RNA that might remain retained in the nucleus and for this or other reasons 
not to be translated into a protein, and RNA giving rise to HIV proteins that could be 
presented on the cell surface or constitute new virions (Lassen et al. 2006). 
Therefore, determination of cell-free RNA (cfRNA) or p24 Ag in culture supernatant 
better estimates virion production. On the other hand, proportion of released virions 
and detectable cfRNA is much lower in comparison with caRNA (1.5 and 7%, 
respectively; (Cillo et al. 2014). 
 
This problem can be partially solved also by a new assay termed Prime Flow 
RNA that combines cell-based detection of proteins with antibodies and detection of 
intracellular RNA with specific probes. It was reported to detect 1 infected cell in 104-
105 cells (comparable numbers found in peripheral blood of patients on cART) 
(Romerio and Zapata 2015). 
 
Apparently, highly sensitive assay for determination of HIV proteins in culture 
supernatant is necessary for a better assessment of the efficiency of LRA. One such 
fully automated assay based on a Quanterix Simoa technology could detect low 
levels of p24 Ag in cell lysates (3 pg/ml; (Howell et al. 2015). 
 
Mechanisms of establishment and maintenance of the latent reservoir 
 
There are two types of HIV latency. A pre-integration latency that occurs after 
infection of non-permissive cells, which is short-lived as unintegrated viral DNA is 
recognized by cytoplasmic DNA sensors like cGAS or IFI-16 leading to activation of 
interferon and inflammasome responses (Gao et al. 2013; Thompson et al. 2014; 
Yoh et al. 2015). On the other hand, the post-integration latency occurring in cells 
that become quiescent after the infection is the cause of virus persistence. The latent 
reservoir is established very early during the HIV-1 infection and its size can be 
limited by an early introduction of cART. It consists of both T-cells and myeloid cells 
(Marban et al. 2007; Wires et al. 2012) and it is very stable with half-life determined 
by qVOA of about 44 months (Crooks et al. 2015; Siliciano et al. 2003). 
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A key determinant of the future fate of the HIV-1 provirus is the site of its 
integration. Most commonly, sites of HIV-1 insertion are found in intragenic regions 
of actively transcribed genes (Lewinski et al. 2006; Serrao and Engelman 2016). 
Perhaps for this reason, the majority of repressed but inducible proviruses is also 
located within the introns of the expressed genes (Lewinski et al. 2005; Shan et al. 
2011). The establishment of HIV latency is thus regulated independently of the 
control of expression of the target host genes (Mbonye and Karn 2014). 
 
Insertion of the HIV-1 provirus in the actively transcribed genes may result in 
transcriptional interference, contributing to the regulation of HIV-1 latency. Divergent 
orientation of the cellular promoter and viral LTR can lead to the lack of recruitment 
of transcription factors, while convergent promoters may lead to a collision of the 
transcription machinery and premature termination of HIV-1 transcription. Parallel 
orientation of the HIV LTR located downstream of the cellular promotor can lead to 
the viral promotor occlusion by a readtrough transcription from the cellular gene, 
displacing key transcription factors on the HIV LTR (Han et al. 2008; Lenasi et al. 
2011). In latently infected cells, a preference for a parallel orientation of the 
promotors was observed, while there was no preference in acutely or persistently 
infected cells, suggesting that transcriptional interference may be one of the 
important factors in the establishment and maintenance of HIV-1 latency (Shan et al. 
2011). 
 
HIV-1 itself does not encode any specific transcription repressors, but high 
levels of HIV-1 transcription activator Tat and its interactions with a cellular cofactor 
p-TEFb, resolving promoter-proximal pausing of RNA polymerase II (RNAP II), are 
absolutely critical for the provirus expression (Yamada et al. 2006). In the absence of 
Tat-pTEFb complex, transcription efficiency decreases drastically and only short Gag 
transcripts are generated (Kao et al. 1987; Lassen et al. 2004; Price 2000). 
Transcriptional silencing of the proviruses thus results from a series of epigenetic 
and non-epigenetic changes occurring at the promoter region and from processes 
during the transcription initiation and elongation phases that decrease levels of Tat 
and availability and/or binding of cellular factors (Mbonye and Karn 2014). 
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In the activated CD4+ T cells, which are productively infected most often, the 
intracellular milieu with high levels of cellular transcription factors, namely 
transcription initiation factors NF-κB, NFAT, and AP-1, drives HIV expression 
(Mbonye and Karn 2014). However, as the host cell returns to the resting memory 
phenotype, cytoplasmic sequestration of these factors causes a significant decrease 
of transcription initiation at the HIV LTR and allows transcriptional silencing of the 
provirus, possibly with help of transcriptional inhibitors (Bodor 2006; He and Margolis 
2002; Tyagi and Karn 2007). 
 
The chromatin structure of the proviral 5‘ LTR is a critical parameter in control 
of HIV expression. Regardless of the site of insertion, 5‘ HIV LTR is occupied by 
nucleosomes Nuc-0 and Nuc-1 in specific positions at the start site, imposing a block 
on RNAP II initiation (Verdin et al. 1993). Several negative DNA-binding factors 
factors (e.g. CBF1, YY1, LSF, BRD2, p50 homodimer (He and Margolis 2002; Karn 
2013; Tyagi and Karn 2007; Williams et al. 2006)) then facilitate recruiting of other 
repressor complexes and histone and DNA-modifying enzymes at both core 
promoter and enhancer regions. Histones of the nucleosomes at the 5‘LTR of silent 
proviruses are deacetylated and trimethylated, which is a feature of the repressive 
heterochromatin. Further, histone methyltransferases (HMTs) can be found 
associated with the latent proviral LTR (du Chene et al. 2007; Friedman et al. 2011; 
Imai et al. 2010; Keedy et al. 2009). Namely, a dominant HMT EZH2 constitutes part 
of the polycomb repressive complex PRC2 which serves as a binding platform for 
additional chromatin-modifying enzymes, histone deacetylases (HDACs) and DNA 
methyltransferases (DNMTs)(Cheng et al. 2011; Friedman et al. 2011; Tae et al. 
2011; Vire et al. 2006). Methylation of DNA (CpG islands; (Bednarik et al. 1990)) at 
transcription start site has been suggested to be the most stable modification of the 
latent provirus LTR. It might stabilize DNA and prevent provirus reactivation 
(Blazkova et al. 2009; Kauder et al. 2009). Lately, relative frequency of proviruses 
with a higher LTR DNA methylation was suggested to be increased by a prolonged 
ARV treatment or multiple rounds of reactivation (Trejbalova et al. 2016). 
 
An additional block in HIV expression may consist in post-transcriptional 
processes inhibiting HIV-1 protein expression. Namely, both unspliced and spliced 
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HIV-1 transcripts may be retained in nuclei. The export of HIV-1 transcritps is 
supported by binding of Rev to RRE (Rev response element) present in partially 
spliced and unspliced genomic HIV-1 RNAs and by the interactions with Exportin 1 
(Crm-1), a nuclear export factor. Further association with PTB (polypyrimidine tract 
binding protein) and related factors seems to affect the export efficiency. Thus, 
unavailability of either factor may promote the retention of HIV-1 RNAs in the 
nucleus. (Kula et al. 2013; Lassen et al. 2004; Lassen et al. 2006; Zolotukhin et al. 
2003).  
 
Further, several cellular miRNAs have been reported to modulate HIV-1 
expression by targeting essential cellular cofactors involved in HIV-1 transcription 
like PCAF and cyclin T1. The former is targeted by miR175p and miR-20a, while the 
latter by miR 27b and miR198 (Sung and Rice 2009; Triboulet et al. 2007). There are 
also several cellular miRNAs (e.g. miR-28, miR-125b, miR-150, miR-223, and miR-
382) that recognize the 3’-end of HIV-1 mRNAs, repressing their expression in 
resting CD4+ T cells (Huang et al. 2007). Finally, there are miRNAs derived from 
viral sequences (vmiRNAs), namely from TAR and Nef (miRTAR5p/3p and 
miRN367, respectively; (Bennasser et al. 2004; Klase et al. 2007; Omoto et al. 2004; 
Schopman et al. 2012). Both cellular and viral miRNAs may cause HIV-1 RNA 
degradation or inefficient expression of HIV-1 proteins. 
 
Mechanisms of reactivation 
 
The reactivation of the functional, inducible latent provirus depends on the 
chromatin status and availability of the cellular transcription factors. Upon 
appropriate stimulation and nuclear translocation, NF-κB and NFAT can bind to HIV 
LTR if the chromatin landscape of the promoter region is favorable (Bhatt and Ghosh 
2014). The accessibility of the HIV LTR can be affected by methylation of CpG 
islands (Bednarik et al. 1990) or binding of other transcription factors like Sp1 that 
are able to promote the chromatin configuration favorable for binding of the main 
transcription factors. In fact, Sp1 is required for the formation of the pre-initiation 
complex and interacts with NF-κB (Perkins et al. 1993). NF-κB and NFAT probably 
bind in a mutually exclusive, possibly sequential way, as their HIV-1 LTR-binding 
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sites overlap (Giffin et al. 2003; Mbonye and Karn 2014). NF-κB is found in cell lines 
and primary naïve T-cells, while NFAT is typically present in memory T-cells (Dienz 
et al. 2007). In primary memory T-cells, NFAT and Lck are required for optimal latent 
virus reactivation and HIV-1 can be activated in an NF-kB-independent way by 
transcription factor DVII-Ets-1, without causing significant T cell activation (Bosque et 
al. 2011; Bosque and Planelles 2009; Yang et al. 2009a). On the other hand, NFAT 
is dispensable in Jurkat cell models. NF-κB is commonly activated by PMA or TNF-α, 
while NFAT is activated by calcium/calcineurin signaling (Bosque and Planelles 
2009; Chan et al. 2013; Kim et al. 2011) (Bosque and Planelles,2009; Kim 
etal.,2011; Chan etal.,2013).  
 
Both NF-κB and NFAT recruit CBP/p300 and other histon acetyl transferases 
(HATs) (Garcia-Rodriguez and Rao 1998) to further acetylate Nuc-1 and to attract 
SWI/SNF chromatin remodeling complex. After the minimal initiation and 
transcription through the TAR element, RNAP II pauses. If Tat and p-TEFb, 
composed of CDK9 and cyclin T1 (Herrmann and Rice 1995; Wei et al. 1998), are 
available to bind and form a complex with TAR RNA hairpin and the transcription 
machinery, kinase activity of p-TEFb mediates phosphorylation of negative 
elongation factors (DSIF and NELF) and of RNAP II and allows formation of a 
superelongation complex and continuation of transcription further into the elongation 
phase. Thus, Tat transactivation and its interaction with p-TEFb is absolutely 
necessary for the efficient transcription elongation of the HIV provirus. When not 
complexed with Tat, pTEFb is sequestered and held inactive in the transcriptionally 
inactive 7SK RNP complex containing 7SK small nuclear RNA (7SK snRNA), 
inhibitory factor HEXIM1 and RNA binding proteins LARP7 and MePCE. Yet, Tat 
may be out-competed by BRD4 in binding to p-TEFb, leading to p-TEFb targeting to 
transcription of cellular genes (Mbonye and Karn 2014). 
 
Latency reversal and purging HIV-1 
 
Latently infected cells represent the major barrier to HIV cure of HIV-1 
(Donahue and Wainberg 2013). The major reservoir is considered to reside in resting 
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memory T cells and therefore this population is in the focus of most efforts to 
decrease the size of the latent reservoir (Bruner et al. 2015).  
 
The initial attempts to eradicate HIV-1 latently infected cells were first 
described by Fauci et al. (Chun et al. 1998; Chun and Fauci 1999). Later, the term 
“shock and kill” strategy was introduced (Archin et al. 2012; Deeks 2012). In short, it 
consists in the attempts to reactivate a dormant provirus silently present in latently 
infected cells, namely long-lived memory CD4 T-cell, that would lead to death of the 
cells harboring the latent provirus and decrease the size of the latent pool in the 
presence of cART. Originally, it was assumed that virus reactivation could be 
achieved with a single agent, namely HDAC inhibitors (HDACi) or PKC inducers, and 
that the replication of the reactivated virus and the virus-induced cytopathic effects 
would be sufficient to kill the host cells, and thus decrease the size of the latent 
reservoir. Today, it is largely accepted that combinations of two or more agents with 
different mechanism of action together with an additional stimulation of anti-HIV 
immune responses would be necessary. Namely, improvement of cytotoxic 
responses using engineered dual-affinity (DART) and broadly specific antibodies 
(bNAbs) towards HIV-1 are intensively investigated (Caskey et al. 2015; Sloan et al. 
2015). Still, there are doubts if the HIV cure can be ever achieved because of 
unknown fraction of the cells remaining refractory to the reactivation strategies. 
Further, it has been suggested that a prolonged antiretroviral treatment together with 
random or intentional cycles of reactivation might lead to an increased methylation of 
HIV-LTR and thus stabilization of the latent provirus (Trejbalova et al. 2016). 
 
Activity of LRA is usually identified in vitro in tissue culture screens involving 
various cell lines and primary cells. The efficiency of the selected compounds must 
then be verified in vivo. Most intensively investigated LRA, namely those in clinical 
trials, involve compounds in use or under development for treatment of various 
cancers and other diseases. These are especially HDACi and PKC agonists (NF-κB 
inducers). There are 11 HDACs subdivided in four classes (Mottamal et al. 2015; 
Wang et al. 2009). Particularly HDACs 1-3 (Class I) seem to be important in 
maintaining HIV latency (Keedy et al. 2009). HDACi non-specifically activate 
transcription of many genes by increasing acetylation of the promotor regions, 
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including HIV LTR. Increased acetylation should modify chromatin status and allow 
for binding of transcription factors, namely NF-κB and NFAT. Among these, 
vorinostat (SAHA) has been the most extensively explored, but newer compounds 
with higher potency like givinostat, panobinostat or romidepsin seem more 
promising. Nevertheless, none of these agents alone was able to induce viral 
outgrowth from cells isolated from HIV-1-infected patients on cART (Bullen et al. 
2014). On the other hand in clinical studies, vorinostat and some other compounds 
were able to increase levels of caRNA, but the size of the latent reservoir was not 
found decreased, suggesting that combination with other agents or strategies 
increasing immunological killing of the infected cells would be necessary 
(Rasmussen et al. 2013).  Other classes of chromatin-modifying enzyme inhibitors 
include inhibitors of histone methyltransferases (HMTi) like Chaetocin, BIX-01294 or 
GSK343, or inhibitors of DNA methyltransferases (DNMTi) like 5-aza-
2′deoxycytidine. However, they are more likely to be effective in combination with 
other LRA (Kumar et al. 2015). 
 
The other important class of LRA represent PKC agonists that induce 
activation and nuclear translocation NF-κB and p-TEFb. They can also trigger 
activation of MAPK and nuclear translocation of AP1. The natural PKC inducer 
effective in HIV-1 reactivation is TNF-α, a cytokine found increased in untreated HIV-
1 infection. However, due to its pro-inflammatory pleiotropic effects, its use as a LRA 
in vivo cannot be considered. Similarly the other very effective agent of this class, 
phorbol myristyl acetate (PMA), cannot be considered for therapy as it reveals a 
strong tumorigenic potential (Kumar et al. 2015). However, newer PKC inducers 
include nontumorigenic phorbol ester prostratin (Biancotto et al. 2004; Kulkosky et al. 
2001), macrolide lactone bryostatin-1 (Mehla et al. 2010) or diterpenoids ingenol B 
and ingenol-3-angelate (Jiang et al. 2014; Jiang et al. 2015). PKC inducers 
downregulate expression of cell surface receptors CD4, CXCR4 or CCR5 in 
uninfected cells, thus limiting the spread of the newly released virus (Hezareh et al. 
2004; Jiang et al. 2014; Mehla et al. 2010). Further, PKC was reported to 
phosphorylate HEXIM1, suggesting that PKC inducers might affect also this 
inhibitory protein (Fujinaga et al. 2012). Hexim phosphorylation is commonly 
mediated by AKT kinase that can be stimulated by HMBA (Contreras et al. 2007), 
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leading to the release of p-TEFb from the inhibitory complex 7SK RNP. Yet another 
compound affecting availability of p-TEFb is JQ1, bromodomain inhibitor affecting 
factors BRD2 and BRD4 (Boehm et al. 2013). 
 
Disulfiram, the inhibitor of acetaldehyde dehydrogenase used in therapy of 
alcohol abuse, induces degradation of PTEN, again allowing AKT-mediated 
phosphorylation of HEXIM1 (Doyon et al. 2013; Xing et al. 2011). This compound 
has been described as an effective LRA in vitro in a relatively artificial model of 
primary CD4+ T cells immortalized with the Bcl-2 protooncogene. However, the 
expectations of its potency were not fulfilled as there was no significant effect on the 
size of the latent reservoir found in vivo (Spivak et al. 2014). 
 
Apart of these mainstream studies, there are many other approaches toward 
latency reversal and HIV cure. Of these, use of a pro-oxidant gold-based drug 
Auranofin is of interest as it was shown to induce a partially selective killing of TCM  
and TTM CD4+ T cells, the main reservoir cells containing the latent HIV-1 (Lewis et 
al. 2011). Consequently, it was demonstrated that TCM and TTM CD4+ T 
lymphocytes are more susceptible to the redox stress and apoptosis (Chirullo et al. 
2013). 
 
Our laboratory has demonstrated independently that Normosang, a hemin 
containing compound used to treat acute hepatic porphyria, could strongly potentiate 
reactivation of the latent provirus induced by PKC inducers like PMA, TNF-α, 
prostratin or Bryostatin-1, while it inhibits HIV-1 replication during the acute infection 
through its effect on reverse transcription. The stimulatory effects of Normosang are 
mediated by a heme/iron-mediated Fenton reaction resulting in the increased redox 
stress, while there was no effect on the activation status of the cells (Melkova et al. 
2015a; Melkova et al. 2015b; Shankaran et al. 2011). Based on our results, we 
propose a model in which redox-modulating agents induce chromatin remodeling, 
affect binding of specific transcription factors to HIV-LTR and potentiate HIV-1 




Historically, there is a case of one HIV+ patient that was administered 
Normosang and consequently remained p24-negative for several months (Pavel 
Martasek, Faculty General Hospital Prague, personal communication). We suggest 
that the outcome in this particular patient resulted from the inhibition of reverse 
transcription by heme (Levere et al. 1991) together with a short-term reactivation and 
death of the infected cells due to heme/iron-mediated redox stress. Consequently, a 
stable heme degradation product, antioxidant bilirubin, might have mediated 
prolonged inhibitory effects on HIV-1 reactivation (Melkova et al. 2015a; Melkova et 
al. 2015b). This scenario would be compatible with the hypothesis of (Chirullo et al. 
2013) that auranofin decreases numbers of latently infected TCM and TTM CD4+ T 
cells by its pro-oxidant effects, and thus reduces size of the HIV latent pool. 
 
The idea of possible involvement and use of redox stress to purge the latent 
reservoir is further supported by work of (Iordanskiy et al. 2015) showing that 
ionizing radiation alone was sufficient to activate the HIV-1 LTR and to effectively kill 
the infected T cells. Consequently, this group proposed that a low-dose ionizing 
radiation could be used therapeutically to reactivate and kill latently infected reservoir 
cells (Iordanskiy and Kashanchi 2016). Additionally in the Berlin Patient, the only 
known case of HIV-1 cure, high-dose irradiation was used after bone marrow 
expression, while irradiation was omitted in Boston patients in which virus rebound 
occurred (Henrich et al. 2013; Hutter et al. 2015). 
 
Finally, any common infection involves increased generation of reactive 
oxygen and nitrogen species. Co-infections are well-known to increase HIV-1 
replication and promote its spread (Modjarrad and Vermund 2010), while decreased 
levels of GSH, indicator of an increased redox stress, have been described early in 
HIV infection (Pace and Leaf 1995). Reactive oxygen and nitrogen species were 
shown to stimulate activation of the redox-sensitive transcription factor NF-κB and 
LTR-driven expression of reporter genes (Jimenez et al. 2001; Pyo et al. 2008). 
Thus, increased generation of free radicals is likely to be helpful in the attempts to 
eliminate the latent HIV-1 in the presence of cART. 
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A major concern when considering testing of LRA in vivo is the induction of 
immune hyperstimulation upon reactivation of the latent HIV-1 and development of a 
harmful cytokine storm. On the other hand, it is not clear if any significant latency 
reversal is achievable without increased cytokine levels (Marsden et al. 2015). 
However, specific anti-HIV immune responses are generally hampered or 
dysfunctional. Further, it was shown that both HDACi (romidepsin, panobinostat) and 
PKC agonists (prostratin and Bryostatin-1, but not Ingenol B) inhibited HIV-specifc T 
cell proliferation (Clutton et al. 2015).  
 
Based on clinical studies, it has been widely accepted that stimulation or 
improved function of immune responses in addition to LRA would be necessary in 
order to achieve death of reactivated cells and thus decrease the size of the latent 
reservoir. Synergistic effects of different agents should also decrease the doses 




In conclusion, in view of the currently described sources of the remaining low-
level HIV-1 replication in the presence of suppressive cART, additional mechanisms 
and processes promoting HIV-1 persistence remain to be identified. Any attempt to 
achieve HIV-1 cure should involve combination of several LRA with different 
mechanism of action together with stimulation or improvement of immune responses 
towards infected cells. To validate the efficiency of individual approaches, 
development of sufficiently sensitive and specific methods allowing accurate 
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Fig. 1  Latency and reactivation (simplified scheme). HIV-1 latency is characterized 
by a repressed chromatin, presence of histone deacetylases (HDACs), histone 
methylases (HMTs) and DNA methylases (DMTs), and lack of transcription factors, 
resulting in a transcription block. Reactivation is associated with epigenetic changes 
that lead to open chromatin structure, namely presence of histone acetylases 
(HATs), nuclear translocation of transcription initiation factors NF-κB and NAFT, 
increased levels of Tat and formation of its complex with p-TEFb. Tat-p-TEFb 
complex binds to TAR RNA, resolving promoter-proximal pausing of RNAP II and 
allowing efficient transcription elongation. p-TEFb can be sequestered in the 7SK 
snRNP inhibitory complex. 
 
Fig. 2  Comparison of HIV-1 RNA and DNA decay curves upon introduction of 
cART. After initiation of cART, plasma viremia and the level of HIV-1 infected cells in 
peripheral blood decays with a well characterized kinetics based on populations with 
different turnover contributing to plasma viremia. HIV-1 DNA reveals a relatively 
smaller decrease. Adapted from (Hilldorfer et al. 2012; Margolis et al. 2016). 
 
Fig. 3  PCR-based detection of HIV-1 RNA and DNA. Determination of cell-
associated RNA (caRNA) and proviral DNA (prDNA) using 2-step seminested (RT-) 
qPCR or using a combination of a limiting dilution assay and 1-step nested RT-PCR 
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